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Abstract 
Cell penetrating peptides (CPPs) have received considerable attention as 
cellular delivery vectors for small-molecule and macromolecular therapeutics. 
Hundreds of CPP sequences have now been described including bioportides 
that serve as single entity modifiers of cell physiology. Translation of 
promising CPP pre-clinical studies have however been disappointing as few 
identified delivery-systems have progressed to clinical trials. This project 
aimed to extend on studies using CPPs for delivering peptides influencing 
NF-B signalling and to search for novel membrane active peptides that could 
be classed as CPPs or bioportides. 
In-house methods measuring IB-α degradation and luciferase expression 
assays were developed to study the capacity of penetratin to influence NF-B 
activity via delivery of the NBD peptide (Pen-NBD: 
DRQIKIWFQNRRMKWKKTALDWSWLQTE). Results from these studies 
highlighted how two methods investigating the same signalling pathway could 
give very different results. Pen-NBD did not reduce TNF-α-induced IB-α 
degradation but induced reduction in TNF-α-induced luciferase activity. This 
effect was also observed in cells treated with penetratin alone or DMSO- 
diluent.  
EJP-18 (LFMRRRHIVRKRTLRRLL) represents a novel peptide from the 
EGFR juxtamembrane region and was found to be membrane active and 
internalised into cells. This thesis further characterised this peptide including 
two other sequences from this region of EGFR (EJP-21- 
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LFMRRRHIVRKRTLRRLLQER and E-64562- RRRHIVRKRTLRRLLQER). 
In studied cancer cell lines, EJP-18 was toxic in an EGFR-dependant manner 
and aside from being a potential bioportide, also effectively delivered protein 
(BSA) and siRNA into cells. EJP-18/BSA was delivered to the lysosome and it 
remains to be determined whether it could be utilised to deliver siRNA to the 
cytosol. Cytotoxicity and protein delivery studies with EJP-21 and E-64562 
highlighted the critical importance of terminal hydrophobicity in the EJP-18 
sequence; this may extend to other studies involving CPPs. 
This thesis provides new information on in vitro activity of CPPs and CPP-
chimeras. Additionally, new peptides were discovered that could potentially be 
classed as bioportides and CPPs. 
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1 Chapter 1: General Introduction 
1.1 Introduction 
Recent decades have witnessed significant efforts to develop new, more 
efficient, less toxic and more cost effective therapeutics for lethal and chronic 
diseases. As an example, cancer can be listed as a chronic and lethal disease 
and despite extensive efforts several cancers remain a major challenge to treat. 
Existing therapeutic approaches such as surgery, chemotherapy and 
radiotherapy often show undesired side effects, including damage to healthy 
cells (Luo et al., 2015). The effectiveness of chemotherapeutics can also be 
limited by the multidrug resistance (MDR) phenomenon in which cells, once 
become resistant to one anticancer drug, develop resistance to structurally and 
mechanistically unrelated compounds (Gottesman et al., 2002, Baguley, 2010). 
In genetic disorders such as cystic fibrosis, where there is a mutation in a 
certain gene, small molecules can generally only be used to deal with the 
symptoms and complications associated with the disease rather than providing 
a real cure for the condition. In theory, the most effective treatment for such 
diseases would involve targeted intracellular delivery of the corrected gene 
sequence. In reality, therapeutic gene delivery is difficult to achieve and as a 
result, there is an urgent need to develop better or alternative approaches 
(Ratjen and Döring, 2003). For both cancer and inherited diseases, there is a 
major opportunity to design drugs that are based on biological molecules and a 
variety of these macromolecular therapeutics have been studied, ranging from 
peptides, proteins, oligonucleotides and whole genes. Their site of action lies 
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inside cells, however, their size, polarity and net negative charge hinder their 
penetration through the plasma membrane (Yin et al., 2014). There is therefore 
great demand for, and potential benefit from, developing effective delivery 
vectors for macromolecular therapeutics. 
1.1.1 Diseases  
Several diseases such as cancer and other genetic disorders have been, and still 
remain, major threats to human life and alternatives to conventional treatment 
regimes is required. The information below summarises some of the major 
disease challenges facing modern day society and how macromolecular drugs 
could provide cures. 
1.1.1.1 Cancer 
Cancer is a major social burden affecting people of all ages and is also a 
leading cause of global mortality. GLOBOCAN figure reveals that 14.1 million 
people were newly diagnosed with cancer in 2012 and 8.2 million died because 
of cancer in the same year (WHO 2012). Cancer develops as a result of 
cumulative and irreparable DNA damage in normal cells that causes those cells 
to undergo uncontrolled proliferation and division. Normally, healthy cells 
have their own repair mechanisms for such damage. However, in some cases, 
errors occur leading to permanent DNA mutations and consequently alterations 
in the genes/proteins expressed (Bertram, 2000). Once formed, cancer cells can 
invade local tissues and if they enter the blood or lymph system, the cancer can 
metastasise to different organs (Nishida et al., 2006). The fact that people now 
live longer will result in cancer becoming an increasing burden unless new 
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effective therapies are discovered. We have now an unprecedented level of 
understanding of cancer at the molecular level and this opens door to the 
design of molecules that could silence proteins that regulate cell growth and 
division (siRNA) or interfere with their activity by inhibiting their interaction 
with binding partners. Therapeutic peptides acting at the intracellular level 
have huge therapeutic potential to do this with high specificity (Raucher et al., 
2009, J Boohaker et al., 2012).  
1.1.1.2 Genetic Diseases 
Genetic disorders are caused by one or more gene abnormalities which may be 
inherited from maternal or paternal DNA or by mutations acquired due to new 
DNA damage. Different types of genetic disorders such as cystic fibrosis, 
Huntington’s disease and severe combined immunodeficiency are well 
described in literature in terms of their epidemiology, cause and symptoms.  
A simple approach for treatment of these diseases and also acquired diseases, 
such as cancer, that has proven very difficult to develop, is based on gene 
therapy i.e. replacement of the faulty gene with the correct version.  
1.2 Macromolecules: Peptides and DNA-based Drugs 
Sequencing of the human genome, in addition to data demonstrating the 
genetic and proteomic basis of many diseases provides a major impetus for the 
development of macromolecular therapeutics such as peptides, proteins and 
genes (Jones, 2008). 
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1.2.1 Therapeutic peptides 
Despite their huge potential, peptides directly interfering with intracellular 
events have yet to materialise to viable therapeutic products. Currently there 
are few clinically approved peptide that functions directly inside cells. Of note 
is that the distinction between therapeutic peptides and therapeutic proteins can 
be vague and unclear.  
Peptides as therapeutic entities offer several advantages over other types of 
therapies. These include their high specificity owing to their high levels of 
chemical and biological diversity. They also, as a result of high specificity and 
biological nature, are relatively non toxic. In addition, small peptides fall below 
the immunogenic threshold and generally do not induce a strong immune 
response (Mason, 2010). Another important consideration is the fact that they 
can be rationally designed to interfere with a known protein-protein interaction. 
Today, more than 60 therapeutic peptides and proteins are marketed 
worldwide. Nearly 270 peptides are still under clinical investigation and almost 
400 are in an advanced preclinical stage. Examples of naturally occurring 
therapeutic peptides and proteins are insulin, oxytocin and cyclosporine but 
few of them act directly on intracellular targets. There is also an active research 
field specifically focusing on delivering more peptides and proteins that have 
intracellular targets. They are, however, unlikely to be membrane permeable in 
their own right and will require some kind of vector system to deliver them to 
the insides of cells. A major focus of work has centred on the use of cell 
penetrating peptides (CPPs) to perform this. 
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1.2.2 Nucleotide-based Drugs  
The genetic basis of many diseases highlights the potential benefit of DNA-
based therapies to cure the problem at its root. The approach is based on the 
introduction of nucleotides intended to functionally replace missing or mutated 
genes or silence the expression of disease causing proteins. Examples of 
nucleotide-based drugs are plasmids, antisense and antigene oligonucleotides 
and short interfering RNA (siRNA). 
Plasmids are double-stranded self replicating DNA constructs that contain 
genes encoding specific proteins (Uherek and Wels, 2000, Patil et al., 2005). 
Plasmids also contain  promoter and enhancer sequences to upregulate 
transgene expression (Fitzsimons et al., 2002). Oligonucleotides, either 
antisense or antigene, are short single-stranded DNA segments that are 
designed to selectively inhibit the expression of a single protein. Antisense 
oligonucleotides function in the cytosol where they interact with mRNA and 
inhibit its translation or processing thereby inhibiting protein synthesis 
(Crooke, 1999). Antigene nucleotides are those targeted to genomic DNA so, 
like plasmids, nuclear entry is a key for them to exert their effect (Stull and 
Szoka Jr, 1995).   
Short interfering RNA (siRNA) is a class of short, double-stranded RNA 
molecules consisting of 21-23 nucleotide bases designed to be complementary 
to the mRNA sequence responsible for the transcription of a specific protein. 
siRNA incorporates into the RNA-induced silencing complex (RISC) where 
the siRNA duplex is unwound. The sense strand is degraded and the antisense 
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strand binds to RISC which then allows the RISC to recognise and degrade 
complementary mRNA. This ultimately leads to loss of protein translation and 
depletion or “silencing” of the corresponding gene (Bhindi et al., 2007).  
1.3 Drug Delivery Vectors 
Today, despite extensive research, the delivery of therapeutic macromolecules 
such as peptides and nucleotides to the insides of cells remains a major 
challenge due to the effectiveness of biological barriers that lie between route 
of administration and site of action. Added to this is the fact that biological 
therapeutics are sensitive to proteases and nucleases. They are fragile to the 
hostile environment of the gastrointestinal tract thus limiting our ability to 
deliver them orally and would also be susceptible to hydrolysis in serum. This 
means they need to be protected until they reach their intracellular targets. The 
plasma membrane functions as a protective and regulatory structure allowing 
the passage of essential small molecules such as sugars, ions and amino acids 
through membrane protein pumps or channels. It acts as an important barrier 
for the passage of macromolecules into the inside of the cell (Conner and 
Schmid, 2003). Biological membranes can also be found inside the cell and 
good examples are endosomal membranes for delivery to the cytosol (e.g. 
siRNA) and if this is overcome then the nuclear membrane poses a challenge if 
gene delivery (e.g. plasmid) is the therapeutic goal. Thus, the delivery vectors 
need to be designed for extracellular protection and for overcoming biological 
barriers (Mintzer and Simanek, 2008, Yin et al., 2014). Alternatively, physical 
methods have also been used for gene delivery.  
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Physical transfection of macromolecules can be achieved by mechanical 
methods (microinjection, pressure-mediated transfection and particle 
bombardment), electrical methods (electroporation) or magnetic field-enhanced 
transfection (Magnetofection). In vitro, these are effective methods but in vivo 
they have significant drawbacks (Luo and Saltzman, 2000, Mehier-Humbert 
and Guy, 2005, Al-Dosari and Gao, 2009, Mellott et al., 2013).  
An ideal drug delivery vector would be cheap to produce, ineffective at 
eliciting an immune response but effective at interacting with its cargo, 
protecting it from degradation, delivering it to its site of action at tissue, cell 
and intracellular level (Crystal, 1995). Given the diversity of the targeted 
diseases and cargo, it is unlikely that a single vector could be designed that 
would suit all applications (Thomas et al., 2003, Gardlík et al., 2005, 
Nayerossadat et al., 2012). 
Vector-assisted delivery techniques can utilise either viral or nonviral systems 
(Wiethoff and Middaugh, 2003, Nayerossadat et al., 2012). In case of peptide 
or nucleotide-based therapeutics, efficient delivery using either systems 
involves a number of steps: (1) complexation and/or entrapment with the 
vector, (2) interaction with the plasma membrane and internalisation via 
endocytosis (3) endosomal disruption and the release of the therapeutic to the 
site of action either in the cytosol or further to the nucleus (Patil et al., 2005).  
1.3.1 Viral Vectors 
Viral vector based gene therapy, was first used in the treatment of hereditary 
single-gene defects. Nowadays, their use in the treatment of cancer and other 
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diseases is the subject of much research. A major reasoning supporting the 
usage of viral delivery vectors lies in the fact that viruses have evolved highly 
efficient strategies for gaining access to host cells and for directing the cellular 
machinery to express their own genetic information (Crystal, 1995, Thomas et 
al., 2003, Vannucci et al., 2013). Five main classes of viral vectors derived 
from oncoretroviruses, lentiviruses, adenoviruses, adeno-associated viruses 
(AAVs) and herpes simplex-1 viruses (HSV-1s) are recognized (Thomas et al., 
2003, Mali, 2013, Vannucci et al., 2013).  
Viral vectors provide high delivery and transfection efficiency in a variety of 
human cells (Hendrie and Russell, 2005). Despite their efficiency, safety issues 
due to possible generation of toxicity and immunogenicity as well as 
mutagenesis at critical regions of DNA are still a concern as is their inability to 
deliver large DNA sequences (Patil et al., 2005, Glover et al., 2005, Al-Dosari 
and Gao, 2009, Yin et al., 2014). 
1.3.2 Nonviral vectors 
Nonviral vectors provide safety advantages over viral vectors in terms of 
reduced pathogenicity and possible mutagenesis in addition to their easier 
formulation and lower cost of production (Glover et al., 2005, Yin et al., 
2014). Traditionally, vectors for delivering nucleotides have been cationic in 
nature and are able to associate with negative charges to form complexes. 
These vectors include polymers forming polyplexes and liposomes forming 
lipoplexes that need to interact with the plasma membrane and be internalised 
into the inside of the cell (El-Aneed, 2004, Guo and Huang, 2011). There is 
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then most often a need to endosomal escape to release the cargo into the 
cytosol. Stabilization and targeting of polyplexes and lipoplexes to specific cell 
types can be achieved by utilizing the interactions between surface receptors 
and ligands attached to the vector. These ligands can be small molecules such 
as galactose and folate, or peptides and proteins such as transferrin and 
antibodies (Davis, 2002, Pathak et al., 2009). 
1.3.2.1 Cationic polymers 
Cationic polymers are synthetic cationic compounds that complex DNA, 
forming polyplexes. These include the widely studied polymers; 
polyethylenimine (PEI) and poly L-lysine (PLL), in addition to chitosan and 
dendrimers (Figure 1-1).  
 
Figure 1-1: Structures of cationic polymers used in delivery. 
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PEI is one of the most widely studied examples of cationic polyamines. PEI 
can be synthesized in different lengths as a branched or linear polymer. It 
possesses a high charge density at reduced pH values due to the presence of a 
nitrogen atom at every third position along the polymer that can be protonated. 
This is responsible for the buffering effect, also named proton sponge effect, of 
PEI. The buffering capacity of PEI is thought to aid in rapid endosomal escape 
resulting in high transfection efficiency (Mintzer and Simanek, 2008).  
PLL polymers are one of the early studied cationic polymers for gene transfer 
that are also biodegradable once administered into the body. PLL are linear 
homopolypeptides of the basic amino acid lysine as the repeat unit. At 
physiological pH, the amine group in PLL structure is positively charged and 
therefore lacks the buffering capacity required for endosomal escape. For the 
enhancement of transfection efficiency, a lysosomotropic agent such as 
chloroquine is often added (El-Sayed et al., 2009, Yin et al., 2014). 
Alternatively, PLL can be substituted by histidine groups which become 
protonated at pH <6 (Midoux and Monsigny, 1999). Relatively stable DNA 
complexes with better DNA condensation and transfection efficiency were 
obtained with high molecular weight PLL, however, this was also associated 
with increased cytotoxicity (Wolfert et al., 1999, Lv et al., 2006). 
Chitosan is a natural biodegradable and biocompatible linear 
aminopolysaccaride. It is obtained by deacetylation of chitin; a polysaccharide 
found in the exoskeleton of crusteans and insects, to form a polymer of N-
acetyl-D-glucosamine and D-glucosamine (Mansouri et al., 2004). Chitosan’s 
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cationic nature enhances electrostatic interaction with mucus and negatively 
charged mucosal surfaces. Chitosan is also able to form electrostatic 
interactions with other macromolecules such as DNA which has the benefit of 
protecting DNA form degradation by nucleases (Morille et al., 2008, Mao et 
al., 2010).  
Dendrimers are spherical, highly branched polymers with tree-like three 
dimensional structures. They are synthetic macromolecules composed of three 
specific domains: (1) a central core, (2) repetitive branch units in a geometrical 
radiated organization forming successive generations, and (3) a large number 
of terminals on the outer surface. Several types of dendrimers are used such as 
polyamines, polyamides and polyesters. Polyamidoamine (PAMAM) is the 
most commonly encountered dendrimer for its high transfection efficiency. The 
primary amine groups on the dendrimer surface are responsible for charged 
molecules (DNA or siRNA) binding and condensation into nanoscale particles 
and promotes its cellular uptake. Moreover, the tertiary amines buried in the 
interior of the dendrimers promote endosomal escape of the DNA or siRNA 
through the proton-sponge effect (Morille et al., 2008, Liu et al., 2012).  
1.3.2.2 Cationic lipids (cationic liposomes) 
Cationic lipids have emerged as one of the most versatile tools for gene 
delivery. Liposomes are vesicles comprised of a phospholipid bilayer enclosing 
an aqueous compartment. Multilamellar vesicles (MLV) are formed when 
multiple bilayers of lipid are formed around the central core in a concentric 
fashion. Unilamellar vesicles can be obtained by sonication of MLV. 
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Liposomes can complex both hydrophilic and hydrophobic drugs. DNA-based 
therapeutics can be either entrapped in the aqueous core of the liposome or 
complexed with the phospholipid lamellae. A cationic liposomal formulation 
usually consists of a mixture of cationic and zwitterionic lipids. Cationic lipids 
such as 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) and N-[1-(2,3-
dioleyloxy)propyl]-N,N,Ntrimethylammonium chloride (DOTMA), help in 
DNA complexation and condensation as well as cellular binding. Zwitterionic 
lipids, also referred to as helper lipids, such as 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) and cholesterol work by promoting membrane 
perturbation and fusion (Patil et al., 2005, Pathak et al., 2009). Several 
commercial formulations of cationic lipids have emerged such as 
Lipofectamine (Invitrogen, Carlsbad, CA), Tranfectam (promega, Madison, 
WI) and others; however their application is restricted to in vitro studies. 
Liposomes offer several advantages in drug delivery. Opposing viruses, 
liposomes are generally nonimmunogenic due to the absence of proteinaceous 
contents and they can be synthesized to have a variety of properties in terms of 
size, composition and surface charge. Liposomes also have the advantage of 
being biodegradable and can be formulated for controlled and targeted delivery 
(Patil et al., 2005, Slingerland et al., 2012). Despite these advantages, toxicity 
and instability of cationic lipids is still a concern in drug delivery (Patil et al., 
2005, Yin et al., 2014, Severino et al., 2015).  
It is clear that viral vectors can provide superior transfection efficiency but 
immunogenicity and possible oncogenic effects limit their application. On the 
other hand, non-viral vectors such as cationic polymers and lipids are less 
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immunogenic than viral counterparts but this is at the expense of reduced 
transfection efficiency and increased cytotoxic side effects. Thus, for 
therapeutic cargos to be delivered intracellularly, there is a need for the design 
of alternative vectors to efficiently cross the plasma membrane and allow their 
cargo to reach their desired target site.  
1.4 Cell Penetrating Peptides (CPPs) 
The term cell penetrating peptide (CPP) is now over 20 years old and describes 
short peptide sequences that have the capacity to deliver themselves and cargo 
of various forms from the outside to the inside of cells. A major discovery in 
CPP history was made in 1988 by Frankel and Pabo while developing an assay 
for measuring the activity of Tat protein from the Human immune-deficiency 
virus-1. Unexpectedly the purified Tat, when added to the culture medium of 
HL3T1 cells, was able to enter cells and translocate into the nucleus (Frankel 
and Pabo, 1988). Another observation was made by the group of Prochiantz in 
1991 who showed that a 60 amino acid polypeptide from the sequence of the 
Drosophila Antennapedia homeodomain protein (pAntp, penetratin) could be 
internalized by neurons, reach the nucleus and cause significant morphological 
changes in the cultured cells (Joliot et al., 1991). This was followed by the 
discovery of the first what we would now term as a CPP; derived from the third 
helix of Antennapedia homeodomain and named penetratin. Penetratin is a 16 
amino acid peptide with the sequence RQIKIWFQNRRMKWKK (Derossi et 
al., 1994). Since the discovery of penetratin, major efforts have been made to 
develop other peptide sequences to deliver covalently or non-covalently 
attached cargos into cells and the number of CPP sequences has increased 
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dramatically. Interestingly, some CPPs have nuclear localisation sequences 
(NLS) that allow for their nuclear translocation across nuclear pores either 
alone or with conjugated cargos. Molecules are transported into the nucleus 
generally across the nuclear pore complexes (NPCs). The inner diameter of 
NPCs is only  9 nM which allows the free diffusion of small molecules, 
however, macromolecules such as DNA cannot diffuse through the pores 
(Morille et al., 2008). NLS are sequences rich in basic amino acids and are 
thought to be transported into the nucleus through binding to cytoplasmic 
receptors known as importins; α/β or both, followed by translocation through 
nuclear pores. NLS can be  monopartite with one cluster of basic amino acids 
such as in the sequence from simian virus (SV40) large tumour antigen 
(PKKKRKV), bipartite with two clusters of basic amino acids such as in p53 
protein (KRALPNNTSSSPQPKKK) (Bolhassani, 2011) or tripartite such as 
the NLS in epidermal growth factor receptor (EGFR) (RRRHIVRKRTLRRLL) 
(Hsu and Hung, 2007). 
The term CPP is now widely used to describe a class of short sequence 
peptides, usually less than 30 amino acid residues, that have been found to 
successfully internalise into many different mammalian cells (Stewart et al., 
2008) and non-mammalian cell types (Nekhotiaeva et al., 2004) including 
yeast (Holm et al., 2005) and plant protoplasts (Mae et al., 2005). A unified 
term for peptide sequences with penetrating properties has not yet been agreed 
upon and alternative terminologies include protein transduction domains 
(PTDs), and membrane translocation sequences (Jarver and Langel, 2004, 
Milletti, 2012). In this thesis, the term CPP will be used to describe a peptide 
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that can enter cells via one or more mechanism and can at the very least deliver 
a small payload such as a fluorophore. 
Today, CPPs have been shown to have the capacity to not only gain access to 
cells but to also deliver a range of cargos of widely different sizes and 
composition. These include siRNA (Eguchi and Dowdy, 2009), small 
molecules such as fluorophores (Jones and Sayers, 2012), proteins, peptides 
(Milletti, 2012), plasmid DNA, PNA (peptide nucleic acid) and liposome 
nanoparticles (Morris et al., 2008, Nakamura et al., 2013). The sequences of a 
range of studied CPPs are listed in Table 1-1. There are many other sequences 
in the literature that have been shown to have similar effects in cells and also 
not included are D-isoforms that are designed to have the same cell penetrating 
function but reduced sensitivity to degradation. Also not included are details of 
the nature of the N- and C-terminus (e.g. acyl, amide) and the various 
modifications that are placed on them for conjugation (e.g. cysteine). Any 
modification of peptides used in this thesis is highlighted when the peptide 
sequence is described in the Materials and Methods. 
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Table 1-1: In alphabetical order, amino acid sequences of studied CPPs; 
adapted from (Jones and Sayers, 2012).  
Peptides Sequence References 
8K KKKKKKKK 
(Davé et 
al., 2007) 
CADY GLWRALWRLLRSLWRLLWRA 
(Crombez 
et al., 2009) 
EB1 LIRLWSHLIHIWFQNRRLKWKKK 
(Lundberg 
et al., 2007) 
GALA WEAALAEALAEALAEHLAEALAEALEALAA 
(Subbarao 
et al., 1987) 
HIV-1 Rev TRQARRNRRRRWRERQR 
(Sugita et 
al., 2008) 
KALA WEAKLAKALAKALAKHLAKALAKALKACEA 
(Wyman et 
al., 1997) 
Kaposi FGF 
derived 
AAVALLPAVLLALLAP 
(Lin et al., 
1995) 
MAP KLALKLALKALKAALKLA 
(Oehlke et 
al., 1998) 
Mastoparan INLKALAALAKKIL 
(Konno et 
al., 2000) 
Maurocalcine GDCLPHLKLCKENKDCCSKKCKRRGTNIEKRCR 
(Estève et 
al., 2005) 
mellittin GIGAVLKVLTTGLPALISWIKRKRQQ 
(Dempsey, 
1990) 
MPG GALFLGFLGAAGSTMGAWSQPKKKRKV 
(Simeoni et 
al., 2003) 
PasR8 FFLIPKGRRRRRRRR 
(Takayama 
et al., 2009) 
Penetratin RQIKIWFQNRRMKWKK 
(Derossi et 
al., 1994) 
Pep-1 KETWWETWWTEWSQPKKKRKV 
(Deshayes 
et al., 2004) 
PepFect 14 Stearyl-AGYLLGKLLOOLAAAALOOLL 
c
 
(Ezzat et 
al., 2011) 
PFVYLI PFVYLI 
(Rhee and 
Davis, 
2006) 
pHLIP 
AEQNPIYWARYADWLFTTPLLLLDLALLVDADE
GT 
(Reshetnya
k et al., 
2008) 
PTD-5 RRQRRTSKLMKRGG 
(Rehman et 
al., 2003) 
pVec LLIILRRRIRKQAHAHSK 
(Elmquist 
et al., 2001) 
R7W RRRRRRRW 
(Maiolo et 
al., 2005) 
R8 RRRRRRRR 
(Fretz et 
al., 2007) 
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R9F2 RRRRRRRRRFFC 
(Nelson et 
al., 2005) 
SAP(E) VELPPPVELPPPVELPPP 
(Martín et 
al., 2011) 
Tat GRKKRRQRRRQ 
(Vives et 
al., 1997) 
TP10 AGYLLGKINLKALAALAKKIL 
(Soomets et 
al., 2000) 
Transportan GWTLNSAGYLLGKINLKALAALAKKIL 
(Pooga et 
al., 1998) 
YTA2 YTAIAWVKAFIRKLRK 
(Lindgren 
et al., 2006) 
c
 O represents ornithine 
1.4.1 Classification of CPPs 
CPPs can be categorised into three major classes: (i) cationic such as Tat, and 
polyarginines (Milletti, 2012), (ii) amphipathic, whereby alterations between 
cationic and hydrophobic residues give rise to α-helical structures (Fernández-
Carneado et al., 2004)- MAP and transportan, and (iii) hydrophobic such as the 
sequence PFVYLI (Watkins et al., 2009b) and Kaposi Fibroblast Growth 
Factor (Lin et al., 1995). There is no specific class for anionic peptides; 
however, SAP(E) is a recently described anionic CPP shown to deliver 
fluorophores into a range of cell lines (Martín et al., 2011, Jones and Sayers, 
2012).  
CPPs can also be classified based on their origin: (i) Protein derived CPPs, 
which refers to those peptides derived from the sequence of a parent 
translocation protein such as Tat and penetratin. (ii) Designed such as R8 or 
“chimeric” CPPs which refers to sequences obtained by the covalent 
attachment of a hydrophilic and a hydrophobic domain of different origin 
separated by a linker. For example, MPG in Table 1-1 is derived from the 
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fusion of the HIV glycoprotein 41 peptide and the NLS sequence of SV40 T-
antigen. Another example is transportan which was derived from the coupling 
of the minimal active part of the neuropeptide galanin and mastoparan. (iii) 
Model CPPs such as MAP, represent sequences synthetically designed to 
produce amphipathic α-helical structures or simulating structures of known 
CPPs  (Zorko and Langel, 2005). 
1.4.2 Internalisation Mechanisms of CPPs 
As more and more CPPs sequences are described, it is becoming increasingly 
more difficult to suggest that a single mechanism is responsible for the 
translocating property of all of them. Added to this is (1) the fact that they have 
been tested in many different model systems from synthetic to in vitro to in 
vivo, (2) some CPPs have been extensively studied (Tat, Penetratin and R8) 
while others have received less attention, (3) that mechanism of action will 
undoubtedly be influenced by choice of cargo. In this section, fragments of the 
literature have been selected to highlight different types of uptake mechanisms 
for the few selected CPPs that have been extensively studied. This ranges from 
direct translocation across the plasma membrane into the cytosol through to the 
use of defined endocytic pathways to initially gain entry in the cytoplasm. 
These studies initially and generally look at CPPs attached to small cargo such 
as fluorophores. 
Initially, it was thought that the uptake of CPPs occurred by direct 
translocation through the lipid bilayer cell membrane in a receptor- and energy-
independent process (Derossi et al., 1994, Vives et al., 1997). This commonly 
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accepted mechanism of internalisation was re-evaluated when in 2002, 
Lundberg and Johansson provided evidence that herpes simplex virus VP22 
protein adhered to the cell membrane of living cells and nuclear import only 
occurred after cell fixation (Lundberg and Johansson, 2002). Later, Richard et 
al. compared the distribution of Tat and (Arg)9 between fixed and unfixed 
cells. The live cell imaging revealed a punctate cytoplasmic distribution 
characteristic of endocytosis and there was overlap between the peptides and 
endocytic markers. Fixed cells showed nuclear localisation suggesting this 
localisation was an artefact induced by fixation (Richard et al., 2003). In 
another study, the internalization of unconjugated Tat was found to involve 
clathrin dependent endocytosis as well as heparan sulphate receptors (Richard 
et al., 2005). As a result, endocytosis gained greater prominence as an uptake 
mechanism, however it should be noted that uptake of CPPs still occurs at low 
temperatures which suggests the involvement of alternative energy-
independent internalization mechanisms (Patel et al., 2007). The study of Fretz 
et al. showed that in leukaemic KG1a cells, R8 peptides attached to the 
fluorophore Alexa488 were particularly prone to allowing the internalisation of 
these CPPs when they were placed on ice and thus when endocytosis was 
inhibited (Fretz et al., 2007). The reason for this has yet to be determined and 
this direct translocation mechanism is further described in the next section. 
Different internalisation mechanisms of CPPs are presented in Figure 1-2. 
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Figure 1-2: Different internalization mechanisms of CPPs; adapted from (Trabulo et al., 
2010). 
 
1.4.2.1 Direct Translocation 
Direct translocation of CPPs across membranes has been observed using 
several different biological and synthetic systems. The proposed models for 
this event to occur include the “inverted micelle model”, the “carpet model” 
and those that induce pores in the membrane. In 1996, Derossi et al. outlined 
the “inverted micelle model” to explain the translocation of penetratin (Figure 
1-2). This model suggests that the interaction of CPPs with cell membranes 
results in a disturbance of the lipid bilayer which leads to the formation of 
inverted hexagonal structures called inverted micelles. Peptides would then be 
entrapped within the hydrophilic medium in the core of the formed micelle up 
to the point at which they interact with the biological membrane leading to an 
inverse process. This would then cause destabilization of the inverted micelles 
and allow the release of the entrapped peptides into the cell interior (Derossi et 
al., 1996).  
In the “carpet model”, the extensive association between the peptide and the 
surface of the cell membrane causes a temporary destabilization of the 
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membrane as well as phospholipid reorganization. As a result, the peptides and 
their conjugates can cross through the membrane (Pouny et al., 1992, Shai, 
1999, Copolovici et al., 2014). 
The membrane pore formation models involve two types of pore: barrel stave 
pores and toroidal pores. In the barrel stave model, peptides form an 
amphipathic alpha-helix structure when introduced into the membrane. This 
allows for an interaction between the hydrophobic face of the amphipathic 
helix and the aliphatic chains of the phospholipids bilayer while the 
hydrophilic face would line the inside of the pore (Madani et al., 2011). 
Toroidal pores differ from barrel stave pores in that the peptides interact 
entirely with the polar groups of the phospholipids of the membrane causing an 
obvious rearrangement of the lipid bilayer (Yang et al., 2001, Trabulo et al., 
2010).  
1.4.2.2 CPP Cell Uptake via Endocytosis 
Endocytosis is a term that describes the process by which a cell internalises a 
portion of its plasma membrane into the cytoplasm in the form of a vesicle that 
also contains extracellular fluid. It can be broadly divided into two forms 
classically termed as phagocytosis and pinocytosis. Phagocytosis only occurs 
in specialized cells (macrophages, monocytes and neutrophils) that function to 
clear large pathogens such as yeast or bacteria, apoptotic cells and cell debris 
(Conner and Schmid, 2003, Doherty and McMahon, 2009). Pinocytosis, on the 
other hand, is used by all cells for the uptake of fluids and solutes (Patel et al., 
2007). This occurs via different pathways such as macropinocytosis, clathrin-
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mediated endocytosis, caveolae-mediated endocytosis and other less known 
pathways (Cleal et al., 2013).  
Macropinocytosis is an actin-dependent form of endocytosis and may be a 
constitutive event or occurs via stimulation with growth factors such as 
epidermal growth factor (EGF) or phorbol esters (Swanson, 1989, Jones, 2007, 
Kerr and Teasdale, 2009). Macropinocytosis involves membrane ruffling with 
the inward folding of the outer surface of the plasma membrane. The formed 
protrusions collapse and fuse with the ruffled membrane to form large vesicles 
named macropinosomes. Macropinocytosis is a means for cells to engulf 
significant volumes of extracellular fluid and macropinocytosis may be the 
major route for the internalization of cationic CPPs such as Tat (Kaplan et al., 
2005, Jones, 2007, Cleal et al., 2013). 
Clathrin and caveolae-mediated endocytosis are the most studied forms of 
pinocytosis and these pathways have also been suggested to be involved in the 
uptake of CPPs. Clathrin-mediated endocytosis is a well characterised 
endocytic pathway by which materials are internalised through clathrin-coated 
vesicles. These vesicles are formed by the sequestration of clathrin proteins to 
form clathrin cage invaginations at the plasma membrane and they enclose the 
extracellular molecule after binding to the membrane. Once internalised, the 
clathrin-coated vesicles lose its coat to enable fusion with early endocytic 
compartments that direct traffic to other cellular compartments including 
recycling endosomes (McMahon and Boucrot, 2011). Caveolae are described 
as flask-shaped, non-coated plasma membrane invaginations that are localized 
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in domains called lipid rafts. They are enriched in cholesterol and 
glycosphingolipids (Reeves et al., 2012). Unlike macropinocytosis that is 
known to engulf material into large vesicles, caveolae are approximately 50 nm 
in diameter while clathrin coated vesicles are slightly bigger, 80-100 nm 
(Conner and Schmid, 2003, Madani et al., 2011).  
To assess the involvement of different endocytotic internalization pathways in 
CPP uptake, several experiments may be performed based on changing the 
experimental conditions: (i) investigating uptake at low temperature 
(approximately 4ºC), (ii) evaluating the colocalisation of peptides with either 
endocytic probes that are known to utilise specific endocytotic internalization 
pathways such as transferrin for clathrin-mediated endocytosis or protein 
markers such as Caveolin-1 expressed in cells as GFP-tagged variants to label 
caveolae, (iii) overexpression of dominant negative mutants of proteins such as 
Dynamin that are involved in defined endocytotic processes (iv) use of 
pharmacological inhibitors that are deemed to inhibit defined pathways and (v) 
siRNA depletion of proteins known to regulate specific endocytic pathways 
(Mundy et al., 2002, Trabulo et al., 2010, Al Soraj et al., 2012, Cleal et al., 
2013).  
1.4.2.3 Factors affecting Translocation Efficiency  
The cellular uptake mechanism of CPPs can be affected by several factors 
including the nature and secondary structure of the CPP (Heitz et al., 2009, 
Copolovici et al., 2014). In order to understand important peptide features 
required for membrane translocation, one can compare physico-chemical 
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characteristics from different CPPs. Generally, CPPs contain a high content of 
basic amino acids resulting in a net positive charge (Lundberg and Langel, 
2003, Jones and Sayers, 2012). Arginine is the most basic amino acid with a 
pKa of 12.5 due to the presence of the guanidine moiety which is positively 
charged at physiological pH. This residue is thought to confer many advantages 
to CPPs regarding interaction with the cell and entry into the cell interior. 
Structurally, the guanidinium group is characterized by a planar Y-shape which 
allows the delocalization of its cationic charge. The molecule is stabilized by 
resonance of the positive charge evenly on the three nitrogen atoms as shown 
in Figure 1-3A. As a result of its unique shape and multiple hydrogen bonding, 
a guanidinium group can form both electrostatic and hydrogen bonding with 
anionic and polar molecules (Schug and Lindner, 2005). The guanidinium 
group forms bi- or multi-dentate hydrogen bonds with the phosphates of more 
than one lipid head groups. Lysine (pKa  10.5) lacks a guanidinium moiety 
and instead has an amino group (Figure 1-3B), which forms a mono-dentate 
hydrogen bond with the phosphate on a single lipid head group. This indicates 
that the guanidinium group of arginine is more efficient in interacting with 
bulky lipid head groups of the cell membrane than the amino group of lysine 
(Rothbard et al., 2004, Schmidt et al., 2010).  
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Figure 1-3: Structures of arginine, lysine. (A) structure of arginine and the guanidinium 
moiety highlighted and (B) structure of lysine with the amino group instead of the guanidinium 
moiety.  
 
The properties of arginine and to a lesser extent lysine allow the peptides to not 
only interact with lipids on the cell surface or possibly the inner surface of the 
endosomal membrane but also with heparan sulphate proteoglycans (HSPG) 
that protrude from the cell surface. These are negatively charged sugars 
attached to surface proteins that are thought to have major influence on the way 
cationic CPPs interact with cells and enter cells (Futaki et al., 2001, Belting, 
2003, Schmidt et al., 2010). It has been also shown that HSPG acts as a surface 
receptor for Tat, which is rich in arginine. HIV-1 Tat protein internalisation is 
impaired in cells lacking all types of glycosaminoglycans (GAGs) or those 
specifically lacking HSPG or cells that were pre-treated with HSPG-degrading 
enzymes (Tyagi et al., 2001). 
Non-electrostatic effects such as hydrophobicity and peptide structural 
transitions can also have a role in the binding affinity of amphipathic CPPs to 
cell membranes (Ziegler, 2008). For example, penetratin adopts a random coil 
structure when in aqueous solution that transforms to an α-helical structure at 
high lipid to peptide molar ratios. A higher degree of β-sheet conformation of 
penetratin is induced by reducing the lipid to peptide ratio (Magzoub et al., 
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2002). These amphipathic secondary structures that penetratin adopts allow the 
hydrophobic peptide residues to directly interact with the non-polar interior of 
the lipid membrane. This causes membrane destabilization and enhances CPP 
internalization (Binder and Lindblom, 2003, Schmidt et al., 2010)  
The nature of the cargo also plays a role in the internalisation mechanism of 
CPPs (Heitz et al., 2009, Koren and Torchilin, 2012, Copolovici et al., 2014). 
Studies on Tat provide a good example of this. When unconjugated, it is 
thought to enter cells mainly by clathrin-mediated endocytosis (Richard et al., 
2005). However, the fusion protein GST-Tat-GFP, is primarily internalised via 
the caveolin-mediated pathway (Fittipaldi et al., 2003), while the Tat-HA2 
fusion peptide is internalized via lipid raft-dependent macropinocytosis (Wadia 
et al., 2004). It should be noted that all these studies predominantly used 
chemical inhibitors of endocytosis to define uptake mechanism and all of  these 
suffer from lack of specificity (Ivanov, 2008). 
1.5 CPPs and Cargo Delivery for Therapeutic Applications 
The discovery of CPPs and their ability to cross the plasma membrane 
provided hope that they could be used as drug delivery vectors. CPPs offer 
potential to improve the delivery of therapeutic cargos such as oligonucleotides 
and peptides that were previously of limited therapeutic value due to their poor 
permeability and rapid degradation (Lindgren et al., 2000, Chugh et al., 2010). 
Examples of cargos delivered by CPPs are described in sections 1.5.1 to 1.5.4, 
and elsewhere in the thesis. 
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1.5.1 Delivery of small molecules 
A good example of small molecular entities that have been delivered into cells 
by CPPs are the numerous fluorophores that have been used to analyse CPP 
uptake. These include fluorescein dyes such as fluorescein isothiocyanate 
(FITC) (Okamura et al., 2005), rhodamine dyes (Fretz et al., 2007) and Alexa 
dyes such as Alexa488 (Kosuge et al., 2008). These dyes all have their unique 
properties (Jones and Sayers, 2012, Bechara and Sagan, 2013) but very few 
studies have been performed to specifically study what effect the fluorophore 
has on cell entry. 
CPPs have also been studies for the delivery of anticancer agents such as taxol 
and doxorubicin. Taxol; a widely used chemotherapeutic agent, when 
conjugated with octaarginine (r8), was delivered in both in vitro and in vivo 
models of taxol-resistant ovarian cancer. The conjugate produced enhanced 
anticancer effect over taxol alone in ovarian-tumour-bearing mouse models 
(Dubikovskaya et al., 2008). In another study, the administration of 
r8-doxorubicin conjugates effectively suppressed tumour proliferation to the 
same extent as doxorubicin without causing the significant weight loss 
associated with the unconjugated drug (Nakase et al., 2012). Coupling of 
doxorubicin with D-penetratin has been shown to enhance its uptake and 
increased its cytotoxicity by 20 fold compared to free doxorubicin in human 
erythroleukemic (k562/ADR) resistant cells (Mazel et al., 2001). Conjugating 
octaarginine with a vinblastine derivative showed an antiproliferative effect 
against sensitive and resistant leukemia HL-60 cells as well as HeLa cells 
(Bánóczi et al., 2010).  
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1.5.2 Nucleic acid delivery 
The delivery of DNA- and RNA-based therapeutics to mediate a physiological 
response represents a major challenge. Several studies have been performed 
using CPPs to deliver DNA cargo for controlling gene expression or for 
silencing the activity of certain proteins. Oligomers of Tat have demonstrated 
the ability to complex plasmid DNA and mediate gene delivery to cultured 
cells (Tat2 and Tat3 ˃ Tat4). The transfection efficiency of Tat2 was enhanced 
by 40 fold in presence of chloroquine (Rudolph et al., 2003). Tat2, Tat3 and 
Tat4 are dimer, trimer and tetramers of Tat repeats [C(YGRKKRRQRRRG)2–4] 
respectively with an intervening glycine. Penetratin and transportan covalently 
attached to thiol-containing siRNAs, targeting luciferase or green fluorescent 
gene (GFP), efficiently reduced transient and stable expression of these 
proteins in different cell lines. Penetratin-siRNA and transportan-siRNA 
conjugates were able to enter the cell and decrease luciferase levels and this 
decrease remained stable for up to 3 days. The conjugates also caused 
knockdown of GFP expression which was shown to persist for up to seven 
days (Muratovska and Eccles, 2004). Further examples of the successful 
delivery of nucleic acids using CPPs will be described in chapter 5. 
1.5.3 Metallic nanoparticle delivery 
CPPs have been successfully used to mediate the delivery of nanoparticles for 
diagnostic, therapeutic and imaging purposes. Superparamagnetic iron oxide 
nanoparticles have been used as powerful non-invasive tools for biomedical 
imaging, clinical diagnosis and therapy (Jin et al., 2014). Iron oxide 
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nanoparticles showed efficient labelling of cells when conjugated with Tat. 
Moreover, increasing the number of Tat per cross linked superparamagnetic 
iron oxide (CLIO) particle (above 10 per CLIO) facilitated their cellular uptake 
and enhanced their intracellular accumulation by 100 fold (Zhao et al., 2002). 
This allows the intracellular magnetic labelling and detection by magnetic 
resonance imaging (MRI). Studies performed by Lewin et al. showed that 
tracking of labelled cells in vivo using MRI was possible using functionalized 
CLIO-Tat (Lewin et al., 2000, Sawant and Torchilin, 2010). In another study, 
gold nanoparticles functionalized with Tat were able to cross the plasma 
membrane and enter the nucleus in human fibroblasts while unconjugated 
particles were only detected in the cytoplasm in vacuoles or around the 
mitochondria and failed to enter the nucleus (de la Fuente and Berry, 2005).  
Quantum dots (QDs) are semiconductor nanoparticles that are used as 
fluorescence probes due to a number of favourable photoproperties such as 
high luminescence efficiency and photostability in addition to broad absorption 
and narrow emission profiles (Gao et al., 2004). In a number of studies, CPPs 
have been used to enhance the cellular uptake of QDs (Xue et al., 2007, Ruan 
et al., 2007, Stewart et al., 2008).  
1.5.4 Peptide and Protein delivery 
CPPs have also been used to deliver a range of peptides and whole proteins. An 
in vivo study that raised significant interest in CPP research emanated from the 
Dowdy lab in 1999 (Schwarze et al., 1999). They studied delivery of 
β-galactosidase (β-gal) conjugated with Tat after intraperitoneal injection into 
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mice. Enzyme activity was found to be distributed in all tissues. Cai et al. also 
showed successful delivery of β-gal using Tat after portal vein, intravenous, 
intraperitoneal and oral administration in mice (Cai et al., 2006). These studies 
opened new opportunities for using this sequence and newly discovered CPPs 
to deliver proteins and peptides to cells. 
It is beyond the scope of this thesis to describe all the attempts now made to 
use CPPs to deliver protein and peptides to cells. Focus will be given to studies 
that have used CPPs to deliver peptide and protein cargo targeting either cancer 
or the NF-B pathway.   
1.6 CPPs and Cancer 
The ideal cancer therapy targets only cancer cells with the aim of eliminating 
all of them from the body. For several types of cancer, with current approved 
approaches, this remains a major challenge. The understanding we now have of 
cancer allows us to think of new types of drugs including peptides and proteins 
that in most cases need a delivery vector to enter cells. 
As cancer cells proliferate and a solid tumour expands, the demand for oxygen 
and nutrition increases (Iyer et al., 2006). The tumour vasculature differs from 
the normal vasculature: in a solid tumour the blood vessels are disorganised, 
irregular in shape, dilated, leaky and of greater density (Skinner et al., 1990, 
Baluk et al., 2005). Tumour endothelial cells have large fenestrations which 
results in the leakage of serum components such as macromolecules and 
nanoparticles into the tumour cells. Tumour cells also show poor lymphatic 
drainage which reduces the clearance of macromolecules from the tumour and 
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leads to their intratumoural accumulation. This phenomenon is termed the 
enhanced permeability and retention (EPR) effect and has been used for the 
targeting of macromolecules to solid tumour cells using nanoparticle 
formulations (Iyer et al., 2006). 
CPPs have been studied as delivery vectors for peptides and proteins in 
formulations that do and do not rely on the EPR effect to gain access to tumour 
cells and a few examples will be given here specifically for protein delivery 
and peptide delivery is covered in later sections in this introduction covering 
NF-B and EGFR and also in introduction to chapters 3, 4 and 6.   
The CPPs are designed to facilitate the targeting and delivery of tumour 
suppressor or proapoptotic proteins to tumour cells. Second mitochondria 
derived activator of caspases (Smac) is a mitochondrial protein that is released 
into the cytosol in response to apoptotic stimuli and is capable of inactivating 
inhibitor of apoptosis (IAP) proteins such as XIAP, c-IAP-1, and c-IAP-2 and 
prevents them from inhibiting caspases (Vucic et al., 2002). Several groups 
have demonstrated that the N-terminus of the Smac protein can be linked to 
CPPs such as penetratin and Tat to increase cellular uptake (Snyder and 
Dowdy, 2004). Smac/penetratin fusion peptide was able to cross the plasma 
membrane of various cell lines and bind to endogenous IAPs, decrease 
caspases-3 aggregation in the cytoplasm and enhance drug-induced caspases 
action. The fusion peptide increased the induced apoptosis and antiproliferative 
effects of a variety of chemotherapeutic agents such as doxorubicin and 
paclitaxel (Arnt et al., 2002). In another study, an intracranial glioblastoma 
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xenograft model was used to test the effect of Smac-Tat peptide in vivo. 
Initially, the effect of tumor necrosis factor–related apoptosis-inducing ligand 
(TRAIL) alone was examined. TRAIL caused reduced tumor volume and 
moderately extended the life of nude mice bearing established intracranial 
U87MG tumors. Smac/Tat alone had no effect on tumor growth but when 
combined with TRAIL strongly enhanced its antitumor activity in a human 
glioma xenograft model in vivo. Moreover, a synergistic effect was observed in 
case of Smac/Tat and TRAIL combinations and mice treated with the 
combination had complete eradication of established intracranially growing 
glioma and showed better survival (Fulda et al., 2002). 
Intraperitoneal (IP) delivery of penetratin-conjugated p16 peptide (an inhibitor 
of cell cycle progression) suppressed the growth of pancreatic cancer cells in 
peritoneal and subcutaneous tumours in nude mice (Hosotani et al., 2002). No 
systemic toxicity was reported in the above study which suggests that cancer 
cells may be more sensitive to the effects of tumour suppressor peptides than 
normal cells. This demonstrates potential for the use of CPP vectors for 
specific, targeted delivery of cytotoxic agents in cancer treatment (Snyder and 
Dowdy, 2004). In a study by Roeder et al., Herpes Simplex Virus VP22 protein 
was used to deliver E2 protein which triggers growth arrest and/or apoptosis 
when overexpressed in cells. VP22-E2 fusion protein was found to induce 
apoptosis in transiently-transfected, human papillomavirus (HPV)-transformed 
cervical carcinoma cell lines (Roeder et al., 2004).  
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Anti-p21 antibodies when conjugated to 17-mer peptides derived from HIV-1 
Tat protein (GRKKRRQRRRPPQGYGC, NLS underlined) sensitized breast 
cancer cells, MDA-MB-468 and MCF-7, to the antiproliferative effects of 
cytotoxic agents depending on the different ability of these agents to induce 
p21 expression in cells. p21 is a cyclin-dependent kinase inhibitor that plays a 
role in protecting cells against lethal DNA damage through cell cycle arrest to 
allow for DNA repair or promote apoptosis in case of DNA repair failure. The 
ability of Tat-anti-p21 immunoconjugates (ICs) to sensitize cancer cells to 
cytotoxic agents offers promising approaches towards more effective 
anticancer treatment (Hu et al., 2006). 
1.7 CPPs and Nuclear factor-kappa B (NF-B) 
1.7.1 Introduction to NF-B 
NF-B is a protein complex first described in 1986 by Sen and Baltimore (Sen 
and Baltimore, 1986). It plays a major role in cell inflammation, 
differentiation, growth and cell survival (Bharti and Aggarwal, 2002, 
Baltimore, 2011). It was so named because it was found bound to an enhancer 
element of the immunoglobulin kappa light chain gene in the nucleus of B cells 
( Ghosh et al., 1995, Sethi et al., 2008). NF-B regulates the expression of 
several genes in response to infection and stress (Müller et al., 1995, 
Baltimore, 2011). In unstimulated cells, NF-B is sequestered in a latent form 
in the cytosol via the formation of a complex with an inhibitory protein known 
as IB (O'Neill and Kaltschmidt, 1997, Wan and Lenardo, 2010).  
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The vertebrate NF-B family includes five cellular proteins: RelA (p65), c-Rel, 
RelB, p50/ NF-B1 and p52/ NF-B2. These protein homo- or heterodimerize 
to generate diverse combinations of dimeric complexes. These complexes bind 
to DNA target sites known as B sites where they directly regulate gene 
expression (Gilmore, 2006). The heterodimer consisting of p50 and p65 is 
considered the main activated variants of the NF-B pathway that translocate 
to the nucleus to mediate transcription and protein expression (Tas et al., 
2005). 
The NF-B pathway has been shown to be activated via three different 
processes (Figure 1-4) (Viatour et al., 2005). The first pathway, also named 
classical pathway, is enhanced by pro-inflammatory cytokines such as tumour 
necrosis factor (TNF). TNF, through TNF receptor, acts on different adaptor 
proteins including TNF-receptor-associated death domain protein (TRADD), 
receptor-interacting protein (RIP) and TNF-receptor-associated factor 2 
(TRAF2). This leads to the activation of IB-kinase (IKK) complex (Lin et al., 
2010). This complex consists of two catalytic subunits named IKK-α and IKK-
β as well as a regulatory subunit known as IKK-ɣ/NEMO (Ghosh and Karin, 
2002). The activated IKK complex phosphorylates IB-α which is then 
ubiquitinated and degraded by the proteosome (Viatour et al., 2005). The free 
NF-B dimmers can then migrate to the nucleus where they regulate the 
transcriptional activation of multiple target genes (Li and Verma, 2002). The 
second pathway, also named the non-canonical pathway, is activated by 
cytokines such as B-cell activating factor (BAFF) (Claudio et al., 2002), 
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lymphotoxin β (Dejardin et al., 2002) or CD40 ligand (Coope et al., 2002). 
This pathway can also be activated by viruses such as human T-cell leukaemia 
virus (Xiao et al., 2001) and Epstein-Barr virus (Eliopoulos et al., 2003). In 
this pathway, NF-B-inducing kinase (NIK) activates an IKKα homodimer 
(ankyrin-containing and inhibitory molecule p100 is its substrate). Upon 
phosphorylation by IKKα, p100 is ubiquitinated and cleaved allowing NF-B 
protein p52 to move as a heterodimer with RelB into the nucleus (Prasad et al., 
2010). Activation of the noncanonical pathway has a major role in the 
regulation of B cell survival and maturation, and in the formation of secondary 
lymphoid organs (Senftleben et al., 2001). The third NF-B pathway is 
triggered by DNA damage induced by mutagenic stimuli such as UV radiation 
or doxorubicin. This pathway is considered atypical as it is independent of IKK 
activation and instead is based on activation of casein kinase 2 (CK2). CK2 
enhances IB-α degradation via the proteosome (Lin et al., 2010). Although 
this pathway has a minor role in normal activation of NF-B, it is thought that 
the pathway may be involved in skin carcinogenesis induced by UV exposure 
(Karin, 2006). 
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Figure 1-4: Different NF-B activation pathways; adapted from (Viatour et al., 2005). 
 
Constitutive IKK activity and high levels of nuclear p65 have been observed in 
inflammatory diseases as well as different solid tumours. This illustrates the 
contribution of NF-B activation in the development of cancer and chronic 
inflammatory diseases. Inhibition of NF-B activity has therapeutic potential in 
the treatment of cancer and inflammatory disorders (Sumitomo et al., 1999, 
Chaturvedi et al., 2011). 
1.7.2 CPPS and delivery of Therapeutic Peptides Targeting NF-B 
As described, aberrant NF-B activity has been associated with the 
development of several diseases as chronic inflammation, auto-immune 
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diseases and certain types of cancer (Orange and May, 2008). This highlights 
this pathway as an exciting target for therapeutic intervention. The 
identification of the components of the pathway and how they interact with 
each other has led to the design of small molecule drugs and macromolecular 
therapeutics that specifically interfere with NF-B activation. This includes 
several approaches aimed at delivering NF-B targeting peptide sequences 
attached to CPPs (Figure 1-5). The strategy is based on using a sequence 
derived from an NF-B protein that inside the cytosol of cells interferes with a 
specific protein-protein interaction regulating the pathway. 
 
Figure 1-5: CPPs-and associated peptide cargos that disrupt the classical NF-B 
pathway; adapted from (Orange and May, 2008). CPPs-cargos targeting the classical 
NF-B pathway are indicated by the circled red “x”. Some are discussed in more detail in the 
text. 
 
Jacek Hawiger and colleagues were the first to design a peptide to interfere 
with NF-B activation. The peptide, SN50, contained the NLS of p50 (N50: 
VQRKRQKLMP) attached to a CPP derived from Kaposi fibroblast growth 
factor (K-FGF). SN50 was found, in cultured monocytic and endothelial cell to 
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block the nuclear translocation of p50/p65 in a dose dependent manner after the 
activation of NF-B pathway with TNF or lipopolysaccharide (LPS) (Lin et 
al., 1995). Nuclear entry of p50/p65 was inhibited due to SN50 binding to the 
importin complex and thereby competitively inhibiting the binding of p50 
(Torgerson et al., 1998). 
Peptides delivered from p65 subunit of NF-B, p65-P1 and p65-P6, have also 
been reported to interfere with the NF-B pathway. Penetratin-p65-P1 and 
penetratin-p65-P6 inhibited cytoplasmic p65 phosphorylation and nuclear 
translocation but had no effect on IB-α phosphorylation and degradation in 
TNF-activated-KBM-5 chronic myeloid leukaemia cells. Penetratin-p65-P1 
(100 µM) suppressed TNF-α-induced NF-B activation by 25% and the 
activation was totally abolished at 150 µM. Penetratin-p65-P1 also inhibited 
NF-B activation induced by different activators such as LPS, interleukin-1 
(IL-1) and others (Takada et al., 2004). Here, penetratin-p65-P1 also 
suppressed NF-B-dependent reporter gene expression induced by TNF-α. 
NEMO Binding Domain peptide (NBD) is a short peptide derived from the 
NBD region of IKKβ corresponding to amino acids 735-745 that disrupts 
NEMO-association with IKKs in vitro and blocks TNF-induced NF-B 
activation in vivo when successfully delivered into cells. The underlined 
sequence in IKKβ (FTALDWSWLQTEEEEHSCLEQAS) is the (NBD). CPPs 
have been used to deliver the NBD peptide in vitro and in vivo. NBD peptide 
(TALDWSWLQTE) fused with penetratin blocked the TNF-α-induced NF-B 
activation in HeLa cells at 100 and 200μM. The inhibitory effect of the NBD 
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peptide was abolished in a mutant peptide where the two tryptophan residues 
(underlined) were replaced with alanine residues (TALDASALQTE) (May et 
al., 2000).  
Tat has also been used to deliver NBD peptide into human polymorphonuclear 
neutrophils (PMNs). Tat-NBD, at 50 and 100μM, showed a high capability to 
block LPS induced NF-B activation thus accelerating apoptosis. This was not 
observed with the W-A mutant peptide (Choi et al., 2003). 
PTD-5-NBD (RRQRRTSKLMKRGGTALDWSWLQTE) was investigated for 
in situ delivery to mouse pancreatic islets where improved islet function was 
observed and IL-1β induced cell death was prevented. As a result, islet 
viability was improved after isolation (Rehman et al., 2003). A cationic CPP 
consisting of eight lysines was also able to transduce NBD peptide into cells 
and tissues (Davé et al., 2007). In a NF-B reporter system, the peptide termed 
8K-NBD inhibited TNF-induced NF-B activation in a dose dependent 
manner. Moreover, it also inhibited the nuclear translocation of NF-B. More 
examples for CPP mediated-NBD delivery will be discussed in section 3.1. 
It should be noted and emphasised here that for all studies using CPPs to 
deliver peptides targeting NF-B, relatively high concentrations (> 50 μM) 
were needed to reach the desired effects. This is much higher than that shown 
to allow CPPs to enter cells and in many cases, this concentration leads to 
direct translocation across the plasma membrane rather than having to depend 
on an endocytic mechanism (Duchardt et al., 2007, Fretz et al., 2007, Watkins 
et al., 2009a). 
Chapter (1) 
 
40 
 
1.8 Epidermal growth factor receptor (EGFR), cancer and CPPs 
1.8.1 Introduction to EGFR 
The EGFR family (also known as type I receptor tyrosine kinases or ErbB 
tyrosine kinase receptors) is composed of four homologous receptors: the 
epidermal growth factor receptor (ErbB1/ EGFR/ HER1), ErbB2 (HER2/neu), 
ErbB3 (HER3), and ErbB4 (HER4). Each receptor is composed of an 
extracellular ligand-binding domain, a transmembrane lipophilic region and 
(bar ErbB3) a cytoplasmic protein tyrosine kinase domain (Olayioye et al., 
2000, Mendelsohn and Baselga, 2000, Riese and Stern, 1998). A group of 
growth factor ligands such as epidermal growth factor (EGF), transforming 
growth factor alpha (TGF-α) and others, bind the extracellular domain of the 
EGF receptor, leading to receptor activation with the exception of HER2 which 
has no known ligands (Olayioye et al., 2000, Nicholson et al., 2001). The 
receptor becomes activated by dimerization of two similar receptors; 
homodimerization, or two different members of the same receptor family; 
heterodimerization (Lemmon and Schlessinger, 1994). Dimerization activates 
the intrinsic kinase activity of the receptors and tyrosine 
transautophosphorylation occurs. This leads to the downstream 
phosphorylation of several intracellular substrates involved in the regulation of 
several signalling cascades (Mendelsohn and Baselga, 2000). ErbB receptors 
are more highly expressed in different tissues of epithelial, mesenchymal and 
neuronal origin and are involved in cellular development, proliferation and 
differentiation. Deregulated expression of ErbB receptors accompanies 
numerous types of human cancer (Olayioye et al., 2000). 
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The overexpression of EGFR can convert a normal cell into a malignant one 
through sustained signals for cell proliferation, angiogenesis, anti-apoptosis 
and metastasis. The extracellular ligand binding domain and the intracellular 
tyrosine kinase have been shown important for EGFR activation. EGFR homo- 
or hetero-dimerization is initiated by the binding of one of the EGF-related 
growth factors (ligands) to the extracellular binding domain. Subsequently, 
autophosphorylation by its kinase domain as well as phosphorylation of other 
cytoplasmic substrates occurs, signalling different cascades of cellular 
responses including proliferation and anti-apoptosis (Sebastian et al., 2006). 
Two major approved potential strategies targeting EGFR family include 
monoclonal antibodies directed towards the extracellular domain of HER2 such 
as Trastuzumab (Herceptin) and small molecule tyrosine kinase inhibitors such 
as gefitinib and erlotinib (Hynes and MacDonald, 2009). 
CPPs have been used to deliver therapeutic cargos targeting EGFR for 
anticancer purposes. A Tat-based Y211 cell penetrating PCNA peptide 
(Y211F;YGRKKRRQRRRGTFALRFLNFFTK) was able to block Y211 
phosphorylation and inhibit the growth of triple-negative and EGFR tyrosine 
kinase inhibitor-resistant breast cancer cells (Yu et al., 2013). Tyrosine 211 
phosphorylation of proliferation cell nuclear antigen (PCNA) coincides with 
pronounced cancer cell proliferation and correlates with poor survival of breast 
cancer patients. RF6 which represents an active motif of the cell penetrating 
PCNA peptide, as a Tat conjugate (YGRKKRRQRRRGRFLNFF), and its 
D-isomer were also toxic in two breast cancer cell lines. The three peptides 
were also active in vivo where they caused a significant reduction in tumour 
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volume in a murine model. In another study, a Tat-derived peptide (P3; 
YGRKKRRQR) was conjugated to an ErbB2-extracellular domain binding 
peptide (AHNP) to specifically target ErbB2-overexpressing breast cancer 
cells. P3-AHNP delivered signal transducers and activators of transcription- 
STAT3BP, a peptide known to inhibit STAT3 signalling that contributes to 
tumour progression, into ErbB2-overexpressing breast cancer cells and inhibit 
tumour growth in vitro and in vivo (Tan et al., 2006). 
1.8.2 EJP-18: A sequence from Juxtamembrane domain with cell 
penetrating properties 
The role of the transmembrane region of EGFR (corresponding to amino acids 
622-644) was initially thought to be a passive anchor of the receptor to the 
membrane. However, it has been found that this region is important in receptor 
association and that EGF-induced dimerization is significantly more efficient 
(at least 10,000 fold higher) for a fragment of EGFR that contains both the 
extracellular and transmembrane domains than it is for a fragment that lacks 
the transmembrane domain (Tanner and Kyte, 1999, Bennasroune et al., 2004). 
This was also supported by the work of Bennasroune et al. who constructed 
expression vectors encoding short fusion peptides encompassing 
transmembrane domains of EGFR, ErbB2 and insulin receptors. In their study, 
the membrane expression of the fusion peptides in human cell lines 
overexpressing EGFR or ErbB2 specifically inhibited the autophosphorylation 
and subsequent signalling of their respective receptor. The juxtamembrane 
(JM) region of EGFR (corresponding to amino acids 645-689) harbours a 
tripartite NLS (RRRHIVRKRTLRR, amino acids 645-657); an NLS 
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containing three clusters (bold) of basic amino acids. A study by Hsu and Hung 
revealed that the tripartite NLS in the EGFR juxtamembrane region is capable 
of mediating nuclear localization of EGFR as well as cytoplasmic proteins such 
as pyruvate kinase tagged with a green fluorescent protein (GFP) (Hsu and 
Hung, 2007). 
From all of the above, an interesting sequence from the JM domain region was 
investigated in the lab for possible therapeutic and delivery purposes. The 18 
amino acid sequence was given the name EJP-18 
(LFMRRRHIVRKRTLRRLL) and corresponds to EGFR amino acids 642-659. 
This peptide, and derivatives of, were studied in detail in this thesis, focusing 
on their interaction with cells and capacity to deliver associated cargo 
(Chapters 4-6).  
1.8.3 Bioportides 
To exert a biological action, CPPs are conjugated either covalently or non-
covalently with bioactive cargos including peptides, proteins, and nucleotides. 
However, the term bioportide has been introduced to describe peptides that in 
their own right are able to enter cells and mediate a biological response. This is 
significantly different from the normal strategy of attaching a CPP to a peptide 
cargo to enhance delivery (Howl and Jones, 2008). In 2005, Hallbrink et al., 
proposed a quantitative structure activity relationship (QSAR) to predict 
polycationic CPP motifs from the primary sequences of proteins (Hällbrink et 
al., 2005). The QSAR prediction algorithm was subsequently employed to 
predict CPPs and also bioportides within the human cytochrome c protein. Two 
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bioportides; Cyt c
77-101
 (H-GTKMIFVGIKKKEERADLIAYLKKA-NH2)
 
and 
Cyt c
86-101
 (H-KKKEERADLIAYLKKA-NH2) were shown to enter  cells and 
induce apoptosis through DNA fragmentation (Howl and Jones, 2008). 
Camptide and nosangiotide are two bioportides derived respectively from the 
human type 1 calcitonin receptor (hCTR-1) and the calmodulin binding domain 
of endothelial nitric oxide synthase (eNOS). Camptide was able to modulate 
hepatitis C infectivity in hepatoma cells and insulin secretion from isolated rat 
pancreatic islets. Nosangiotide was found to be a potent anti-angiogenic agent 
(Howl et al., 2012). Bioportides clearly are interesting alternatives to 
conventional CPP-peptide chimeras and are discussed later in chapters 4 and 7 
in conjunction with studies involving EJP-18. 
1.9 Hypothesis underlying this thesis 
Understanding the mechanism by which CPPs associate with cells and enter 
cells is fundamental to their transition from the in vitro to the in vivo setting. 
New CPP sequences need to be investigated as alternatives to identified 
variants that to date have not fulfilled their promise.  
The hypothesis for this study is: 
Identifying new peptide sequences with cell penetrating properties or 
modifying existing CPP sequences can be used to more effectively deliver 
therapeutic entities or act as bioactive components or bioportides. 
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1.10 Aim of thesis 
The overall aim of this thesis is to expand our knowledge on CPPs and their 
cargo delivery capacity as well as identifying new sequences with cell 
penetrating capacities. This will be achieved through the following: 
- Characterisation of the capacity of penetratin to deliver a therapeutic 
peptide targeting NF-B signalling pathway. This will include 
developing in vitro protocols for analysing NK-B activation and 
inhibition. 
- Characterising new peptide sequences derived from the JM domain of 
EGFR for cell penetrating capacity and assessing their toxicity in a 
panel of cancer cell lines. 
- Assessing the effectiveness of these EGFR derived sequences as 
delivery vectors for small molecular weight cargo, proteins and 
nucleotides.  
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2 Chapter 2: Materials and Methods 
2.1 Materials 
Tissue culture plasticware was manufactured by Corning® and supplied by 
Fisher Scientific (Loughborough, UK). Laboratory disposables and organic 
solvents were also purchased from Fisher Scientific. Details of experimental 
materials, associated suppliers and relevant catalogue numbers are provided in 
Appendix A and therefore are omitted from this Chapter. General usage 
chemicals and reagents were supplied by Sigma-Aldrich (Poole, UK) unless 
otherwise mentioned in Appendix A. Cell lines and plasmids that were gifts to 
the laboratory are stated in the text, along with the source. The peptides used 
throughout this thesis are listed in Table 2-1. 
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Table 2-1: List of peptides used in this thesis. 
 
Peptide Origin Sequence 
Mass 
unlabelled 
Mass 
Rhodamine 
labelled 
Penetratin 1 NH2-DRQIKIWFQNRRMKWKK-COOH 2361 - 
Penetratin- 
NBD 
1 NH2-DRQIKIWFQNRRMKWKKTALDWSWLQTE-COOH 3692 - 
EJP-18 2 Ac-LFMRRRHIVRKRTLRRLL-NH2 2462.13 2832.55 
EJP-21 2 Ac-LFMRRRHIVRKRTLRRLLQER-NH2 2875.56 3245.97 
E-64562 2 Ac-RRRHIVRKRTLRRLLQER-NH2 2484.03 2854.44 
R8 2 Ac-RRRRRRRR-NH2 1308.58 1678.99 
R8-GC 3 NH2-RRRRRRRRGC-COOH 1427.7 - 
(1) Imgenex, (2) EZ-biolab and (3) American peptide company 
(2) NBD, NEMO binding domain  
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2.2 In vitro procedures 
2.2.1 General cell culture 
All tissue culture procedures were carried out in a class II laminar flow hood 
after decontamination of all sterilised consumables with 70% ethanol solution. 
All cells were maintained at 37ºC with 5% CO2 in a humidified incubator. 
Routinely (3 months), all cell lines in the laboratory were tested for 
mycoplasma using a LookOut
®
 Mycoplasma PCR Detection Kit (Sigma) 
(Wymant, 2014). 
2.2.2 Cell lines 
A number of suspension and adherent cell lines were studied during this 
project. These are cell lines routinely used in the laboratory for CPP and other 
studies. HeLa and KG1a cell lines have been extensively used as cell models 
for CPP research in the Jones laboratory. 
2.2.2.1 Suspension cells (non-adherent cells) 
KG1a; acute myeloid leukaemia (AML), cells were obtained from European 
Collection of Authenticated Cell Cultures (ECACC). 
2.2.2.2 Adherent cells 
HeLa cervical cancer cells from two sources were used in this thesis. HeLa 
used in Chapter 3 were obtained from the European Molecular Biology 
Laboratory (Simpson et al., 2004). In subsequent chapters, HeLa cells used 
were purchased from the American Type Culture Collection (ATCC).  
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NF-kB Luciferase Reporter HeLa stable cell line was a kind gift from Professor 
Michael Taggart (Newcastle University) and originally obtained from Signosis 
(California, USA, # SL-0001). 
Low passage (P9) MCF-7 and MDA-MB-231 breast cancer cells were a kind 
gift from the Breast Cancer Molecular Pharmacology Group (BCMPG) at the 
Cardiff School of Pharmacy and Pharmaceutical Sciences. The authenticated 
cells were donated to the group by AstraZeneca or purchased from the ATCC. 
A431 epidermal cancer cells were a kind gift from Dr Elaine Ferguson, School 
of Dentistry, Cardiff University. 
2.2.3 Media 
KG1a, MCF-7 and MDA-MB-231 cells were cultured in Roswell Park 
Memorial Institute medium (RPMI) supplemented with 10% Foetal Bovine 
Serum (FBS), 100 U/mL penicillin and 100 µg/mL streptomycin. HeLa and 
A431 cells were maintained in Dulbecco’s Modified  agle Medium (DM M) 
supplemented with 10% FBS, 100 U/mL penicillin and 100 µg/mL 
streptomycin. HeLa NF-B Luciferase Reporter HeLa stable cells were 
maintained in the same medium used for HeLa but with the addition of 100 
µg/mL hygromycin.  
2.2.4 Maintenance 
2.2.4.1 Routine maintenance 
The cells were passaged every 3-5 days. For adherent cells: cells were washed 
with phosphate buffered saline (PBS) then incubated for 3 min with 0.05% 
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trypsin/ethylenediaminetetraacetic acid (EDTA) to detach the cells. A431 
required longer incubation with trypsin ( 10 min) for complete detachment. 
After trypsinisation, the cells were collected in 10 mL of culture medium then 
centrifuged at 900 x g for 3 min. For non-adherent cell line, cells were directly 
centrifuged at 900 x g for 3 min. 
For both adherent and non-adherent cell lines, the supernatant was then 
aspirated and the pellet was resuspended in 5 mL fresh, pre-warmed medium. 
1-2 mL of cells was then transferred to a new T-75 flask. 
All experiments were carried at passage number below 30 and in antibiotic free 
medium, other than HeLa NF-B Luciferase Reporter HeLa stable cell line that 
is cultured in hygromycin. 
2.2.4.2 Cryogenic freezing of cells 
Stocks of cells were produced by freezing down 70% confluent cells in 
freezing medium. Freezing medium for all cell lines contained 20% FBS and 
5% dimethyl sulphoxide (DMSO) except for KG1a: 32% FBS and 8% DMSO. 
Before freezing, cells were centrifuged, the supernatant was removed and cells 
were resuspended in the appropriate volume of freezing medium to yield a cell 
density of 1 x 10
6
 viable cells/mL. One mL aliquots of cell suspension were 
then transferred to sterile cryogenic vials. The cryovials were frozen in a Mr. 
Frosty
TM
 freezing container filled with isopropanol at -20ºC for 5 h then at -
80ºC overnight before being transferred to liquid nitrogen for long-term 
storage.  
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2.2.4.3 Cell recovery from cryogenically frozen stocks 
Cryogenic vials were thawed in the water bath at 37ºC and were then 
immediately transferred into a sterile centrifuge tube containing 9 mL 
pre-warmed culture medium and centrifuged at 900 x g for 3 min. The 
supernatant was aspirated and the pellet resuspended in 5 mL culture medium 
and transferred into T-25 flask with the medium being changed every 2 days. 
The cells were then seeded into T-75 flasks.   
2.2.4.4 Determination of cell number and viability 
To determine viable cell numbers prior to seeding for in vitro experiments, 
trypan blue exclusion assay and haemocytometer counting were used. Trypan 
blue is membrane-impermeable in viable cells and can therefore only penetrate 
and stain dead cells. During cell counting, blue-stained (dead) cells were 
therefore excluded from counting. To determine the number of viable cells, 20 
μL of cell suspension was mixed with an equal volume of Trypan blue (0.2% 
v/v in PBS). A coverslip was mounted onto the haemocytometer and 
approximately 10 μL was applied under the edge of the coverslip. The slide 
was placed under an inverted light microscope and viable cells were counted in 
each quadrant. The average of 4 quadrants was determined and the cell density 
(number of cells/mL) was calculated using the following equation: 
Cell density = mean number of cells per quadrant x dilution factor x 10
4 
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2.3 Cell viability assay 
Cell viabilities were determined using the CellTiter-Blue® assay in accordance 
with manufacturer’s instructions (section 2.3.1 and 2.3.2). The assay depends 
on the fact that viable cells have the ability to convert the nonfluorescent redox 
dye named resazurin into a fluorescent end product, resorufin. Resazurin acts 
as an intermediate electron acceptor in the electron transport chain that takes 
place between the final reduction of oxygen and cytochrome oxidase through 
the exchange of molecular oxygen. Table 2-2 shows the tested compounds, 
range of concentrations and cell lines used in each case. The diluent control of 
all tested compounds was distilled water unless otherwise stated. 
Table 2-2: List of tested compounds for cell viability, range of concentrations 
evaluated and cell lines used for each compound. 
Tested Compounds Concentrations Cell lines tested 
D-Nu-BCP-9-r8 and r8 0.005-20 μM MCF-7 and KG1a 
*Penetratin-NBD and 
penetratin 
0.2-50 μM 
HeLa**, MCF-7 
and KG1a 
TNF 0.1-20 ng/mL 
HeLa, MCF-7, 
MDA-MB-231 and 
KG1a 
EJP-18, EJP-21, E-64562, 
R8 and their rhodamine 
conjugates*** 
0.1-100 μM 
HeLa, MCF-7, 
MDA-MB-231, 
A431 and KG1a 
peptides/labelled bovine 
serum albumin (BSA-
Alexa 647) complexes 
10 μM peptide/10 
μg/mL BSA-Alexa 
647 
HeLa 
* The diluent control was DMSO 
** 100 μM was also tested for HeLa cells 
*** R8 and rhodamine conjugates of R8, EJP-21 and E-64562 were only tested 
in HeLa cells 
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2.3.1 CellTiter-Blue assay in non-adherent cells 
KG1a cells (1.5 x 10
4 
cells/well in a total volume of 100 μL) were seeded in 
black 96-well plates in complete medium (media supplemented with 10% 
FBS).  A number of different compounds were tested across a range of 
concentrations (listed in Table 2-2). Cells were incubated under tissue culture 
conditions (37ºC, 5% CO2) with the compounds, or diluent controls, diluted in 
complete medium for a total period of 24 h. After 20 h incubation, 20 μL of 
CellTiter-Blue reagent was added per well and the plates were returned to the 
incubator for 4 h. Fluorescence (544Ex/590Em) was measured using a Fluostar 
Optima Fluorescent plate reader. The percent of cell viability was then 
calculated using the following equation: 
               
                                        
                                           
      
Where: 
F = fluorescence 
Background = fluorescence of medium alone 
Positive control= fluorescence of untreated cells 
2.3.2 CellTiter-Blue assay in adherent cells 
Cells were seeded at suitable density (listed in Table 2-3) in black 96-well 
plates in complete medium and were incubated overnight at 37ºC, 5% CO2. 
The following day, cells were treated with a range of concentrations of tested 
compounds. Cells were incubated with the compounds for 24 h (37ºC, 5% 
CO2). In case of peptide/BSA-Alexa647 complexes, cell viability was also 
evaluated after 72 h incubation. The following day, 20 μL of CellTiter-Blue 
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reagent was added to each well and the plates were returned to the incubator. 
Fluorescence intensity was measured and cell viability was calculated as 
described in section 2.3.1. 
Table 2-3: Seeding density of different cell lines in 96-well plate for Cell-Titer 
Blue assay  
Cell Line Cell Density (cells/well) 
HeLa 8 x 10
3
  
MCF-7 2.5 x 10
3
 
MDA-MB-231 2 x 10
3
 
A431 2 x 10
4
 
 
2.4 Microscopy 
2.4.1 Confocal microscopy 
Confocal fluorescence microscopy analysis was performed on a Leica SP5 
inverted confocal laser scanning microscope. The microscope was equipped 
with a 63x, 1.4 NA oil-immersion objective and 405, 488, 543 and 633 nm 
lasers. Gain and offset settings were optimised for each fluorescent channel 
within a single experiment but kept consistent throughout each experiment. 
Sequential scanning mode was used to record images to prevent channel 
crosstalk/bleedthrough. Images were scanned at 400 or 700 Hz with a line 
average of three to reduce noise. Live cell imaging was performed to exclude 
any fixation artefacts and maximal projection images were taken through 
z-axis. For single section images, the midpoint was identified by initial 
scanning of the cells through the z-axis and identifying the central section. 
Where Hoechst is employed as a nuclear marker, the midpoint most often 
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represents the section that contains the largest nuclear area. Complete 
microscope and image acquisition settings can be found in Appendix B (Table 
B-1). For live cell imaging experiments performed at 37˚C, the imaging dishes 
were housed on the microscope temperature control stage set to 37˚C. The 
maximum excitation and emission wavelengths of the fluorophores used are 
listed in Table 2-4. 
After acquisition, images were analysed in ImageJ software to create single 
sections or max projections, for adding scale bars and performing 
colocalisation analysis based on Pearson’s coefficient (Moody et al., 2015). 
Brightness and contrast were adjusted consistently within an experiment 
(where required) so that images can be compared directly.  
Table 2-4: List of fluorophores used with their maximum excitation and 
emission wavelengths. 
Fluorophore Maximum Excitation 
(nm) 
Maximum Emission 
(nm) 
Tetramethylrhodamine* 554 578 
Alexa 488 494 519 
Alexa 647 651 671 
Indodicarbocyanine 
(Cy5) 
650 670 
DRAQ7 599/646 678/694 
Hoechst 33342 350 450 
*From here on in tetramethylrhodamine is referred to as Rhodamine or Rh. 
All confocal microscopy studies were performed in HeLa cells as a well 
characterised CPP-in vitro model in our laboratory. Rhodamine labelled 
peptides were used for peptide uptake and colocalisation studies. In some 
cases, unlabelled peptides were mixed with cargo (siRNA, Protein) labelled 
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with one of the fluorophores listed in Table 2-4. Information on these is 
presented in subsequent sections. 
All experiments were performed three times, unless otherwise stated in the 
figure legends, and representative images from one experiment is shown.  
2.4.1.1 Cellular uptake of Rh-labelled peptides 
Cells (2.5 x 10
5
) were seeded into 35 mm MatTek dishes and incubated 
overnight in complete medium at 37ºC, 5% CO2. The following day, the 
medium was aspirated and the cells were washed three times with serum free 
medium (SFM) or complete medium according to experiment type. A range of 
concentrations (1-20 μM) of Rh-peptides were added to the cells in a total 
volume of 200 µl in the imaging region of the dish. The dishes were then 
returned to tissue culture conditions for 1 h. The medium was then aspirated 
and the cells were washed three times with imaging medium (phenol red free 
DMEM supplemented with 20 mM HEPES pH 7.4 and 10% FBS). Imaging 
medium (500 μL) was added to the cells and live cells were immediately 
visualised by confocal microscopy. When nuclei were needed to be visualised 
during the experiment, imaging medium (500 μL) was supplemented with 0.5 
μL of 10 mg/mL Hoechst before and during imaging. To test membrane 
integrity of cells, 2.5 μL of DRAQ7 (0.3mM) (instead of Hoechst) was added 
to the imaging medium. 
2.4.1.2 Uptake of 10 μM Rh-peptides at different temperatures 
Cells (2.5 x 10
5
) were seeded and incubated as described in section 2.4.1.1. The 
following day, they were incubated with 10 μM Rh-peptides in 200 μL of SFM 
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at either 4ºC (on ice) or 37ºC in the tissue culture incubator. After 1 h 
incubation, the medium was aspirated and the cells were washed as previously 
described. Imaging medium (500 μL) containing 0.5 μL Hoechst (10 mg/mL 
stock) was added and live cells were visualised immediately by confocal 
microscopy. 
2.4.1.3 Uptake of BSA-Alexa488/647 alone or complexed with peptides 
Cells (2.5 x 10
5
) were seeded and incubated as described in section 2.4.1.1. The 
following day, BSA-Alexa488/647 were incubated with cells alone or 
complexed with peptides. Peptide/BSA-Alexa488/647 complexes were formed 
by incubating 2, 5 or 10 μM peptide with 10 μg/mL BSA-Alexa488/647 for 30 
min at 37ºC in distilled water (total volume 50 μL). Complexes were then 
diluted 1 in 4 in SFM or complete medium and incubated with cells for 1 h at 
37ºC. Cells were then washed and imaging medium was added as previously 
described in section 2.4.1.1. Live cells were visualised immediately by 
confocal microscopy. For all experiments, BSA-Alexa488/647 treated as above 
with diluent (distilled water) was incubated with cells to determine the effect of 
peptide on cell uptake. 
2.4.1.4 Uptake of EJP-18/Cy5-Cav-1 siRNA and 
oligofecatmine/Cy5-Cav-1 siRNA complexes 
Cells (2.5 x 10
5
) were seeded and incubated as described in section 2.4.1.1. The 
following day, cells were treated with EJP-18 complexed with Cy5-siRNA 
targeting caveolin-1 (Cav-1) or oligofectamine/Cy5-siRNA complexes in 200 
μL  pti-MEM at 37ºC for 3 h. EJP-18/Cy5-siRNA complexes were formed by 
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mixing a fixed concentration of Cy5-siRNA, 50 nM or 100 nM, with increasing 
concentrations of peptide to achieve different molar ratios (peptide/cargo) in 
Opti-M M (total volume = 50 μL). Molar ratios and volumes for 50 nM and 
100 nM Cy5-siRNA are listed in Appendix C (Tables C-1 and C-2 
respectively). Complexes were diluted 1 in 4 in Opti-MEM and incubated with 
cells for 3 h at 37ºC before being washed and imaged as live cells as described 
in section 2.4.1.1. For oligofectamine/50 nM Cy5-siRNA complexes, 1 μL of 
10 μM stock Cy5-siRNA was diluted in 99 μL  pti-M M and 0.8 μL 
oligofectamine was diluted in 99.2 μL  pti-MEM in two separate eppendorfs. 
The diluted Cy5-siRNA and diluted oligofectamine were then combined and 
mixed gently and incubated at room temperature for 30 min and then incubated 
with cells as described earlier. Double the amounts of both Cy5-siRNA and 
oligofectamine were used for 100 nM Cy5-siRNA complexes. 
5´-Cy5-Caveolin-1 siRNA sequence (MWG sequence) 
Sense sequence 5´ Cy5-AGACGAGCUGAGCGAGAAG-3´ 
 
2.4.1.5 Colocalisation studies of Rh-peptides with Dextran-Alexa488 
Cells (2.25 x 10
5
) were seeded into 35 mm MatTek imaging dishes and 
incubated in complete medium at 37ºC, 5% CO2. After 4-6 h, 150 μL of 0.1 
mg/mL dextran-Alexa488 were added to the cells that were returned to the 
incubator for 2 h. The cells were then washed 3-4 times with complete medium 
to remove any traces of dextran-Alexa488 and the cells were then incubated 
with 1.5 mL complete medium overnight at 37ºC and 5% CO2. Following this 
overnight chase of dextran-Alexa488 through the endocytic system to terminal 
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lysosomes, 40 μL of 50 μM stock Rh-peptides were added to 160 μL SFM (the 
final concentration of the peptide is 10 μM) and incubated with the cells for 1 
h. Cells were then washed three times with imaging medium and visualised 
immediately by confocal microscopy using the 488 and 543 lasers. 
Rhodamine-Alexa488 colocalisation was also measured after the Rh-peptides 
were similarly incubated with the cells for 1 h and then chased for a further 
hour in peptide free medium. Images were processed using ImageJ as described 
in section 2.4.1. and colocalisation values were obtained using Pearson 
Coefficient analysis as described in Moody et al. (Moody et al., 2015). 
2.4.1.6 Colocalisation studies of peptides/BSA-Alexa647 complexes with 
Dextran-Alexa488 
Cells (2.25 x 10
5
) were seeded and treated with dextran-Alexa488 as described 
in section 2.4.1.5. Following the overnight dextran-Alexa488 chase, complexes 
of peptides/BSA-Alexa647 were prepared and diluted as described in section 
2.4.1.3. The complexes were added to the cells and incubated for 1 h. Cells 
were then washed three times with imaging medium and visualised by confocal 
microscopy using the 488 and 633 lasers. Colocalisation was also measured 
after the complexes were similarly incubated with the cells for 1 h and then 
chased for a further hour in complex free medium. Images were processed and 
colocalisation values were obtained as described in section 2.4.1.5. 
2.4.2 Wide field system microscopy (for eGFP expression in HeLa cells)  
Wide field microscopy analysis was performed using a Leica DMIRB inverted 
microscope equipped with a 10 x 0.25 NA objective. Microscope settings can 
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be found in Appendix B (Table B-2). The system operates on Openlab 5.5.0 
software and captured samples were processed using ImageJ. 
2.5 Western blotting 
2.5.1 Cell culture 
HeLa cells were seeded in 6 or 12-well plates and grown in complete medium 
overnight at 37ºC and 5% CO2. Cells were then subjected to one of several 
different experimental procedures as described in the next section and section 
2.9.1. Seeding densities (per well) in 6-well plates for different treatments 
(experiments) were as follows: 
TNF-α stimulation (in absence and presence of peptides): 250,000 cells  
siRNA transfection: 180,000 cells. 
For all experiments the cells were 70-80% confluent at the point of lysate 
collection. Seeding densities were adjusted accordingly when 12 well plates 
were used. 
2.5.1.1 TNF-α treatment in the absence and presence of peptides 
HeLa cells were plated overnight in CM. The following day, they were serum 
starved by overnight incubation in DMEM supplemented with 0.1% FBS (low 
serum medium) or incubated in complete medium. The cells were then 
incubated with TNF-α as described in Chapter 3. In the case of peptide 
(penetratin and penetratin-NBD) treatments, cells were incubated overnight in 
CM then preincubated with peptides for 3 h in medium containing 0.1% FBS 
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prior to addition of TNF-α. Lysates were then collected and prepared for 
analysis of IB-α degradation as described in sections 2.5.2 - 2.5.7. In this 
section, data presented as N=1 describe experiments performed to confirm 
information provided in the literature. 
2.5.1.2 Determination of EGFR levels in cancer cell lines 
For adherent cell lines (HeLa, A431, MCF-7 and MDA-MB-231), cells were 
grown to 70% confluency in T-75. The medium was aspirated and the cells 
were washed three times with PBS. Lysis buffer 0.5 mL (plus protease 
inhibitors) was added on ice and the cells were scraped from the flask surface. 
The flask content was transferred to an eppendorf tube and kept on ice for 5-15 
minutes then centrifuged (13,800 x g 4ºC) for 15 minutes. The supernatant was 
then transferred to a clean eppendorf. For non-adherent KG1a cells, the total 
volume of a T-75 flask was transferred to a 15 mL centrifuge tube, centrifuged 
at 900 x g and then resuspended in 5 mL fresh medium. A volume containing 1 
x 10
6
 cells was then centrifuged and resuspended in 1.5 mL medium and 
transferred into an eppendorf. This was centrifuged (900 x g) then the 
supernatant was discarded and the pellet was resuspended in PBS, re-
centrifuged and resuspended in PBS one more time before resuspending the 
pellet in lysis buffer (620 μL). After 5-15 minutes, the eppendorf was 
centrifuged (13,800 x g 4ºC) and the supernatant was collected. Following 
lysate collection and protein quantification, 20 μg of protein was loaded on 
10% precast gel. Proteins were then transferred to polyvinylidene fluoride 
(PVDF) membranes and EGFR was detected via immunoblotting and ECL as 
described in sections 2.5.5-2.5.7. 
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2.5.2 Lysate collection and preparation 
2.5.2.1 Lysate collection 
According to each experiment, the cell culture plates were placed on ice and 
the medium was aspirated from the wells. The cells were then washed twice 
with ice-cold PBS. Lysis buffer (150 mM NaCl, 50 mM Tris base pH 8.0, dH20 
and 1% Triton X-100 including protease inhibitor) was added to each well (60-
80 μL) and the plates were placed on ice on a lateral, circular shaker for 5 min. 
The cells were then scraped off the wells and the cell suspension was pipetted 
into pre-cooled eppendorfs. Samples were then centrifuged (13,800 x g 4ºC) 
for 10 min. The eppendorfs were then returned to ice and the supernatant was 
transferred to fresh, pre-cooled eppendorfs.  
2.5.2.2 Bicinchoninic acid assay (BCA assay) 
The protein concentration of each sample was determined by BCA assay. BSA 
protein standards were prepared in lysis buffer in concentrations 0, 0.2, 0.4, 
0.6, 0.8 and 1 mg/mL. Cell lysates were diluted 1:6 for the sample absorbance 
measurement to fit in the linear range of the assay. The BCA working solution 
was prepared by mixing 49 parts of biochoninic acid with 1 part copper 
sulphate pentahydrate. This working solution (200 μL) was pipetted into a flat-
bottomed 96 well plate and 10 μL of the standards/samples were added per 
well. The standards were added in duplicates and the samples in triplicates. The 
plate was incubated at 37º for 30 min before the absorbance was measured at 
562 nm on a plate reader.  
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A calibration curve was constructed by plotting the absorbance measurements 
against the known BSA standard concentrations. The equation of the line that 
best fits the calibration graph was then used to calculate unknown sample 
concentrations (allowing for the dilution factor). 
2.5.2.3 Lysate preparation for polyacrylamide gel electrophoresis 
(PAGE) 
Sample concentrations from BCA assays were equalised using lysis buffer. 
Four times strength (4 x) loading buffer (8% sodium dodecyl sulphate (SDS), 
40% glycerol, 0.008% bromophenol blue, 0.25 M Tris-HCL and newly 
prepared 2M dithiothreitol (DTT to give a concentration of 400 mM) were 
added in the ratio of 3 parts sample: 1 part buffer. The samples were then 
denatured by heating on a heating block at ≥ 95ºC for 5 min. Samples were 
returned to ice to cool then centrifuged at 13,800 x g for 30 s at 4ºC to pellet 
debris. Samples were stored at -20ºC. 
2.5.3 Standard SDS-PAGE gel preparation 
Precast Mini-PROTEAN TGX
TM
 gels were used for SDS-PAGE for the 
experiments in this thesis except for chapter 3 in which the gels were freshly 
prepared on the day of experiment according to the recipes in Tables 2-5 and 
2-6.  
The gels were cast and run using a BioRad Mini-Protean II SDS-PAGE 
assembly system. The front and back plates were assembled in the clamp frame 
and secured into the casting stand. The resolving gel was prepared according to 
the following recipe table (TEMED was added last): 
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Table 2-5: Resolving gel recipes for 10% and 12% acrylamide gels 
Contents 10% gel 12% gel 
40% 
acrylamide/Bis 
2.5 mL 5 mL 3 mL 6 mL 
3M Tris pH 8.8 1.25 mL 2.5 mL 1.25 mL 2.5 mL 
10% SDS 100 μL 200 μL 100 μL 200 μL 
dH2O 6.10 mL 12.2 mL 5.6 mL 11.2 mL 
10% APS (freshly 
prepared) 
75 μL 150 μL 75 μL 150 μL 
TEMED 7.5 μL 15 μL 7.5 μL 15 μL 
Total volume of 
gel 
10 mL 20 mL 10 mL 20 mL 
 
Once TEMED has been added, the resolving gel contents were quickly mixed 
by inverting the capped universal tube. The mixture was then poured into the 
casting mould leaving a 2.5 cm gap at the top which was then filled with 100% 
isopropanol.    
The resolving gel was allowed to set for 45 min. Once the gel had solidified, 
isopropanol was discarded and the gap at the top was gently washed eight 
times with dH2O. Meanwhile, the stacking gel was then prepared using the 
following recipe table: 
Table 2-6: Stacking gel recipes for 2 gels 
Contents 4% gel 
40% acrylamide/Bis 1 mL 
3M Tris pH 6.8 1.3 mL 
10% SDS 100 μL 
dH2O 7.22 mL 
0.1% Bromophenol blue 300 μL 
10% APS (freshly prepared) 75 μL 
TEMED 10 μL 
Total volume of gel 10 mL 
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The gel contents were mixed by inversion and the mixture was added on top of 
the set resolving gel and the well comb was positioned at the top of the 
stacking gel. The stacking gel was allowed to polymerise for 30 min before the 
comb was removed. The gels (in their casting plates and clamps) were 
transferred to the running tank and immersed in running buffer (385 mM 
glycine, 250 mM Tris base and 0.5% SDS) ready for sample loading. 
2.5.4 Sample loading and SDS-PAGE 
Protein (15-20 μg) from each sample was loaded onto a 4% acrylamide 
stacking gel using gel loading tips. Protein standard molecular weight marker 
(8-10 μL) was loaded in most cases onto the outermost wells. The gels were 
run at 100V for 85 min or until the sample was visible at the end of the gel. 
The glass plate was pulled apart and the gel was carefully removed and placed 
into a container and rinsed with dH2O. 
2.5.5 Protein transfer and Ponceau staining 
Proteins were transferred to a PVDF membrane at 100 V for 1 h at 4ºC. 
Initially the gel was equilibrated for 5 min in transfer buffer (150mM glycine, 
20 mM Tris-base and 20% methanol) cooled to 4ºC. The transfer cassette was 
placed into a container filled with cold transfer buffer. An ice unit was placed 
in the tank to cool down the transfer system to ensure efficient transfer. The 
transfer sandwich was assembled in order of sponge, blotting paper, gel, PVDF 
membrane, blotting paper and sponge. Prior to assembly, the PVDF membrane 
was soaked in 100% methanol for 1 min before immersion in transfer buffer 
for 10 min and all other components were equilibrated in cold transfer buffer 
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for 10 min. The tank containing the electroblotting apparatus was filled with 
pre-cooled transfer buffer and a magnetic stirrer was placed at the bottom of 
the tank to evenly circulate any heat generated during transfer. Following 
transfer, the PVDF membrane was removed and rinsed with dH2O before being 
immersed in ponceau S solution to visualise transferred protein. The membrane 
was returned to dH2O and the staining was checked to ensure even transfer and 
sample loading. The membrane was cut into strips to separate light and heavy 
weight proteins. The positioning of the cut was dependent on the molecular 
weight of the protein analysed versus the loading control. The Ponceau solution 
was recycled and the membrane was washed 4 x 5 min in PBS until the red 
Ponceau stain had been removed.  
2.5.6 Protein detection by immunoblotting 
The membrane strips were incubated for 1 h at room temperature with 5% milk 
in PBS containing 0.025% Tween20 (PBST) to block non-specific binding 
sites. The milk was then discarded and the strips were incubated for 1 h with 
primary antibodies, listed in Table 2-7, diluted in 2% milk in PBST overnight 
at 4°C.  
The following day, membrane strips were washed 3 x 5 min in PBST prior to 1 
h incubation at room temperature on an orbital rotator with the appropriate 
secondary antibody (listed in Table 2-7), diluted in 2% PBST. Secondary 
antibody incubation was performed at room temperature on the rotator. The 
membranes strips were washed 3 x 5 min in PBST before development (section 
2.5.7).  
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Table 2-7: Primary and secondary antibodies and dilutions for Western blotting 
Primary antibodies Dilution 
Secondary antibodies 
(all Pierce) 
Dilution 
Mouse anti-Tubulin 
(#T9026, Sigma) (Al 
Soraj et al., 2012) 
1:2000 
Goat anti-mouse HRP 
(#32430, 
Thermoscientific) 
1:2000 
Rabbit anti-IKB-α      
(#sc-847, Santa Cruz 
Biotechnology) 
(Aldieri et al., 2003) 
1:200 
Goat anti-rabbit HRP 
(#32460, 
Thermoscientific) 
1:10,000 
Rabbit anti-
GADPH(#2118S, 
Cell Signalling) (Hou 
et al., 2011) 
1:1000 Goat anti-rabbit HRP 1:2000 
Rabbit anti-EGFR 
(#HPA018530, 
Sigma) (Arabi et al., 
2012) 
1:1000 Goat anti-rabbit HRP 1:2000 
Rabbit anti-Caveolin-
1 (#3238S, Cell 
Signalling) (Al Soraj 
et al., 2012) 
1:1000 Goat anti-rabbit HRP 1:2000 
Rabbit anti-PAK-1 
(#2602S, Cell 
Signalling) 
(Williamson and 
Bass, 2015) 
1:200 Goat anti-rabbit HRP 1:2000 
Mouse anti-β-tubulin 
HRP conjugated (# 
AB21058, Abcam) 
(Castro-Diaz et al., 
2014) 
1:50,000 -  
 
2.5.7 Enhanced chemiluminescence detection of transferred proteins 
Equal volumes of enhanced chemiluminescence (ECL) reagents were mixed 
together then added to the PVDF membrane strips and left for 5 min. Clarity
TM
 
Western ECL was used for the majority of Western blotting procedures but 
SuperSignal West Femto was used for low level expression (where indicated). 
The PVDF membrane strips were gently shaken to remove excess solution and 
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wrapped in cling film. The membranes were then either imaged using a BioRad 
ChemiDoc system or were placed inside a developer cassette and transferred to 
the dark room for imaging with ECL hyperfilm that was then processed in an 
x-ray developer. 
2.5.8 Band intensity quantification using ImageJ 
Band intensities were quantified using the gel analyzing tool in ImageJ to 
obtain the average intensity of each band. The values were exported to excel 
where they were normalised against the loading control. For full experimental 
procedure see (Wymant, 2014). 
2.6 Native PAGE under non-reducing conditions 
These gels were used to investigate the electrophoretic migration of 
peptide/protein complexes. They were prepared as described in section 2.5.3 
with some modifications. Here, DTT was removed from the sample buffer only 
and SDS was excluded from the sample buffer, reagents used to make the 
resolving and stacking gels and also the running buffer. The heat denaturing 
step following the addition of the sample buffer was also omitted. Gel running 
also was performed as described in section 2.5.4. 
2.7 Agarose gel electrophoresis 
2.7.1 Gel preparation 
A gel casting tray was cleaned with dH2O and autoclave tape was fixed at both 
ends. Agarose gels (0.8, 1or 2%) were prepared according to the molecular 
weight of the studied components. To prepare a 1% gel, 1 g of agarose was 
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dissolved in 100 mL 0.5 x Tris-Borate/EDTA (TBE) from a 10 x TBE stock 
solution composed of 54 g Tris Base, 27.5 g boric acid, 40 mL of 0.25 M 
EDTA made up to 1 L with dH2O. The agarose-TBE mixture was microwaved 
for 6 x 30 s on full power to dissolve the agarose and destroy any nucleases. 
The mixture was gently swirled between each heating interval to ensure even 
heat distribution and mixing. The solution was allowed to cool for 3 min before 
50 μL of 5 mg/mL ethidium bromide was added and the solution was poured 
into the gel casting tray. The ethidium bromide was omitted when the gels were 
analysed for protein visualisation only. A well comb was placed into the liquid 
agarose and the gel was left to set in the electrophoresis tank for 40 min. Once 
solidified, the comb and autoclave tape were removed and the electrophoresis 
tank was filled with 0.5 x TBE running buffer ensuring complete coverage of 
the gel. 
2.7.2 Peptide/cargo complex preparation 
EJP-18 was complexed with different cargos including BSA-Alexa647, two 
different siRNA sequences targeting Caveolin-1 and p21-activated kinase-1 
(PAK-1) (sequences below), and also a pEGFP-N1 plasmid. pEGFP-N1 was a 
kind gift from Dr. Pete Watson, School of Bioscience, Cardiff University 
(Wakana et al., 2008). 
Caveolin-1 siRNA was described in 1.4.1.4 and PAK-1 siRNA had sense 
sequence 5´ -AUAACGGCCUAGACAUUCA-3´. Both, obtained from MWG, 
had previously been validated for silencing their respective targets using 
Oligofectamine as a transfecting reagent (Al Soraj et al., 2012). 
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2.7.2.1 EJP-18/protein complex preparation  
The EJP-18/BSA-Alexa647 complexes were prepared by mixing increasing 
concentrations of EJP-18 with 1 μg BSA-Alexa647 (1mg/mL stock) giving 
peptide/protein molar ratios ranging from 1 to 100 (the final complexing 
volume was always 10 μL). The solutions were mixed by gently pipetting up 
and down and incubated at 37ºC for 30 min before being loaded onto a 0.8% 
agarose gel.   
2.7.2.2 EJP-18/siRNA complex preparation 
To prepare the complexes, 0.5 μg siRNA was mixed with increasing 
concentrations of EJP-18 giving rise to peptide/siRNA molar ratios ranging 
from 1 to 200. The mixture was prepared by incubating increasing 
concentrations of EJP-18 with 3.8 μL of Cav-1 or PAK-1 siRNA respectively 
(10 μM stock solution) in nuclease free water (the final complexing volume = 
12 μL) at room temperature for 30 min. The commercial siRNA transfection 
reagent Oligofectamine is routinely used in the laboratory for silencing proteins 
and was also mixed (5.6 μL), as a complexing control, with 3.8 μL siRNA.  
2.7.2.3 EJP-18/plasmid complex preparation 
p-EGFP-N1 plasmid (1 µg from 1 mg/mL stock) was mixed with increasing 
concentrations of EJP-18 to give a peptide/plasmid charge ratio up to 50:1 
positive charges on EJP-18 to negative charges on pEGFP-N1. This is based on 
the fact that pEGFP-N1 has a molecular weight of 2.82 x 10
6
 and 4700 base 
pairs (thus 9400 negative charges) while EJP-18 has a molecular weight of 
2462.13 and 8 positive charges. The complex was formed as described in 
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section 2.7.2.2. As a positive control for complexation, the commercial 
transfection reagent Fu  N  6 (3 μL) was mixed with 1 μL p-EGFP-N1 and 
the mixture was also incubated at room temperature for 30 min before loading 
on to gels. 
2.7.3 Agarose gel electrophoresis 
EJP-18/cargo complexes were mixed with 5 x sample loading buffer (30% 
glycerol, 0.2% bromophenol blue in dH2O) at a ratio of 5:1. Samples were 
loaded onto the agarose gel and molecular weight markers were loaded to the 
first lane of the gel. The gel was run at 80 V for 2 h before the gel was imaged 
on the BioRad Chemidoc imaging system. The gel used for 
EJP-18/BSA-Alexa647 complexes was imaged using the Typhoon 9410 
Variable Mode Imager (GE Healthcare) using filter: 670 BP 30 Cy5, (Red laser 
– 633nm), focal plane (+ 3 mm for agarose gels and platen for native gels). 
2.8 Coomassie Brilliant Blue staining of native gels 
Native gels were prepared as described in section 2.6 and EJP-18/BSA-
Alexa647 complexes were prepared as described earlier in section 2.7.2.1. The 
complexes were loaded onto the gel and were separated by electrophoresis as 
described in section 2.5.4. The gel was then rinsed gently in dH2O before being 
immersed in coomassie blue staining solution (1 g coomassie blue dye, 50% 
(v/v) methanol, 10% (v/v) glacial acetic acid and 40% (v/v) dH2O). The gel 
was incubated with the staining solution for 1 h. The gel was then washed 
several times with the destaining solution (50% methanol, 10% glacial acetic 
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acid and 40% dH2O) until the dye was removed and the background is clear. 
The gel was imaged on the BioRad Chemidoc imaging system.  
2.9 Transfection experiments 
2.9.1 siRNA transfection 
The following method describes volumes and quantities per well of a 6-well 
plate and is based on a previous publication (Al Soraj et al., 2012). 
HeLa (1.8 x 10
5 
cells/well) were seeded in 6-well plates and cultured to 60% 
confluence in DMEM supplemented with 10% FBS. Cells were transfected 
with siRNA (sequences below) 24 h after plating. The transfection reagent 
consisted of oligofectamine/siRNA complexes or EJP-18/siRNA complexes. 
To prepare oligofectamine/siRNA complexes, 4.8 μL of oligofectamine was 
gently mixed with Opti-M M to a final volume of 24 μL. A volume (1.2 μL) 
from a 50 μM siRNA stock solution was diluted in 214.8 μL of  pti-MEM. 
The diluted siRNA and oligofectamine solutions were then combined and 
mixed gently and incubated at room temperature for 30 min. EJP-18/siRNA 
transfection mixture was prepared by incubating for 30 min at room 
temperature in sterile eppendorfs 1.2 μL of 50 μM stock siRNA with 12 μL of 
1 mM EJP-18 stock solution in Opti-M M to a final volume of 50 μL. Then 
190 μL  pti-MEM was added to give a final volume of 240 μL. For each well, 
the medium was aspirated and the cells were washed twice with Opti-MEM 
and replaced with 960 μL  pti-MEM. The complete oligofectamine/siRNA 
and EJP-18/siRNA complexes (240µl) were then added dropwise to the cells. 
These were incubated at 37ºC, 5% CO2 for 4 h before 600 μL of  pti-MEM 
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medium containing 30% (v/v) serum was added to the culture medium. The 
cells were then incubated under tissue culture conditions for 48 h prior to 
further experimentation.  
In the above experiments, the final siRNA concentration was 50nM and where 
indicated in the results chapters, was increased to 100 nM. In this case, 2.4 μL 
of 50 μM stock siRNA and 9.6 μL oligofectamine were used to prepare the 
transfection reagent. The concentration of EJP-18 was unchanged. 
siRNA sequences 
GFP siRNA (Al Soraj et al., 2012) 
Sense sequence 5´-GGCUACGUCCAGGAGCGCAdTdT-3´ 
siRNA sequences targeting Caveolin-1 and PAK-1 have previously been stated 
in sections 2.4.1.4 and 2.7.2. 
2.9.2 DNA plasmid transfection 
Hela cells (6.7 x 10
4
) were seeded into 12-well plate on coverslips (No. 1.5, ϕ 
16 mm, 0.13-0.17 mm thick) and cultured for 24 h in complete medium at 
37ºC, 5% CO2. After 24 h, the cells were  60% confluent. FuGENE 6 
transfection mixture was prepared by mixing 3 μL of Fu  N  6 with 97 μL of 
SFM and incubating at room temperature for 5 min. The diluted FuGENE 6 
was then added to 1 μg of plasmid DNA (1 μg/μL stock) in 99 μL of SFM. The 
mixture was incubated at room temperature for 30 min. EJP-18/plasmid DNA 
complexes were prepared by mixing in sterile eppendorfs 1 μL of plasmid 
DNA (1 μg/μL stock) with increasing amounts of peptide to give peptide: 
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plasmid charge ratios up to 50:1 (the final complexing volume was always 25 
μL). The eppendorfs were then incubated at room temperature for 30 min 
before adding 175 μL SFM. The medium in the wells was replaced with 800 
μL SFM then 200 μL of the complexes was added dropwise to the cells. These 
were then incubated for 4 h at 37ºC, 5% CO2. The medium was changed for 
fresh complete medium after 4 h and the cells were then returned to the 
incubator. Post-transfection (24 h), the cells were fixed with 3% 
paraformaldehyde as described in the following section. 
2.10 Fixation protocol: paraformaldehyde 
The medium was aspirated and the cells were washed three times in PBS then 
fixed in 3% paraformaldehyde for 15 min. The cells were then washed with 
PBS three times before blocking the free aldehyde groups with 50 mM 
ammonium chloride for 10 min. The cells were washed again three times with 
PBS and Hoechst in PBS (1:10,000 from 10 mg/mL stock solution) was added 
for 10 min to stain the nuclei. The cells were washed with PBS and the 
coverslips were lifted from the wells, dipped once in PBS then into water and 
mounted on glass slides with 12 μL Dako oil. The slides were then placed in a 
dark cupboard for 30 min before imaging and then sealed with clear nail 
varnish. Images from this experiment were acquired on the Leica Wide Field 
system as described in section 2.4.2. 
2.11 Luciferase assay 
The method was developed following initial consultation with the Signosis and 
Promega luciferase assay protocol and then the method was optimised as 
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described below. The NF-B Luciferase Reporter HeLa stable cell line was 
used for all these experiments. 
2.11.1 Measuring luciferase expression in NF-B Luciferase Reporter HeLa 
Cells 
This below describes the final assay used to test a variety of reagents and was 
based on optimisation that is summarised below. Cells (8 x 10
3
 per well) were 
seeded in black 96-well plates in complete medium and incubated overnight at 
37ºC, 5% CO2. The following day, cells were incubated with a range of 
concentrations of tested compounds (penetratin-NBD, penetratin, R8) for 2 h. 
TNF-α (20 ng/mL in SFM) was then added into each well and the plate was 
returned to the incubator for 8 h. The plate was then removed from the 
incubator and the medium was aspirated. Lysis buffer (20 µL) (Promega) was 
added to the cells and the plate was placed on an orbital shaker for 15 min. The 
plate was then subjected to a freeze-thaw cycle by incubating at -80ºC for 15 
min then at room temperature for 15 min. Luciferase substrate (100 μL) was 
added to each well with gentle pipetting and the luminescence intensity was 
immediately analysed using a Fluostar Optima luminescent plate reader.   
2.11.2 Optimisation of the cell-based luciferase assay 
2.11.2.1 Number of cells required 
Cells (1 x 10
3
 to 5 x 10
4
 cells/ well) were seeded in 96-glass well plate and 
were incubated at 37ºC, 5% CO2 for 24 h. The confluency of the cells was 
checked 24 h later to determine the seeding density required to achieve 80-90% 
confluency at 24 h. 
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2.11.2.2 Concentration of TNF-α 
The cells were seeded as described in section 2.11.1. and on the following day, 
were incubated with TNF-α (0-100 ng/mL) for 8 h. After TNF-α incubation, 
the medium was aspirated and the cells were treated as described in section 
2.11.1. 
2.11.2.3 Freezing-thawing cycle 
The cells were seeded in two black 96-well plates as described in section 
2.11.1. On the following day, the cells were incubated with TNF-α (20 ng/mL) 
for 8 h followed by medium aspiration and addition of 20 μL lysis buffer.  ne 
plate was frozen at -80°C for 15 min then thawed at room temperature for 15 
min. This process was omitted for the second plate. The experiment was further 
continued as described in section 2.11.1. 
2.12 Statistical methods 
Statistical analysis was performed using one-way ANOVA followed by Tukey 
post-hoc test to reveal significance between groups. Data were analysed using 
GraphPad Prism 5 software. 
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3 Chapter 3: Experimental analysis of CPP-NBD chimeras 
designed to target canonical NF-B signalling 
3.1 Introduction 
NF-B is a ubiquitous and essential transcription factor for genes involved in 
inflammation, cell proliferation, survival, adhesion, and differentiation. 
Dysregulation of NF-B has been linked to numerous diseases including 
cancer and inflammatory conditions such as rheumatoid arthritis (Strickland 
and Ghosh, 2006). Activation of NF-B promotes cell survival and suppresses 
apoptosis in tumour cells (Naugler and Karin, 2008). Various genes that are 
involved in tumour cell invasion and angiogenesis have also been found to be 
regulated by NF-B (Bharti and Aggarwal, 2002). These include cell adhesion 
molecules, COX-2, VEGF, chemokines and inflammatory cytokines. Owing to 
its regulatory role in the expression of oncogenic and inflammatory genes, 
NF-B is an attractive therapeutic target in a number of diseases. 
In unstimulated cells, NF-B protein complexes in the cytosol are sequestered 
by a family of inhibitors termed inhibitory IBs. Cellular stimulation leads to 
phosphorylation and activation of Ikk complex which in turn phosphorylates 
IB-α and targets it for ubiquitination and proteosomal degradation as shown 
in Figure 1-4. Removal of the inhibitory IB-α then allows NF-B dimers to 
translocate to the nucleus to activate transcription (Karin et al., 2002, Hayden 
and Ghosh, 2008).   
As previously described in section 1.7.2, the classical (canonical) NF-B 
pathway has been targeted by therapeutic peptides, such as the NBD peptide, 
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that have been delivered to their cellular targets by CPPs (Orange and May, 
2008). 
The NBD peptide is a chimera of a selective IKK inhibitor sequence fused with 
penetratin to mediate membrane translocation- from herein it is termed 
Pen-NBD. The IKK inhibitor sequence consists of 11 amino acids that 
correspond to a domain located at the carboxy terminus of the catalytic IKK-β 
subunit that binds to the scaffold protein NEMO (May et al., 2000). Examples 
of CPP mediated delivery of NBD inhibitory peptides were listed in section 
1.7.2 and more specific examples are described below.  
 A variety of CPPs (penetratin, K-FGF, PTD-5, Tat, 6R and 8K; listed in Table 
1-1) have in fact been studied as delivery vectors for IKK inhibitor sequence 
and to produce biological effects in vitro and in vivo (Kahja and Robbins 
2010). In vitro, pretreatment of HeLa luciferase reporter cells with the 
described CPPs-NBD peptides at high concentrations of 100 μM, resulted in 
reduced IL-1β-induced NF-B transcriptional activity. At this concentration, 
cytotoxicity was, however, reported with both penetratin- and K-FGF-NBD 
peptide treatments. In vivo, from the several studied CPP-NBD peptides, 8K- 
and 6R-NBD peptides were the most effective in blocking footpad swelling in 
a KLH-induced delayed-type hypersensitivity (DTH) murine model of 
inflammatory arthritis (Khaja and Robbins, 2010).  
NBD peptide, as a delivered sequence, has also been shown to inhibit 
constitutive NF-B activity in different cancer cell lines resulting in increased 
sensitization to chemotherapeutic agents and increased apoptosis. For example, 
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cotreatment of BT-474 breast cancer cells with Pen-NBD peptide and 
doxorubicin prevented doxorubicin-induced NF-B activation and sensitised 
BT-474 cells to doxorubicin antitumor activity (Tapia et al., 2007). In an in 
vitro melanoma study, Pen-NBD peptide treatment resulted in concentration-
dependent inhibition of cell proliferation through direct inhibition of 
constitutive NF-B DNA-binding activity. The peptide was shown to induce 
apoptosis in the A375 human melanoma cells via activation of caspase-3 
(Ianaro et al., 2009). In a separate study, Pen-NBD peptide inhibited both 
TNF-α-induced and constitutive NF-B activation in both in vitro and in vivo 
models of mouse oral squamous cell carcinoma (OSCC) (Furuta et al., 2012). 
OSCC is a malignant tumour of the oral cavity, head and neck (Haddad and 
Shin, 2008). OSCC invade the maxilla and mandibular bone and bone invasion 
is a common problem associated with OSCC; bone destruction is thought to be 
mediated by osteoclasts (Jimi et al., 2011). Pen-NBD peptide treatment 
reduced the number of osteoclasts, induced apoptosis and reduced cancer cell 
proliferation (Furuta et al., 2012). The most aggressive and least 
chemoresponsive subtype of diffuse large B-cell lymphoma (DLBCL), called 
spontaneous activated B-cell like DLBCL (ABC-DLBCL), is characterized by 
constitutive canonical NF-B activity (Lenz et al., 2008). In a canine model of 
ABC-DLBCL, the Pen-NBD peptide (100 μM) inhibited this constitutive 
NF-B activity and rapidly induced apoptosis in primary malignant B-cells in 
vitro. Reduced expression of NF-B target genes (e.g. Bcl-2, cyclin-D1 and 
IB-α) and reduced tumour burden have also been reported following 
intratumoral injections of Pen-NBD peptide in dogs with relapsed DLBCL 
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(Gaurnier-Hausser et al., 2011). It has also been shown that inhibition of 
NF-B activity through retroviral transduction of super-repressor form of 
IB-α that cannot be phosphorylated was toxic to ABC-DLBCL which 
established the NF-B pathway as a molecular target for drug development of 
this aggressive subtype (Davis et al., 2001). These publications led to a phase 1 
clinical trial in which Pen-NBD peptide was systemically administered to dogs 
with ABC-DLBCL. The overall results from the trial illustrated that 
intravenous administration of Pen-NBD peptide to dogs was safe and could 
effectively block constitutive canonical NF-B activity, promote apoptosis, 
decrease malignant B cell proliferation and reduce tumour burden in a subset of 
dogs with ABC-DLBCL. A single dose of Pen-NBD peptide was not able to 
reverse chemoresistance and further studies are required to decide if multiple 
administration of Pen-NBD peptide can reverse this chemoresistance and 
improve clinical response (Ndikuyeze et al., 2014). 
In addition to inhibiting canonical NF-B activation in different cancer cell 
lines, systemic administration of Pen-NBD has been reported to reduce acute 
and chronic inflammation in multiple murine models without altering basal 
NF-B activity. In a murine model of cerulein-induced pancreatitis, a single IP 
injection of Pen-NBD immediately before the first cerulein injection attenuated 
some of the inflammatory responses associated with acute pancreatitis. 
Treatment with Pen-NBD reduced pancreatic inflammation and lung 
haemorrhage but had no effect on oedema of either the pancreas or the lung 
(Ethridge et al., 2002). In an experimental model of inflammation in mice, 
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carrageenan-induced paw oedema and NF-B activation in inflamed paw 
tissue, IP injection of Pen-NBD significantly inhibited oedema formation in a 
dose-dependent manner. Cellular infiltration in the inflamed mice paws 
through suppression of NF-B activity was also reported and was associated 
with reduced COX-2 and TNF-α mRNA levels (di Meglio et al., 2005). 
Pen-NBD peptide also effectively reduced inflammation and enhanced 
regeneration in the muscles of mdx mice; a widely used mouse model for 
Duchenne muscular dystrophy (DMD) (Peterson et al., 2011). DMD is a severe 
genetic disorder characterised by progressive skeletal muscle weakness and 
causing high mortality rates as a result of diaphragm and/or cardiac muscle 
failure (Blake et al., 2002). Pen-NBD effectively improved diaphragm muscle 
contractile dysfunction in mdx mice, the murine animal model (Peterson et al., 
2011). 
For several Pen-NBD studies, the inhibitory effect of the Pen-NBD peptide was 
abolished when the NBD sequence was mutated in which the two tryptophan 
residues (TWLDWSALQTE) were replaced with alanine residues 
(TALDASALQTE) (di Meglio et al., 2005, Ianaro et al., 2009, Khaja and 
Robbins, 2010, Gaurnier-Hausser et al., 2011, Furuta et al., 2012). It remains 
to be determined whether this is an appropriate control for these kinds of 
studies as a 2x W-A switch could also influence the interaction of the peptide 
with cells. 
In this thesis, Tumour necrosis factor-alpha (TNF-α) was used for stimulation 
of the classical NF-B pathway. TNF-α is a potent pro-inflammatory, 
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multifunctional cytokine and has roles in inflammation and immunity in 
addition to cell survival and apoptosis. TNF-α is produced primarily by 
activated macrophages, though a variety of other TNF-α-producing cell types 
have also been described including lymphocytes, fibroblasts, smooth muscle 
cells, tumour cells and natural killer cells (van Horssen et al., 2006). Despite 
being named for its ability to promote tumour necrosis, there are many studies 
which show that TNF-α can also act as a tumour promoter in numerous cancer 
cell models (Karin, 2006). 
TNF-α is present in two forms: precursor and soluble. TNF-α precursor is a 26 
kDa transmembrane protein homotrimer comprised of three polypeptides, 233 
amino acids in length. The soluble form of TNF-α is released upon cleavage of 
the precursor protein by metalloproteinases such as TNF-α-converting enzyme 
(TACE). Soluble TNF-α is a 17 kDa homotrimer of 157 amino acid residues 
(Horiuchi et al., 2010). 
TNF-α exerts its main effects through two receptors: TNF receptor1 and 2 
(TNFR-1, TNFR-2) (Li et al., 2002). These have regulatory roles in apoptosis, 
the immune response, organ development and metabolism (Costelli et al., 
1993, Takada et al., 2003, Popa et al., 2007). The majority of the biological 
responses induced by TNF-α are triggered by TNFR-1 despite the cytokine 
having greater affinity for TNFR-2 (Tartaglia and Goeddel, 1992). TNFR-1 
and TNFR-2 have a number of key differences in structure and function: 
TNFR-1 is expressed on all cell types while TNFR-2 is expressed mainly on 
immune cells (van Horssen et al., 2006).  
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Figure 3-1 highlights the signalling response to TNF-α by TNFR1. Upon 
TNF-α binding, the receptor forms a trimmer that is then associated with the 
release of the silencer of death domain (SODD) protein from the intracellular 
domain. TNFR-associated domain (TRADD) is then able to bind to the freed 
death domain of TNFR-1 and this in turn activates one of the adaptor proteins: 
receptor interacting protein (RIP), TNFR-associated factor 2 (TRAF-2) and 
FAS-associated death domain (FADD) (Wajant et al., 2003, van Horssen et al., 
2006). Adaptor protein activation initiates several intracellular signalling 
cascades that ultimately either induce or inhibit apoptosis (Horiuchi et al., 
2010). The pro-apoptotic pathway is initiated when activated (TNFR-1 
associated) FADD binds pro-caspase-8 that instigates a protease cascade 
leading to activation of endonucleases and consequently DNA fragmentation 
and apoptosis.  
Activation of NF-B transcription factor is responsible for inhibition of the 
TNF-α-induced apoptosis. This anti-apoptotic pathway occurs when TNFR-1 
signals cell survival via activation of the adaptor proteins TRAF-2 and RIP 
(instead of FADD). Activation of these adaptors causes downstream activation 
of the NF-B transcription factor via NIK. Active NF-B mediates 
transcription of different proteins which promote cell proliferation and survival 
and proteins involved in inflammatory responses and cell protection via anti-
apoptotic factors. Usually activation of TNFR-1 is accompanied by the 
activation of the NF-B pathway and therefore by the promotion of cell growth 
and survival. Apoptosis occurs when new protein synthesis is blocked or when 
Chapter (3) 
 
103 
 
the NF-B activation is hindered before TNF-α stimulation (van Horssen et al., 
2006). 
 
Figure 3-1: The different signalling pathway of TNF-α; adapted from (van Horssen et al., 
2006). 
 
3.2 Summary, Aims and Objectives  
There is extensive documentation to suggest Pen-NBD peptide inhibits NF-B 
signalling but only at relatively high concentrations of between 100 and 200 
μM in many studies. This is much higher than that required to show cell uptake 
of penetratin attached to fluorophores suggesting the cargo sequence (NBD 
sequence) is having strong effects either in cell uptake or that there is 
inefficient targeting of the peptide cargo to the desired site. The aims of this 
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chapter were to perform more studies to further investigate these effects with a 
view to lowering the amount of peptide to give the same or, ideally, enhanced 
physiological effects. 
The objectives of this chapter were to:  
1. Analyse the viability using the CellTiter-Blue assay of cancer cell lines 
treated with TNF-α. 
2. Develop in-house in vitro protocols for analysing NF-B activation and 
inhibition using degradation of IB-α or expression of luciferase 
expression.  
3. Further characterise the ability of Pen-NBD peptide to interfere with 
NF-B signalling via inhibition of TNF-α-induced NF-B activation. 
4. Design and study new peptide sequences containing modifications in 
the NBD peptide sequence or the arrangement with CPP to enhance the 
efficiency of NF-B inhibition via a CPP based delivery approach.  
3.3 Results 
3.3.1 Evaluating the suitability of the CellTiter-Blue assay for measuring 
cell viability 
A variety of methods can be used to assess cell viability and upon initiation of 
this project, the CellTiter-Blue assay had very recently been introduced into the 
lab as an alternative to the MTT assay. This was found to give more 
reproducible results and was easier to perform (Helen Wiggins, PhD thesis 
submitted). Initially, the assay was tested in cell lines treated with the chimeric 
cytotoxic peptide, D-NuBCP-9-r8 that had been previously characterised as a 
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membrane active cytotoxic peptide in the laboratory using the MTT assay 
(Watkins et al., 2011). This then served as a positive cytotoxic peptide control. 
D-NuBCP-9-r8 is comprised of two key functional sequences: a Nur-77 
derived D-isoform sequence (fsrslhll) attached to r8 for intracellular delivery. 
For this thesis, the viability of KG1a cells treated with increasing 
concentrations (0.1 - 20 μM) of r8 alone or D-NuBCP-9-r8 was initially 
investigated and the results in Figure 3-2A highlights the cytotoxicity of this 
peptide as opposed to r8 that was non-toxic at these concentrations. 
These results were in general agreement with those obtained by MTT assay in 
the Watkins et al. study (Watkins et al., 2011). Similar results with a very steep 
loss of viability at > 2 µM were obtained in MCF-7 breast cancer cells that had 
not previously been tested (Figure 3-2B). It should be noted that a major 
finding of the Watkins et al. study was that this peptide was in fact inducing 
Bcl-2 independent necrosis rather than Bcl-2 dependent apoptosis. 
D-NuBCP9-r8 did however serve as a good positive cytotoxic peptide marker 
for viability assays. 
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Figure 3-2: Viability of (A) KG1a leukaemia and (B) MCF-7 cells incubated with 
D-NuBCP9-r8. Viability of cells were evaluated using CellTiter-Blue assay following 24 h 
incubation with 0.1-20 μM r8 alone or D-NuBCP9-r8. Results represent means ± SD for three 
independent experiments performed in triplicate. 
3.3.2 Cell Viability assays of Penetratin, Pen-NBD and TNF-α 
3.3.2.1 Penetratin and Pen-NBD peptide  
Initially, cell viability assays were performed in cells treated with increasing 
concentration of the commercial Imgenex Pen-NBD peptide or Penetratin (# 
IMG-2000). This was initially performed in three routinely cultured cell lines- 
KG1a, MCF-7 and HeLa. Cells were incubated with the peptides (0.1-50 µM) 
under tissue culture conditions for 24 h. Diluent/vehicle controls were 
performed by incubating cells with various concentrations of DMSO, 
equivalent to those used in the peptide treatments. The results of three 
independent assays, shown in Figure 3-3 (A & B), showed that neither 
penetratin nor Pen-NBD caused cytotoxicity up to 20 μM but toxic effects were 
noted in KG1a cells at 50 µM. In HeLa cells that were the subject of further 
studies with this peptide, the peptide concentration was increased to 100 μM 
and some toxicity was noted at this value (Figure 3-3C). However, this same 
extent of cytotoxicity was also observed in the diluent control samples showing 
a DMSO contribution to loss of cell viability.  
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Figure 3-3: Viability of different cell lines incubated with penetratin or Pen-NBD (NBD) 
peptide. Viability of cells was evaluated using CellTiter-Blue assay following 24 h incubation 
with 0.2-50 μM penetratin alone or Pen-NBD peptide in KG1a and MCF-7 cells and 0.1-100 
μM in HeLa cells. Control cells were treated with peptide diluent control; DMS . Results for 
(A & B) represent means ± SD for three independent experiments performed in triplicate and 
results for (C) represent means ± SD for three independent experiments performed in duplicate. 
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3.3.2.2 Effects of TNF-α on cell viability 
The effects of TNF-α on NF-B activation has been described in section 3.1 
and this was the chosen ligand for investigating the putative effects of the 
Pen-NBD peptide and variants on NF-B signalling. As the name suggests, this 
protein can also have cytotoxic effects and therefore the same panel of three 
cell lines including a further breast cancer cell line MDA-MB-231 were 
investigated to determine whether TNF-α induced cytotoxicity. These data 
were needed as later experiments would involve the use of this protein as an 
NF-B activator.  
Cell viability assays were performed following 24 h exposure to increasing 
concentrations of TNF-α (0.1-20 ng/mL) and control cells were incubated with 
TNF-α diluent. Figure 3-4 highlights that TNF-α treatment did not alter cell 
viability across all the studied concentrations and that HeLa cells gave very 
consistent data. This cell line was chosen for future experiments in this chapter 
for this reason and the fact that the NF-B luciferase reporter stable cell line 
became available to us via collaboration with Professor Michael Taggart at 
Newcastle University.    
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Figure 3-4: Viability of different cell lines incubated with TNF-α. Viability of cells was 
evaluated using CellTiter-Blue assay following 24 h incubation with 0.1-20 ng/mL TNF-α. 
Control cells were treated only with medium. Results for (A & D) represent means ± SD for 
three independent experiments performed in triplicate and results for (B & C) represent means 
for two independent experiments performed in triplicate. 
3.3.3 Analysing the effect of TNF-α on NF-B signalling 
To measure any potential inhibitory effects of NBD peptides on NF-B 
signalling, it was important to have a robust assay showing NF-B activation. 
IB-α is rapidly ubiquitinylated and degraded in response to TNF-α (Machleidt 
et al., 1994, Traenckner et al., 1994, Moon et al., 2006) and this can be 
measured in cell lysates using Western Blotting. Through collaboration with 
the University of Newcastle that provided a general method, HeLa cells were 
serum starved by overnight incubation in DMEM supplemented with 0.1% 
FBS (low serum medium). Serum starvation is commonly employed to 
sensitise cells to the effects of this ligand on signalling (Ozes et al., 1999). In 
the case of cationic CPPs, serum can also significantly alter cellular uptake and 
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potentially the capacity to reach the cytosol (Jones and Sayers, 2012). The 
following day, the cells were treated for 0-240 min with 20 ng/mL TNF-α 
(diluted in low serum medium) or with low serum medium alone (diluent 
control). Lysates were then collected and Western blotting for IB-α was 
performed to measure its degradation versus α-tubulin as a housekeeping 
loading control. The data in Figure 3-5 show that 10 min incubation with 20 
ng/mL TNF-α caused a considerable reduction in IB-α. Almost complete 
disappearance of IB-α band was observed after 30 min incubation and points 
thereafter up to 240 min when a faint IB-α band reappeared as newly 
synthesised material. Based on these data, it was decided that for further 
experiments, the degradation of IB-α would be determined after 60 min TNF-
α incubation. 
 
Figure 3-5: TNF-α -induced IB-α degradation in HeLa cells. (A) Cells were treated with 
20 ng/mL TNF-α for the indicated time periods, (B) Control cells were treated with medium 
alone. Lysates were collected and Western blotting was performed for IB-α and tubulin. 
Three independent experiments were performed and a representative blot is shown. 
3.3.4 Analysing the effect of serum starvation on TNF-α-dependent 
degradation of IB-α 
To exclude any potential effects of overnight serum starvation on the cells 
treated with TNF-α, the TNF-α stimulation experiment was repeated with cells 
serum starved overnight or incubated in CM. The next day, the cells were 
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treated with 20 ng/mL TNF-α in medium containing 0.1% FBS for 0-240 min 
before measuring IB-α degradation. Figure 3-6 reveals that the effect of 
TNF-α on IB-α degradation was not affected by serum starvation. In both 
cases, the IB-α band disappeared after 30 minutes and reappeared by 240 min. 
Based on these findings, subsequent experiments were performed in the 
absence of serum starvation, TNF-α (in absence or presence of peptides) was 
added in medium containing 0.1% FBS to minimise the possible interaction 
between cationic CPPs and serum contents. 
 
Figure 3-6: TNF-α dependent degradation of IB-α in HeLa cells in different starvation 
conditions. Cells were incubated overnight in either (A) complete medium or (B) medium 
containing 0.1% FBS (serum starved) then treated with 20 ng/mL TNF-α in medium containing 
0.1% FBS. Lysates were collected and Western blotting was performed for IB-α and tubulin. 
Red arrow denotes an underloaded lane. (N=1) 
3.3.5 Assessing the effect of TNF-α concentration on the degradation of 
IB-α 
Typical concentrations of TNF-α used in in vitro studies of NF-B activation 
range between 10 ng/mL (May et al., 2000, Tas et al., 2005) and 20 ng/mL 
(Choi et al., 2003). To investigate the response of NF-B to different TNF-α 
doses, HeLa cells were incubated with different concentrations of TNF-α for 1 
h in medium containing 0.1% serum before performing Western blotting 
analysis for IB-α degradation. Interestingly, NF-B activation manifested as 
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degradation of IB-α occurred at the lowest TNF-α dose of 1 ng/mL (Figure 
3-7).  
 
Figure 3-7: Effect of TNF-α concentration on degradation of IB-α in HeLa cells. Cells 
were treated with 0-40 ng/mL TNF-α in medium containing 0.1% FBS for 1 h. Lysates were 
collected and Western blotting was performed for IB-α and tubulin. (N=1) 
3.3.6 Analysing the effect of Pen-NBD and penetratin on IB-α 
degradation 
Investigations were then performed to explore the effect of penetratin and 
Pen-NBD on IB-α levels after TNF-α stimulation (IB-α degradation). HeLa 
cells were treated with 100 μM of penetratin, Pen-NBD or DMSO (as peptide 
diluent) in medium containing 0.1% FBS for 3 h prior to treatment with 20 
ng/mL TNF-α. Figure 3-8 demonstrates that 100 µM Pen-NBD and penetratin 
had no effect on the degradation of IB-α induced by TNF-α.  
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Figure 3-8: Effect of penetratin and Pen-NBD on the degradation of IB-α in HeLa cells 
in response to TNF-α. Cells were treated with 100 μM Pen-NBD (NBD) or penetratin for 3 h 
in medium containing 0.1% FBS. DMSO was used as a diluent control. Where shown, TNF-α 
(20 ng/mL) was then added for 1 h. Lysates were collected and Western blotting was 
performed for IB-α and tubulin. Three independent experiments were performed and a 
representative blot is shown. 
The data above suggested that even at these high concentrations, Pen-NBD was 
unable to inhibit TNF-α-induced degradation of IB-α and suggested that it 
could therefore not inhibit the downstream effects of NF-B activation. To 
further investigate this, use was made of the Luciferase reporter stable cell line 
that expresses luciferase in a NF-B dependant manner. The assay is described 
in section 2.11.1 whose optimisation is described below. 
3.3.7 Luciferase expression in NF-B Luciferase Reporter HeLa stable cell 
line 
Signosis has established an NF-B luciferase reporter stable cell line by 
transfection of NF-B luciferase reporter vector containing a hygromycin 
resistance gene followed by hygromycin selection. The luciferase activity of 
this reporter cell line is proportional to activity of NF-B, and so luminescence 
can be measured as a reporter of NF-B activation. 
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3.3.7.1  Optimisation of the luciferase assay 
3.3.7.1.1 Number of cells required for luciferase activity measurements 
For viability assays, HeLa cells were seeded as 8 x 10
3
 cells/well in 96 black 
well plates. To determine the seeding density of NF-B luciferase reporter 
stable cells, different number of cells (ranging from 1 x 10
3
 to 5 x 10
4
 cells/ 
well) were seeded in a 96 glass well plate in DMEM supplemented with 10% 
FBS, 100 U/mL penicillin, 100 μg/mL streptomycin and 100 μg/mL 
hygromycin according to manufacturer’s protocol and incubated overnight at 
37ºC, 5% CO2. The following day, the cells confluency was observed by 
microscopy and to reach 70-90 % confluency, 8 x 10
3
 cells/well were required 
and this seeding density was used for all further experiments. 
3.3.7.1.2 Optimising TNF-α concentration for luciferase activity 
measurements 
Investigations were performed to determine the concentration of TNF-α 
required to activate the NF-B pathway in the reporter cell line. For this, cells 
were seeded and incubated for 8 h with TNF-α concentrations ranging from 0-
100 ng/mL. The medium was aspirated and the cells were treated for 
measuring luciferase activity. The data in Figure 3-9 demonstrated that TNF-α 
addition was accompanied by the stimulation of NF-B as illustrated by a dose 
dependent increase in luciferase activity compared to unstimulated cells. 
Statistical significance was evaluated by one-way ANOVA which indicated 
that the difference between groups were statistically significant F(12, 26) = 
15.01, p < 0.0001. Tukey post-hoc tests revealed that the luciferase activity 
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increased significantly between cells treated with and without TNF-α at 
concentrations ≥ 5 μM.   
 
 
Figure 3-9: TNF-α induced a dose dependent NF-B activation. NF-B luciferase reporter 
HeLa stable cells were stimulated for 8 h with 0-100 ng/mL TNF-α prior to lysis and analysis 
of luciferase activity. Results represent means ± SD for three separate experiments performed 
in triplicate. Statistical Significance *** p ≤ 0.001, ** p ≤ 0.01 and * p ≤ 0.05.  
3.3.7.1.3 The Effect of Freezing and Thawing 
A freezing and thawing step is described in the Signosis protocol for the 
luciferase assay; the reason for this is not explained. This step follows the 
addition of lysis buffer to cells as described in section 2.11.1. It involves 15 
min freezing at -80ºC then thawing at room temperature for another 15 min 
before adding the luciferase substrate. However, the Promega luciferase assay 
reagent protocol did not include a freezing-thawing step. To evaluate the effect 
of this step on relative luciferase activity, cells were seeded in two plates and 
treated as described in section 2.11.2.3. As shown in Figure 3-10, TNF-α 
induced NF-B activation in both conditions, however, the luciferase activity 
was of higher intensity when freeze-thaw step was utilised. For this reason, this 
step was used for all subsequent experiments. 
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Figure 3-10: Effect of freeze-thaw cycle of TNF-α-induced NF-B activation. NF-B 
luciferase reporter HeLa stable cells were stimulated for 8 h with 20 ng/mL TNF-α prior to 
lysis and analysis of luciferase activity without or with a freeze-thaw step.  (N=1) 
3.3.7.2 Penetratin and Pen-NBD inhibit TNF-α-induced NF-B activation  
Western blotting showed that incubation of HeLa cells with TNF-α was 
accompanied by NF-B activation, assessed by the degradation of IB-α 
(Figure 3-5). However, using this assay, pre-incubation with Pen-NBD at 100 
μM was unable to prevent TNF-α-induced degradation of IB-α. To evaluate 
the ability of this chimera to interfere with the TNF-α-induced activation of 
NF-B, luciferase activity was assessed using the reporter cell line as described 
in section 2.11.1. Cells were incubated with various concentrations of Pen-
NBD chimera, penetratin and serial dilutions of DMSO were also included as 
controls. From three independent experiments, pretreatment of the cells with 
Pen-NBD, as well as with penetratin, induced inhibition in TNF-α-stimulated 
NF-B activity that was clearly identified at 100 μM (Figure 3-11D). This 
suggests that the reduced luciferase activity in TNF-α-stimulated cells is not 
specific to the NBD-inhibitory cargo and that penetratin alone can decrease the 
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transcriptional activity of NF-B in TNF-α-stimulated cells. Surprisingly, the 
data also showed inhibition of TNF-α-stimulated NF-B activity in cells 
pretreated with 2% DMS  (the concentration of DMS  present in 100 μM 
peptides). The difference between groups was statistically significant by 
one-way ANOVA F(12, 26) = 5.634, p = 0.0001. Tukey post-hoc tests revealed 
that the reduction in luciferase activity was statistically significant in cells 
pretreated with 100 μM penetratin, 100 μM Pen-NBD or 2% DMSO compared 
to those treated with TNF-α alone (p < 0.01).  
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Figure 3-11: TNF-α-induced NF-B activation is inhibited by Pen-NBD chimera (NBD) 
and penetratin. Peptide-treated cells were incubated with various concentrations of Pen-NBD 
(NBD), penetratin (PEN) or DMSO (diluent control) for 2 h before TNF-α (20 ng/mL) was 
added. Luciferase activity was measured 8 h later. (A, B & C) single experiments performed in 
triplicate and (D) are means ± SD for the three separate experiments, A-C. Statistical 
Significance ** p ≤ 0.01.  
 
3.3.7.3 Effect of penetratin and R8 on NF-B activity 
The results from the previous section suggest a role for penetratin and also the 
peptide diluent (DMSO) in inhibiting NF-B activity in the NF-B Luciferase 
Reporter HeLa stable cell line. A study by Fotin-Mleczek et al. showed that 
three cationic CPPs- penetratin, Tat and nona-arginine interfered with TNF-α-
mediated signal transduction (Fotin-Mleczek et al., 2005). To examine the 
effect of an alternative and very cationic CPP on NF-B activity in vitro, the 
experiments described in section 3.3.7.2 were repeated using R8. Cells were 
exposed to various concentrations of R8 (0.1-100 μM) for 2 h. Cells were also 
treated with 100 μM penetratin or 2% DMSO. Figure 3-12D confirms that 100 
µM penetratin and 2% DMSO inhibited TNF-α induced NF-B transcriptional 
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activity. This suggests that the diminished NF-B activity can be due to a 
diluent effect rather than the peptides used here. The difference between cells 
pretreated with various concentrations of R8 (dissolved in dH2O) and cells 
treated with TNF-α was not statistically significant as confirmed using one-
way ANOVA analysis (p < 0.05). 
.  
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Figure 3-12: Effect of cationic CPPs (penetratin and R8) on TNF-α-induced NF-B 
activation. Peptide-treated cells were incubated with various concentrations of R8, penetratin 
(100 μM) or DMS  (diluent control of penetratin) for 2 h before TNF-α (20 ng/mL) was 
added. Luciferase activity was measured 8 h later. (A, B & C) single experiments performed in 
triplicate and (D) are means ± SD for the three separate experiments, A-C. 
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3.3.8 F-NBD-Pen sequence 
One of the aims of this study was to investigate the possibility of designing 
new CPP chimeras to target NF-B signalling. The data shown in this chapter 
together with the fact that the pen-NBD peptide was insoluble in aqueous 
solutions was a major concern and only one more peptide sequence was 
investigated with sequence 
Ac-FTALDWSWLQTERQIKIWFQNRRMKWKK-amide and termed 
F-NBD-Pen. The sequence was chosen based on the fact that the Jones 
laboratory had discovered that phenylalanine on the N-terminus of a short 
peptide cargo had pronounced positive effects on cell uptake (Watkins et al., 
2011). The NBD sequence lies at the N-terminus of F-NBD-Pen and 
additionally a phenylalanine residue that sits naturally at the N-terminus of the 
IKKγ N M  binding domain occurring before the NBD sequence was 
included to see if this could influence cell uptake and allow us to perform 
experiments at much lower concentrations- thus reducing the DMSO effect.  
Unfortunately, F-NBD-Pen precipitated out of solution immediately upon 
addition to aqueous medium from a DMSO stock and no further experiments 
were performed with it. 
3.4 Discussion 
Elevated NF-B activity can lead to inflammatory diseases and cancer 
(Baltimore, 2011) and CPPs have been widely studied as  delivery vectors for a 
variety of macromolecules including therapeutic peptides (Milletti, 2012). For 
this reason, a range of CPPs have been used to deliver NF-B targeting 
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peptides including the NBD inhibitory peptide used here (sections 1.7.2 and 
3.1). The initial goal of this study was to assess the inhibitory effect of Pen-
NBD peptide in TNF-α-stimulated (NF-B activated) cells. The work also 
allowed for analyses of the effects of penetratin alone and another cationic CPP 
(R8) on NF-B activity in a TNF-α-stimulated NF-B luciferase reporter cell 
line.  
TNF-α was used to activate the canonical NF-B pathway measured initially 
using Western blotting for the IB-α protein whose degradation was rapid and 
clearly visible after 10 minutes of TNF-α addition. Complete loss of the band, 
indicative of extensive proteasomal degradation, was observed after 30 and 60 
min incubation. The IB-α band reappeared after 4 h incubation due to 
resynthesis. This occurs because NF-B activation is transient and the IB-α 
gene is inducible by NF-B which produces an inhibitory feedback loop 
(Baltimore, 2011). The fact that TNF-α mediates rapid NF-B activation and a 
strong negative feedback regulation resulted in an oscillatory NF-B activation 
profile. This leads to the alternating regulation of IB-α expression seen in 
Figure 3-5 and in the literature (Smale, 2011).   
The effect of TNF-α on IB-α degradation was not affected by overnight serum 
starvation. To our knowledge the effect of serum starvation on TNF-α-induced 
IB-α degradation has not been previously explored in NBD literature and with 
this knowledge, it is easier to compare the results from other TNF-α studies 
carried out in the presence or absence of serum or where serum information is 
not provided.   
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Serum is also known to affect CPP performance; especially cationic variants 
(Kosuge et al., 2008, Jones and Sayers, 2012). For example internalisation of 
CPPs can be reduced in the presence of serum due to non specific binding of 
the CPP to serum proteins such as albumin thus reducing the amount of peptide 
that can interact with the cell. The effects of serum on CPP or CPP-cargo 
internalisation will be further discussed in chapters 4 and 5. 
In HeLa cells, TNF-α activated the NF-B classical signalling pathway at 1 
ng/mL, approximately 10 fold lower than commonly used concentration of this 
cytokine. This is in line with data showing strong NF-B activity even at 0.1 
ng/mL in immortalized 3T3 mouse embryonic fibroblasts (MEFs) (Cheong et 
al., 2006). Thus, with an assay available to measure NF-B activation, the 
NBD peptide was selected as a targeting entity for this activity and penetratin 
as the CPP. Pen-NBD peptide is commercially available and well described in 
the literature to influence NF-B activity, albeit at high concentrations (May et 
al., 2000). The ability of Pen-NBD peptide to prevent the degradation of IB-α 
in TNF-α-stimulated cells was initially assessed by Western blotting and 
surprisingly the data showed no effect in TNF-α-stimulated cells. This is in 
contrast to claims that pretreatment of SCCVII cells with Pen-NBD for 30 min 
prior to TNF-α stimulation for 15 min inhibited TNF-α-induced p65 
phosphorylation and IB-α degradation (Furuta et al., 2012). Another study 
used an immune-complex kinase assay to show that high, 100 and 200 μM, 
concentrations of Pen-NBD peptide reduced TNF-α-induced IKK activity 
(May et al., 2000). It has also been reported that pretreatment of dendritic cells 
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with 50 μM Pen-NBD peptide inhibited the phosphorylation of IB-α and 
reduced the level of phospho-IB-α in LPS-stimulated cells. Surprisingly, the 
data showed that although LPS stimulation reduced total IB-α protein, the 
Pen-NBD peptide appeared to be unable to rescue IB-α levels, despite 
inhibiting its phosphorylation (Tas et al., 2005). The difference in results from 
these studies and those produced in this thesis could be due to several factors 
including cell types but even at 100 μM, Pen-NBD was unable to rescue IB-α 
degradation when HeLa cells were treated with TNF-α. Interestingly, and 
conversely, the results for the NF-B reporter HeLa cell line showed a 
significant reduction in TNF-α-induced luciferase activity when cells were pre-
treated with the peptide at 100 μM. These findings support published findings 
of SCCVII cells transiently transfected with PBII x luciferase reporter plasmid 
that were pre-treated with Pen-NBD prior to TNF-α stimulation. In these cells, 
Pen-NBD (40 μM) suppressed TNF-α-induced transcriptional activity (Furuta 
et al., 2012). Another study showed that Pen-NBD (10 μM and 100 μM) could 
inhibit luciferase activity in IL-1β-stimulated HeLa cells transiently transfected 
with NF-B luciferase reporter plasmid, however, cytotoxicity was observed at 
100 μM (Khaja and Robbins, 2010). In this study, pretreatment of the same 
reporter HeLa cells with NBD peptides conjugated with Tat, 8K, 6R, PTD-5 
and K-F F (100 μM) for 3 h significantly inhibited luciferase activity after IL-
1β stimulation. 
A reduction in luciferase activity was also observed in our stable HeLa cells 
pre-treated with penetratin alone. These findings are in agreement with the 
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results of Letoha et al., who in 2006 demonstrated that penetratin could inhibit 
NF-B transcriptional activity in mouse L929 fibroblasts and RAW 264.7 
macrophages transformed with pNF-kB-luc4. Pretreating these cells with 25 
μM penetratin for 30 min before TNF-α or LPS stimulation caused a significant 
reduction in NF-B transcriptional activity. The penetratin studies were also 
extended in a rat model of cholecystokinin octapeptide (CCK) induced-acute 
pancreatitis in which activation and nuclear translocation of NF-B peaks at 30 
min after CCK administration. Western blotting of pancreas samples were 
performed and showed that penetratin pre-treatment prevented degradation of 
IB-α whereas, a glycine mutant analogue of penetratin devoid of positive 
charges did not have any effect on NF-B activity (Letoha et al., 2006). 
According to these results and earlier results by Bolton et al. (2000), penetratin 
could be considered to have intrinsic biological activity rather than just being 
an inert delivery vector. They reported that direct injection of penetratin into 
rat brain induced neurotoxic effects in a dose-dependent pattern (Bolton et al., 
2000). Fotin-Mleczek et al., (2005) also demonstrated that penetratin and nona-
arginine could inhibit the TNF-α-mediated signal transduction. Preincubation 
of HeLa cells with penetratin reduced the TNF-α/cycloheximide-induced 
caspase activity and protected cells against apoptosis. Penetratin and nona-
arginine also inhibited TNF-α-induced IL-8 secretion in TNF-α-stimulated 
HeLa cells and in absence of cycloheximide. Both peptides were able to inhibit 
the translocation of p65 from the cytoplasm into the nucleus in TNF-α-
stimulated cells. They concluded that penetratin was found to induce the 
endocytosis of TNF-α receptors through a dynamin-dependent manner without 
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the activation of the receptor (Fotin-Mleczek et al., 2005). These separate 
findings could explain the reduced luciferase activity in cells preincubated with 
penetratin before TNF-α stimulation seen in Figure 3-11. Penetratin alone 
could have potentiated the effect of the NBD inhibitory peptide cargo, by 
inducing receptor internalization and inhibiting TNF-α-dependent signal 
transduction. Alternatively, penetratin-induced receptor internalization 
(without receptor activation) could cause reduced NF-kB transcriptional 
activity measured by the luciferase assay i.e. the penetratin exerts an inhibitory 
effect independent of the NBD cargo. Using a mutant NBD sequence would 
provide more information about the different contributing effects of the CPP 
and the cargo and previously used is the NBD sequence where the tryptophans 
are replaced with alanines- TALDWSWLQTE to TALDASALQTE (di Meglio 
et al., 2005, Ianaro et al., 2009, Khaja and Robbins, 2010, Gaurnier-Hausser et 
al., 2011, Furuta et al., 2012). This was not tested in this study but it is 
questionable whether this represents a true control bearing in mind that a W-A 
mutation twice in the same short sequence, could very easily influence cell 
binding and uptake rather than just binding with NEMO once internalised into 
the cytosol. In support of this is that tryptophan residues have previously been 
shown to influence CPP interactions with artificial membranes and also cells 
(Mishra et al., 2011, Jones and Sayers, 2012).  
Davé et al. (2007) showed that a CPP consisting of eight lysine residues (8K) 
was able to transduce the NBD inhibitory peptide into cells and tissues. In 
HEK293 cells stably transfected with a multimerized NF-B DNA binding 
element-luciferase reporter gene, pretreatment with 8K-NBD for 1 h before 
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TNF-α stimulation caused a dose-dependent inhibition of NF-B activity. It 
should, however, be noted that no effect were seen below 50 µM and 400 μM 
of peptide was needed to show maximal effects. The effect of the 8K CPP 
alone on TNF-α-stimulated NF-B reporter cells was not examined. 
One unanticipated finding was that DMSO alone caused a reduction in 
luciferase activity in TNF-α-stimulated NF-B reporter cells. Pen-NBD and 
penetratin were dissolved in DMSO to a final stock concentration of 5 mM 
according to the manufacturer’s instructions. In other published studies, higher 
stock solutions of Pen-NBD were prepared in DMSO: 20 mM (May et al., 
2000) and 50 mM (Tas et al., 2005). Pen-NBD has also been solubilised in 
saline but to what concentration was not noted (Dasgupta et al., 2004). In 
previous studies evaluating the effect of Pen-NBD or other CPPs-NBD 
chimeras, there was little mention of any DMSO effects. This may have been 
due to the use of lower DMSO concentrations in these studies. However, in this 
chapter, the effect of DMSO was consistently evaluated as a peptide diluent, in 
volumes equal to the volumes used for different peptides concentrations. 
DMSO is one of the most common solvents used to dissolve hydrophobic 
compounds for in vitro and in vivo experimental studies (Santos et al., 2003) 
and previous studies have shown that DMSO can exert a wide range of 
pharmacological effects in experimental animal models. This includes 
nociception and inflammation depending on route of administration. Oral 
administration of DMSO produced reduced inflammation in zymosan-induced 
oedema in the mouse paw, whereas local administration of DMSO alongside 
zymosan enhanced the inflammatory response in the same mouse model. This 
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provides evidence that the anti-inflammatory effect of DMSO can be masked 
by its ability to transport drugs and chemicals across tissue membranes and 
facilitate the drug diffusion in cellular tissues (Colucci et al., 2008). A study by 
Kelly et al. in histiocytic lymphoma cell line, J774, demonstrated that 
pretreating cells with 2% DMSO 15 min prior to LPS exposure reduced the 
level of NF-B activation. DMSO alone had no stimulatory effect on NF-B 
activation (Kelly et al., 1994). This could be a possible explanation for our 
results in which 2% DMS  (equivalent to the volume in 100 μM Pen-NBD 
and penetratin) reduced the TNF-α-induced NF-B activation (Figure 3-11). 
Time of exposure to DMSO may also be an important variable. In the earlier 
noted study by Kelly et al., the cells were treated with DMSO for 15 min, 
however, in the experiments for Figures 3-11 and 3-12, the cells were 
pretreated with DMSO for 2 h prior to TNF-α stimulation. DMS  (10%) has 
also been used as a penetration enhancer in cellular uptake of Tat and was 
found to increase the uptake of FITC-labelled Tat and Tat-GFP fusion protein 
(Wang et al., 2010). Although the concentration of DMSO in the Tat study is 
higher than the highest DMSO concentration in experiments used in this thesis 
(2%), it suggests that the presence of DMSO may enhance the uptake of 
penetratin and Pen-NBD peptides, and consequently, increases their non-
specific and possibly specific effects.  
R8 effects on TNF-α-induced NF-B activation in the reporter cells were 
assessed in this thesis but no reduction in luciferase activity was observed up to 
100 μM. From this, it can be inferred that not all commonly used CPPs affect 
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NF-B activity and that the effects observed in Figure 3-11 are mainly due to 
the influence of DMSO.  
3.5 Conclusions 
The initial aims of this chapter were to develop models for analysing activation 
of NF-B and to then look at CPP mediated delivery of peptides that inhibit 
NF-B inhibition. Present in the literature are sequences that have been shown 
to have effects but only at high concentrations. Two assays were successfully 
developed and are now available in the laboratory for subsequent studies. As a 
control peptide, the commercial Pen-NBD sequence was used and data from 
the few studies that were conducted raise important questions regarding a 
number of factors that could influence the data including: the influence of the 
CPP alone, the specifics of the assays with respects to when and how long the 
reagents are included with cells, the choice of cell lines, the solubility of the 
peptides and the influence of diluents. All in all this makes data interpretation 
very difficult and also results in a significant challenge for those comparing 
similar work in the literature. Further work with NF-B targeting peptides was 
not performed. 
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4 Chapter 4: Cellular Uptake and Viability assays of the 
EGFR-Derived Peptide- EJP-18 
4.1 Introduction 
Cancer cells which overexpress EGFR (ERbB1) have increased activation of 
downstream signalling pathways driving cell proliferation, survival, 
angiogenesis, and metastasis. Because of this, it is a very well studied member 
of the ErbB family of receptor tyrosine kinases and the target for several 
different therapeutic strategies based on small molecule drugs and 
biopharmaceuticals, including peptides. Though these, in some cases, have 
proved to be effective, there is still a need for better systems to target this 
receptor as anti-cancer therapy. For example, the development of drug 
resistance to small molecule drugs remains a major problem (Chen and Fu, 
2011, Tartarone et al., 2013).   
EGFRs’ extracellular ligand binding, dimerisation and intracellular tyrosine 
kinase domains are critical for receptor activation. This process begins when 
EGFR homo- or hetero-dimerisation is initiated by the binding of one of 
several ligands including EGF to the receptor extracellular binding domain. 
Subsequently, autophosphorylation by the kinase domain occurs leading to 
phosphorylation of other cytoplasmic substrates and activation of oncogenic 
signalling  cascades (Sebastian et al., 2006). Clinically approved strategies 
targeting EGFR include monoclonal antibodies directed towards its 
extracellular domain such as trastuzumab (Herceptin) and small molecule 
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tyrosine kinase inhibitors gefitinib and erlotinib (Hynes and MacDonald, 
2009). 
The role of the EGFR transmembrane region (corresponding to amino acids 
622-644) was initially thought to be a passive anchor of the receptor to the 
membrane. However, it has been found that this region plays an important role 
in mediating EGF effects  (Tanner and Kyte, 1999, Bennasroune et al., 2004). 
Interestingly, studies based on construction of expression vectors encoding 
short fusion peptides encompassing the transmembrane domain of EGFR and 
ErbB2 (HER2) showed they could inhibit the autophosphorylation and 
subsequent signalling of these target receptors. Identical results were obtained 
using chemically synthesized shorter peptides corresponding to the 
hydrophobic core of their transmembrane domains (Bennasroune et al., 2004).  
The juxtamembrane (JM) region of EGFR (corresponding to amino acids 645-
682 (RRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRI)) lies 
immediately downstream of the transmembrane region and harbours a tripartite 
nuclear localisation sequence (NLS) (RRRHIVRKRTLRR, amino acids 645-
657); containing three clusters of basic amino acids, in bold. The NLS in the 
EGFR JM region is capable of mediating nuclear localization of EGFR (Hsu 
and Hung, 2007) and the JM region itself has functions relating to receptor 
dimerization, signalling and endocytosis (Hubbard, 2009, Jura et al., 2009). 
Upstream of the JM region in the transmembrane domain lies the triplet LFM 
which when added to residues 645-59 of the JM region gives the peptide 
sequence 642-LFMRRRHIVRKRTLRRLL-659. As an unmodified peptide, it 
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would have a mass of 2421.0, and isoelectric point of 12.88 and net charge of 
8.1 at pH 7.0 (pepcalc.com). Interestingly, the cationic (hydrophilic residues) 
are spaced between hydrophobic residues and based on other CPP sequences 
and findings that terminal hydrophobicity of CPPs influences peptide-cell 
interactions (Watkins et al., 2011), it was hypothesised that this peptide, 
termed EJP-18, could have interesting properties including membrane binding 
ability and that it may be able to internalise into cells. If it gained access to the 
cell cytosol, it could potentially interfere with EGFR signalling and the NLS 
within the sequence may drive it to the nucleus. Of interest is that Thr654 of 
EGFR (residue 13 of EJP-18) is phosphorylated and this was found to be 
required for nuclear localisation of the receptor that occurs following 
irradiation (Dittmann et al., 2010). The same study demonstrated that a short 
peptide termed T654 from this region of EGFR (RKRTLRRLK) entered cells 
as a fluorescein labelled conjugate and when added as a Threonine 
phosphorylated entity, it could also inhibit nuclear localization of EGFR 
following irradiation. Confocal microscopy data were rather inconclusive with 
respects to subcellular localisation of the labelled peptide. Microscopy 
experiments were performed 16 h after peptide addition and there was no 
information as to whether they were fixed or imaged as live cells. It should also 
be noticed that the C-terminal lysine in T654 was added solely for labelling 
with fluorescein and in EGFR this residue is hydrophobic (L). In conclusion, it 
appeared that T654 was internalising into cells and acting as a short bioportide.  
As described in section 1.8.3, bioportides are peptide sequences that have 
intrinsic cell penetration capacity and bioactivity when located in the 
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cytoplasm. Attempts have been made to deliver other EGFR cytosolic domain 
sequences to influence EGFR signalling (Kuroda et al., 2013). In another 
study, a short peptide sequence SVDNPHVC from the cytosolic domain of 
EGFR that is involved in dimerization was shown as a Tat-chimera to enhance 
EGFR degradation (Ahsan et al., 2013). It should be noted that the peptide, 
termed Disruptin, was added at a final concentration of 125 µM to show 
maximum effect that was first noted at 12.5 µM. 
Immediately prior to my period in the laboratory, EJP-18 had been purchased 
as a Rhodamine-labelled peptide and very preliminary live cell confocal 
microscopy studies were performed in HeLa and KG1a cells by Dr Edward 
Sayers. These two cell lines are routinely used in the laboratory for CPP 
studies. It was immediately apparent that this peptide was very effectively 
internalised into cells but at concentrations of 20 µM in KG1a cells, there was 
also evidence for the occurrence of plasma membrane perturbation (Figure 
4-1).  
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Figure 4-1: Uptake of Rh-EJP-18 peptide into cells after 1 h incubation in CM. (A) KG1a 
cells were incubated with 20 µM Rh-EJP-18 (pseudocoloured green) for 1 h in CM containing 
the cell permeable dye DRAQ7 (red). The cells were then analysed by live cell imaging 
confocal microscopy. All the cells contained cytoplasmic peptide labelling and some 
(arrowheads) had gross morphological damage and thus DRAQ7 positive. The DRAQ7
+
 
nucleus has been expelled from the cell at the top left of the image. Scale Bars = 20 µm. (B) 
HeLa cells were treated with 10 µM peptide in SFM for 1 h, washed and imaged in imaging 
medium containing DRAQ7 by confocal microscopy. Large punctate structures were observed 
inside the cells (arrows), on the plasma membrane (arrowheads) and in the cytosol of the cell 
labelled with an asterisk. Scale bars = 10 µm. Figure kindly supplied by Dr Edward Sayers. 
 
4.2 Summary, Aims and Objectives 
The search for new membrane active peptides that could then be termed as 
CPPs for delivering therapeutics or as bioportides is an ongoing process. 
EJP-18 (Table 2-1) represented a novel peptide with interesting physical 
characteristics beyond that afforded by T654 and was clearly entering cancer 
cells and labelling intracellular vesicles. The aims of this chapter were to 
further characterise the cellular uptake and toxicity of the new sequence- 
EJP-18. 
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The objectives of this chapter were to: 
1- Analyse the effect of EJP-18 and its rhodamine conjugate on cancer cell 
viability using CellTiter-Blue assay.  
2- Analyse using live cell confocal microscopy the cellular uptake and 
subcellular distribution of EJP-18 under different experimental 
conditions and in comparison with a well characterised CPP- R8.  
4.3 Results 
4.3.1 Cell Viability assays for EJP-18 and Rh-EJP-18 
4.3.1.1 Effect of EJP-18 on the cell viability in a panel of cancer cell lines 
In order to assess the cytotoxicity of EJP-18, cell viability was examined in a 
panel of cancer cells that are routinely cultured in the laboratory for CPP and 
other work. Briefly, cells were seeded in 96-well plates and incubated with 0-
100 μM   P-18 for 24 h under full tissue culture conditions. Cell viability was 
then determined via CellTiter-Blue assay as previously described in sections 
2.3.1 and 2.3.2. Figure 4-2 shows that up to concentrations of 10 μM,   P-18 
had no effect on viability in any of the tested cell lines. However, varying 
degrees of cytotoxicity was then seen when different cells were treated with 20 
μM peptide for 24 h; KG1a being the most sensitive followed by HeLa and 
MCF-7 cells. At 100 μM,   P-18 reduced cell viability of the three cell lines 
by > 85%. A431 and MDA-MB-231 were the most resistant to toxicity as only 
23% and 45% loss in cell viability was respectively observed with 100 μM 
peptide. 
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Figure 4-2: Viability of different cell lines incubated with EJP-18. Viability of cells was 
evaluated using CellTitre-Blue assay following 24 h incubation with 0-100 μM   P-18 and is 
expressed as the percentage of viable cells relative to untreated controls. Results represent 
means ± SD for three independent experiments performed in duplicate. 
 
4.3.1.2 Effect of Rh-EJP-18 on the cell viability in a panel of cancer cell 
lines 
Cell viability experiments were also performed on the rhodamine labelled 
peptide (Rh-EJP18) at 0-50 μM. Since CellTiter-Blue is a fluorescence based 
assay, steps were taken to exclude possible interference of rhodamine 
fluorescence (554 Ex /578 Em) with the resorufin fluorescence produced by the 
conversion of resazurin in viable cells at (544Ex/590Em). Rhodamine correction 
was performed by performing parallel cell-free experiments i.e. by adding the 
same serial dilutions of Rh-EJP-18 in medium alone. The fluorescence 
readings of the Rh-EJP-18 and medium-only controls were then subtracted 
from the readings of the Rh-EJP-18 treated cells. Figure 4-3 shows that up to 
10 μM, Rh-EJP-18 had no effect on viability in any of the cell lines tested. As 
with EJP-18, concentrations above 20 μM showed varying degree of toxicity 
according to the cell line; MDA-MB-231 and A431 being the most resistant. 
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Rh-EJP-18 was very toxic to KG1a, HeLa and MCF-7 at 50 μM but A431 and 
MDA-MB-231 cells were unaffected even at this higher concentration.  
 
Figure 4-3: Viability of different cell lines incubated with Rh-EJP-18. Rhodamine 
corrected viability of cells was evaluated using CellTitre-Blue assay following 24 h incubation 
with 0-50 μM Rh-EJP-18. Cell viability is expressed as the percentage of viable cells relative 
to untreated controls. Results represent means ± SD for three independent experiments 
performed in duplicate. 
 
4.3.1.3 Effect of R8 and Rh-R8 on the viability of HeLa cells 
R8 is a very well characterised cationic CPP and was used during this study as 
a comparative CPP to EJP-18 for cell uptake and delivery. Cell viability of R8 
and Rh-R8 were also examined in HeLa cells seeded in 96-well plates and 
incubated as above with 0-100 μM peptides for 24 h prior to performing cell 
viability assay. R8 was non toxic to HeLa cells at all studied concentrations but 
the rhodamine conjugate was toxic at concentrations above 20 μM (Figure 
4-4). 
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.  
Figure 4-4: Viability of HeLa cells incubated with R8 and Rh-R8. Viability of cells was 
evaluated using CellTitre-Blue assay following 24 h incubation with 0-100 μM R8 or Rh-R8 
and is expressed as the percentage of viable cells relative to untreated controls. Rhodamine 
correction was considered. Results represent means ± SD for three independent experiments 
performed in duplicate. 
 
4.3.2 Detecting EGFR levels in different cell lines 
Viability studies revealed that both A431 and MDA-MB-231 cells were the 
most resistant to the toxicity of EJP-18 and its rhodamine conjugate. As EJP-18 
is derived from the JM region of EGFR, it was hypothesised that the 
differences in the toxicity profiles of the cells may be related to their EGFR 
levels. Relative EGFR expression in the cells was then determined in each of 
these cell lines. Cells were cultured and lysed with detergents as described in 
section 1.5.1.2 and proteins were separated using SDS-PAGE. Following 
protein transfer, membranes were probed with antibodies recognising EGFR 
and α-tubulin as protein loading control. A431 and MDA-MB-231 are well 
characterised high EGFR expressing cells (www.proteinatlas.org) (DeFazio et 
al., 2000, Araki et al., 2007, Al Soraj et al., 2012, Boran et al., 2012) and 
Figure 4-5 confirms this. A faint band was observed in HeLa cells but EGFR 
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expression could not be detected in KG1a or MCF-7 cells. This also confirms 
proteinatlas information for MCF-7/EGFR but no documentation was available 
regarding expression of this protein in KG1a cells. Overall the viability data 
suggested that high EGFR expressing cells were protected from the effects of 
EJP-18 compared with low or non expressing lines.  
 
Figure 4-5: EGFR expression in different cell lines. Cell lysates were collected and Western 
blotting was performed for detection of EGFR and tubulin. 
 
4.3.3 Cellular uptake (subcellular distribution) of Rh-EJP-18 and Rh-R8 in 
HeLa cells in presence or absence of serum 
Preliminary investigation showed that EJP-18 could rapidly enter cells and 
label internal vesicles suggesting it was being internalised by endocytosis. 
Further analysis was then performed on this peptide in comparison with R8 that 
was similarly labelled with rhodamine. HeLa cells have been widely used in 
our laboratory for CPP studies with R8 and were the chosen cell line for these 
studies. Cells grown in glass bottomed imaging dishes were incubated for 1 h 
with serum free medium or complete medium containing 1-20 μM Rh-EJP-18 
or 5-20 μM Rh-R8. The cells were washed then imaged as live cells by 
confocal microscopy as described in section 2.4.1.1. The cell permeable dye 
Hoechst 33342 was added at the end of the experiment to label the nucleus. 
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Figure 4-6 shows that in the absence of serum, 5 μM Rh-R8 was localised to 
vesicular structures in HeLa cells but as the concentration increased, the 
localisation changed significantly. At 10 μM, the cell population is 
heterogeneous: some cells have only punctate cytosolic vesicles while others 
exhibit additional diffuse cytosolic labelling. At 20 μM, Rh-R8 labelled the 
entire cell cytoplasm and nucleus; nucleolar labelling was also observed 
(Figure 4-6). Enlarged sections of single section images from Figure 4-6 are 
shown in Appendix D (Figure D-1). 
 
Figure 4-6: Uptake of Rh-R8 peptide into HeLa cells at 5-20 μM in SFM. Cells were 
incubated with 5-20 μM Rh-R8 in SFM for 1h at 37ºC, washed and imaged by confocal 
microscopy. Representative images (N=3) show either a single section through the cell at the 
mid-point of the nucleus or maximum projection of the whole cell. Nuclei were labelled blue 
with Hoechst. White arrows indicate nucleolar labelling. Scale bars = 20 μm. 
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Rh-EJP-18 was shown to label punctate vesicles, many of which were 
accumulating in a distinct perinuclear region (Figure 4-7). At 5 µM peptide 
concentration, these were very clearly seen and the fluorescence increased in 
these structures as the concentration was increased to 20 µM. Unlike Rh-R8 at 
20 µM which labelled the entire cell, Rh-EJP-18 at this concentration was 
predominantly located in vesicular structures but in approximately 25% of the 
cell population, the fluorescence was observed throughout the cytoplasm and 
nucleus. Enlarged sections of images from Figure 4-7 are shown in Appendix 
D (Figure D-2). Experiments were also performed at 1 µM Rh-EJP-18 
concentration but the fluorescence signal was below that which could be easily 
detected above cellular background autofluorescence (Data not shown).  
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Figure 4-7: Uptake of Rh-EJP-18 peptide into HeLa cells at 5-20 μM in SFM. Cells were 
incubated with 5-20 μM Rh-EJP-18 in SFM for 1h at 37ºC, washed and imaged by confocal 
microscopy. Representative images (N=3) showing either a single section through the cell at 
the mid-point of the nucleus or maximum projection of the whole cell. Nuclei were labelled 
blue with Hoechst. White arrows indicate distinct perinuclear labelling. Scale bars = 20 μm. 
To detect whether the cytoplasmic labelling observed at 20 µM was due to 
general plasma membrane leakage, noting that this concentration reduced cell 
viability (Figure 4-3), cells were initially incubated with the peptide and at the 
end of the experiment, the medium was removed and the cells were incubated 
in imaging medium containing the fluorescent probe DRAQ7. This will only 
enter cells and nucleus of those with a damaged plasma membrane and Figure 
4-8 shows some DRAQ7-stained nuclei suggesting that cytosolic labelling may 
be due to either cell death or permeabilization. In other cells, there was 
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evidence of cytosolic peptide (pseudocolour green) but no clear DRAQ7 
labelling. 
 
Figure 4-8: Uptake of 20 μM Rh-EJP-18 peptides into HeLa cells in SFM. Cells were 
incubated with 20 μM Rh-EJP-18 in SFM for 1h at 37ºC, washed and imaged in imaging 
medium containing DRAQ7 by confocal microscopy. Representative images (N=2) showing 
either a single section through the cell at the mid-point of the nucleus or maximum projection 
of the whole cell (top row: experiment 1, bottom row: experiment 2). Dead or permeabilized 
nuclei were labelled red with DRAQ7 and the rhodamine peptide labelled green. Scale bars = 
20 μm.   
The uptake of cationic CPPs can be affected by the presence of serum; for 
example, serum albumin can bind a significant amount of peptide thus reducing 
the concentration of ‘active’ peptide in the solution (Kosuge et al., 2008, Jones 
and Sayers, 2012). To study the effect of serum on the internalisation and 
subcellular localisation of the peptides, uptake experiments described in the 
earlier section were repeated in the presence of serum. Figure 4-9 shows that 
incubation of HeLa cells with Rh-R8 in presence of serum reduced the uptake 
of the peptide (compared to uptake in Figure 4-6). At 20 μM Rh-R8, there was 
again evidence of cells labelled with rhodamine in punctate structures or 
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diffusely through the cytoplasm. The extent of cytosolic labelling was much 
lower than in the absence of serum. Reduced fluorescence was observed at 10 
µM and 5 µM when compared to 20 μM. The uptake of Rh-EJP-18 also 
decreased in the presence of serum and was predominantly labelled in vesicles 
at 10 μM but at 20 μM, the peptide had in some cells entered into the cytosol as 
diffuse labelling. Very little fluorescence was detected in cells treated with 5 
μM extracellular peptide concentration (Figure 4-10). 
 
Figure 4-9: Uptake of Rh-R8 peptide into HeLa cells at 5-20 μM in CM. Cells were 
incubated with 5-20 μM Rh-R8 in CM for 1h at 37ºC, washed and imaged by confocal 
microscopy. Representative images (N=2) showing either a single section through the cell at 
the mid-point of the nucleus or maximum projection of the whole cell. Nuclei were labelled 
blue with Hoechst. Scale bars = 20 μm  
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Figure 4-10: Uptake of Rh-EJP-18 peptide into HeLa cells at 5-20 μM in CM. Cells were 
incubated with 5-20 μM Rh-EJP-18 in CM for 1h at 37ºC, washed and imaged by confocal 
microscopy. Representative images (N=2) showing either a single section through the cell at 
the mid-point of the nucleus or maximum projection of the whole cell. Nuclei were labelled 
blue with Hoechst. Scale bars = 20 μm  
4.3.4 Cellular uptake of 10 μM Rh-EJP-18 and Rh-R8 in HeLa cells at 4 
and 37ºC 
Temperature has been shown to affect both the uptake and subcellular 
distribution of CPPs (Fretz et al., 2007, Watkins et al., 2009a, Watkins et al., 
2009b). To test this on Rh-EJP-18 uptake, HeLa cells were incubated for 1 h 
with 10 μM peptide at 4 and 37ºC and the cells were examined by confocal 
microscopy as described in section 2.4.1.2. Here, experiments were also 
performed with Rh-R8. Figure 4-11A reveals that Rh-EJP-18 labelled vesicular 
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structures in HeLa cells at 37 ºC and the uptake was inhibited at 4ºC (Figure 
4-11B). As expected, R8 effectively internalised the fluorescent cargo to cells 
incubated at 37 and 4ºC, but giving different subcellular localisation. At 37ºC, 
Rh-R8 labelled vesicular structures and exhibited diffuse cytoplasmic, 
cytosolic and nuclear distribution (Figure 4-11A). However, when cells were 
incubated with Rh-R8 at 4ºC, the peptide also strongly labelled the nucleolus 
(Figure 4-11B). At this temperature, some of the cells had very little 
fluorescence inside them and the figure clearly demonstrates high 
heterogeneity of peptide labelling within a single cell population.  
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Figure 4-11: Uptake of Rh-EJP-18 and Rh-R8 into HeLa cells at 10 μM in SFM at (A) 
37ºC or (B) 4ºC. Cells were incubated with 10 μM Rh-EJP-21 or Rh-E-64562 in SFM for 1h 
at (A) 37ºC or (B) 4ºC, washed and imaged by confocal microscopy. Representative images 
(N=3) showing either a single section through the cell at the mid-point of the nucleus or 
maximum projection of the whole cell. Nuclei were labelled blue with Hoechst. Scale bars = 
20 μm. 
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4.4 Discussion 
The primary aim of this chapter was to test the cellular uptake, subcellular 
distribution and cytotoxicity of a peptide sequence termed EJP-18 that was 
obtained after close scrutiny of the JM region of EGFR. The sequence has three 
hydrophobic and three hydrophilic regions suggesting it could behave as an 
amphipathic CPP. Within the CPP world, amphipathic variants include MPG, 
TP10 and Transportan ( Pooga et al., 1998, Soomets et al., 2000, Deshayes et 
al., 2011, Madani et al., 2011). Their amphipathicity can in part be attributed to 
the sequential running of hydrophobic and hydrophilic residues along the 
sequence and the fact that when they interact with lipids they change their 
structures to form ß-sheets or alpha helices. EJP-18 is a relatively short peptide 
and has very clearly defined hydrophobic and hydrophilic regions to suggest 
that it may also do the same. 
Initial cell uptake analysis performed on Rh-EJP-18 by Dr Edward Sayers 
suggested it was effectively endocytosed into cells but that at extracellular 
concentrations > 10 µM it was causing plasma membrane perturbation. This 
was particularly noticeable in the leukaemia cell line KG1a (Fig 4-1). It was 
then decided to test if this membrane effect was having any effects on cell 
viability. For this a number of cell lines were tested in this thesis. 
These assays revealed that neither EJP-18 nor Rh-EJP-18 affected cell viability 
up to 10 μM in any of the cell lines tested; however, clear cytotoxicity was 
seen above 20 μM in some cell lines. Of interest from this data was the finding 
that sensitivity of the cells was dependent on expression of EGFR that was also 
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measured in this thesis. A431 and MDA-MB-231 are well known high 
expressors of EGFR and were the most resistant to the effects of this peptide.  
Of note is that they are not derived from the same tissue, as A431 and 
MDA-MB-231 are derived from skin and breast respectively. There are a 
number of explanations for this apparent dependency on EGFR expression. 
First, the more sensitive cell lines may have plasma membranes that are more 
susceptible to EJP-18-mediated damage causing cell lysis (necrosis). This 
could be by forming pores or the peptide acting as a detergent. Interestingly, 
the plasma membrane of KG1a, the most sensitive cell line, was relatively 
porous, compared to other cell lines, to allow direct translocation of cationic 
CPPs such as Tat and R8 at relatively low concentrations (Al-Taei et al., 2006, 
Watkins et al., 2009a). A more complex explanation derives from the origin of 
this sequence in the JM domain of EGFR. EJP-18 when located in the cytosol 
could sequester endogenous interactors of the corresponding EGFR domain. 
This could potentially interfere with downstream EGFR signalling for cell 
growth and survival. Because A431 and MDA-MB-231 have more EGFR, they 
may also have a corresponding increase in the expression of EGFR interacting 
proteins. This would mean a higher dose of EJP-18 would potentially be 
required to sequester the partner proteins and impinge on EGFR signalling. The 
evidence for this comes from the fact that the previously described EGFR JM 
derived peptide T654 was able to affect nuclear localisation and EGFR 
degradation in response to irradiation (Dittmann et al., 2010). The T residue 
common to T654 and EJP-18 was phosphorylated in T654 and it remains to be 
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determined whether a phosphorylated EJP-18 would also influence EGFR 
biology in the same way. 
Based on a similar strategy to T645, peptides targeting other cytosolic domains 
of EGFR have been described including those involved in autophosphorylation 
(Kuroda et al., 2013). Here, the peptides are attached to CPPs such as Tat that 
is required for cytosolic delivery. Recently and during the course of this 
studentship, a peptide with a very similar sequence to EJP-18 termed E-64562 
(RRRHIVRKRTLRRLLQER) was attached to the C-terminus of Tat to give 
TE-64562 (RKKRRQRRRGRRRHIVRKRTLRRLLQER) and found to have 
strong anti-cancer activity that was dependent on EGFR expression. The model 
presented was that Tat was aiding E-64562 internalization to the cytosol where 
it was then interfering with EGFR signaling (Boran et al., 2012). TE-64562 
also had in vivo activity in nude mice bearing MDA-MB-231 tumors. Further 
mention and discussion of this peptide will be provided in Chapter 6 when data 
are presented on analysis of derivatives of EJP-18.  
For Low EGFR expressing KG1a, MCF-7 and HeLa cells, that are more 
sensitive to EJP-18, a smaller amount of peptide would be needed to sequester 
interactors, inhibit signalling and induce toxicity.  
An alternative scenario to explain our findings is that because EGFR promotes 
growth and survival, even if EJP-18-induced toxicity is independent of EGFR, 
there might be a protective effect of the receptor in overexpressing cells. This 
could be further investigated by testing the peptide in cells transiently 
overexpressing EGFR or by stably transfected, inducible cell lines.  
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Rh-EJP-18, at all studied concentrations, labelled vesicular structures in HeLa 
cells which suggests an endocytic uptake mechanism. Some cells with 
cytosolic labelling were observed with 20 μM Rh-EJP-18 but this could be due 
to increased cell porosity or even cell death as illustrated by red staining of 
nuclei by DRAQ7 (Figure 4-8). R8 is a well characterised cationic CPP and 
was used during this study as a benchmark to the new peptide. Rh-R8, as 
expected (Duchardt et al., 2007, Fretz et al., 2007, Watkins et al., 2009a), was 
predominantly localised to vesicular structures at low concentrations but at 20 
µM, was directly translocated across the plasma membrane without showing 
any evidence of membrane damage (Appendix D- Figure D-3). It was 
noticeable that in several of these microscopy experiments, within the same 
cell population, that not all cells contained the same amounts of peptide. This 
heterogeneity in pattern of uptake and distribution of R8 resembles data 
published by Duchardt et al. who showed increasingly heterogeneous uptake 
and nucleo-cytoplasmic enrichment of two arginine-rich CPPs (R9 and Tat) as 
the peptide concentration was increased (Duchardt et al., 2007). The authors 
concluded that above a critical threshold, internalization of R9 and Tat occurs 
through a highly efficient nonendocytic pathway originating from spatially 
confined areas of the plasma membrane (nucleation zones) and leads to rapid 
release of the peptides into the cytosol without affecting the overall integrity of 
this structure. Similar results have been reported by Kosuge et al. in the uptake 
of an Alexa488-labelled oligoarginine; R12. Time-course imaging of HeLa 
cells revealed that initial translocation of R12 peptide occurred at defined 
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locations before diffusing through the cytosol and nucleus (Kosuge et al., 
2008).  
A different fluorescent conjugate of R8; R8-Alexa488, was shown to be 
efficiently internalised into HeLa and KG1a cells at a range of concentrations. 
In HeLa cells, concentrations of up to 20 μM R8-Alexa488 localised to 
vesicular structures but cytosolic labelling was observed at higher 
concentration (Watkins et al., 2009a). No evidence of R8-Alexa488 
localisation in the nuclei was described in the report by Watkins et al. which 
contrasts with the nuclear Rh-R8 observed in Figure 4-6. Together these data 
indicate that the nature of the cargo (the fluorophore in this case) may affect 
the subcellular distribution of the peptide conjugate. It has been previously 
reported that fluorophore tagging of a CPP can affect transport pathway and its 
subcellular localisation (Palm-Apergi et al., 2012). The localisation of 
luminescent complexes of ruthenium (metal complexes to examine cellular 
uptake) attached to octaarginine (Ru-D-R8) has been shown to be altered by 
the presence of a fluorophore. The addition of fluorescein to Ru-D-R8 changes 
the peptide conjugates’ distribution in HeLa cells from punctate structures in 
the cytosol (Ru-D-R8 alone) to diffuse cytosolic and nuclear labelling, strong 
nucleolar staining and some punctate cytosolic staining (Ru-D-R8 conjugated 
to fluorescein) (Puckett and Barton, 2009). The authors suggested that the 
greater lipophilicity of fluorescein versus the Ru moiety caused an increased 
interaction with the plasma membrane and this high concentration at the cell 
surface aided nonendocytic uptake. All this needs to be taken into 
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consideration when interpreting results from CPP studies involving 
fluorescently-labelled peptides.  
The uptake of Rh-EJP-18 and Rh-R8 was reduced in the presence of serum 
(Figures 4-9 and 4-10). At 10 μM, serum altered the distribution pattern of 
Rh-R8 from a mixture of punctate vesicles and cytosolic labelling into punctate 
vesicles only (Figures 4-6 and 4-9). The same figures show that at 20 μM 
Rh-R8, the presence of serum reduced the number of cells with 
nucleocytoplasmic labelling. This could be due to an interaction of both the 
peptides here with serum proteins such as albumin. Serum bound CPPs could 
have reduced cellular uptake as their interaction with serum proteins impairs 
their ability to engage with the cell membrane. The effective concentration of 
peptide in serum containing medium is therefore reduced as there is less 
free/active peptide to interact with the cell (Kosuge et al., 2008, Jones and 
Sayers, 2012). It has also recently been reported that presence of serum 
reduced the uptake of a Voltage-dependent L-type calcium channel subunit 
alpha-1D protein-derived arginine-rich CPP; P8 (RRWRRWNRFNRRRCR) 
into HeLa cells which could be due to non-specific electrostatic interaction of 
the peptide with serum proteins (Gautam et al., 2015).  
EJP-18 entered cells in a temperature-dependent manner (Figures 4-11).  The 
peptide was internalised at 37ºC and its uptake was abolished at 4ºC which 
strongly suggests the involvement of an active process, most likely 
endocytosis. Rh-R8 as expected was able to freely diffuse through the plasma 
membrane and at the highest 20 µM concentration, labelled the entire cell 
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including the nucleolus. In contrast, there was no evidence that Rh-EJP-18 was 
able to label the nucleolus and the reason behind this is unknown.  
Nucleolar labelling as presented here with Rh-R8 has previously been observed 
when leukaemia cells were treated with CPPs including D-R8-Alexa488 (Fretz 
et al., 2007) and CPPs have even been mentioned as being candidate probes for 
labelling these structures in the nucleus (Martin et al., 2007). In this chapter, 
HeLa cells incubated with Rh-R8 at 4ºC showed a very heterogeneous labelling 
pattern with some cells showing very little uptake. The reason for this is 
unknown. Nucleolar labelling was observed when cells were incubated with 
Rh-R8 at 4ºC and also at 37˚C, though to a much lesser extent. One possibility 
is that intracellular proteolysis is a contributing factor, reducing the fraction of 
peptide that is able to migrate to the nucleus and nucleolus. However, protease 
effects should be significantly diminished at 4ºC and this allows more peptide 
to translocate to the nucleus (Fretz et al., 2007).  
4.5 Conclusions 
The hypothesis underlying the study of EJP-18 was based on its sequence, its 
origin in the JM region of EGFR and the possibility that it could have 
bioportide properties to influence EGFR biology. Cell viability experiments in 
a panel of cancer cell lines revealed toxicity, the extent of which was EGFR 
dependent. Of concern before assigning the term bioportide to EJP-18 is the 
possibility that it could also be classed as a lytic/necrotic peptide. This 
warranted more detailed analysis of its interaction with cells as a fluorescent 
conjugate.  
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The first Rh-EJP-18 microscopy analysis at relatively low peptide 
concentration highlighted vesicular labelling, strongly suggesting it was 
entering cells by endocytosis. As the concentration of EJP-18 increased, there 
was evidence that it was localised to the cytosol but it is difficult to determine 
whether this is due to translocation across the plasma membrane or membrane 
damage. The impressive capacity of EJP-18 to enter cells by endocytosis 
without showing extensive plasma membrane labelling led to questions 
regarding the possibility that it could deliver cargo much larger than rhodamine 
to cells at concentrations that does not cause cell death.   
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5 Chapter 5: Complexation and Cellular Delivery of 
Macromolecular cargo by EJP-18 
5.1 Introduction 
5.1.1 CPPs and endosomal escape 
CPPs have significant potential as vectors to facilitate the intracellular delivery 
of various cargos including those with therapeutic capacity. Access to the 
inside of the cell is not a simple criterion for successful delivery especially if 
this is via endocytosis. For example, endosomal entrapment is believed to be a 
rate-limiting step in efficient intracellular delivery of different cargos by CPPs 
(El-Sayed et al., 2009, Lee et al., 2013). Poor nuclear delivery is also a major 
limitation for CPP and other vector based DNA-based therapies but CPPs 
containing an NLS can be used to improve nuclear delivery (Cartier and 
Reszka, 2002, Kerkis et al., 2006). In most cases, for a cargo to exert its 
cellular effects, it needs to escape the endolysosomal network and enter the 
cytosol, or the nucleus if the cargo is DNA-based (Mäe et al., 2009). A number 
of different approaches have been reported that enhance the endosomal escape 
of CPP/cargo conjugates. Treatment of cells with lysosomotropic agents such 
as chloroquine is one such approach (Caron et al., 2004). Chloroquine is a 
weak base that raises the pH of endocytotic compartments thereby preventing 
endosome acidification and maturation. At high concentrations, chloroquine 
can cause accumulation of counter ions to protons in endosomes resulting in 
endosomal swelling and rupture (El-Sayed et al., 2009). Elevating the pH of 
endocytotic vesicles provides a suboptimal pH environment for lysosomal 
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enzymes (Ciftci and Levy, 2001). Chloroquine has been found to significantly 
increase TP-10-mediated splice correction of 2´ -OMe RNA oligonucleotides 
(Mäe et al., 2009). Alternatively, addition of peptides with certain sequences 
such as penetration-accelerating sequence (Pas; FFLIPKG) to CPPs has been 
found to enhance the intracellular delivery of peptides by promoting endosomal 
escape. Pas is a short peptide segment derived from the cleavable sequence 
(GKPILFF) of the lysosomal protease cathepsin D. When linked to R8, Pas has 
been shown to greatly enhance the uptake of the CPP (Takayama et al., 2009). 
A CPP comprised of R9 and Pas also enhanced the delivery of non-covalently 
attached quantum dots into A549 cells (Liu et al., 2013). Other approaches to 
enhance endosomal escape include the use of endosome-disruptive peptides 
(fusogenic peptides) such as the influenza hemagglutinin derived peptide; HA2 
and GALA peptide. HA2 is a subunit of hemagglutinin (HA); an envelope 
glycoprotein of human influenza virus, responsible for endosomal escape. A 23 
amino acid sequence taken from the N-terminus of the HA2 subunit 
(GLFGAIAGFIENGWEGMIDGWYG) is relatively hydrophobic and is 
referred to as fusion peptide. At reduced endosomal pH, conformational 
changes in HA2 take place that promote its fusion with the endosomal 
membrane leading to pore formation. This mechanism has been exploited 
through using HA2 peptide to enhance CPP-mediated endosomal escape of 
cargos (Cross et al., 2009, Liou et al., 2012). R9 tagged with HA2 significantly 
enhanced the cytosolic delivery of a red fluorescent protein (mcherry) at 
concentration much lower than that observed for R9 alone (Liou et al., 2012). 
GALA is a pH-sensitive synthetic peptide that has seven glutamic acid residues 
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(Glu) in its sequence (Table 1-1) and is negatively charged at neutral pH. The 
reduced endosomal pH decreases the negative charge of Glu residues and leads 
to the conversion of the structure from random coil to an amphipathic α-helical 
structure. The α-helix conformation promotes its interaction with and 
disruption of endosomal membranes thereby promoting endosomal escape (Li 
et al., 2004, Li et al., 2012). GALA enabled cytosolic delivery of proteins 
(EGFP and avidin) and nanoparticles (QDs) into HeLa cells when administered 
in presence of cationic liposomes (Kobayashi et al., 2009). 
Development of histidine-containing CPP has also been used to enhance 
endosomal escape. For example, Tat peptide covalently fused with 10 
histidines provided much higher levels of transgene expression (7000 fold 
higher than Tat alone) in human U251 glioma cells (Lo and Wang, 2008). The 
imidazole group of histidine has a pKa of 6.0 and in the acidic environment of 
endosomes (pH 5-6.5), facilitates proton influx (proton sponge effect) leading 
to endosomal swelling, bursting and thus escape.  
EB1 (LIRLWSHLIHIWFQNRRLKWKKK); is an endosomolytic peptide and 
a penetratin variant in which selected residues are replaced with histidines to 
yield, in theory, an α-helical structure upon protonation in acidic early-late 
endosomal compartments and thus aids endosomal escape. EB1 has 
demonstrated the ability to complex and deliver siRNA and reduce luciferase 
expression in HeLa cells transiently transfected with the pGL3 luciferase 
plasmid (Lundberg et al., 2007). Penetratin and HA2-penetratin were also 
tested alongside EB1 for their ability to deliver functional siRNA and reduced 
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luciferase expression was observed for the HA2-CPP but not for penetratin 
alone. The study highlights the importance of endosomal escape for obtaining 
biological effects. 
Although endosomal entrapment and downstream delivery to lysosomes is 
considered a major limitation for CPP-mediated delivery of cargo such as 
siRNA and plasmids, it provides a potential advantage in the treatment of 
lysosomal storage diseases (LSDs) (Urbanelli et al., 2011). Lysosomes are 
specialised degradative compartments in the cells known to be involved in 
many cellular processes such as digestion of intra- and extracellular material, 
plasma membrane repair, cholesterol homeostasis and cell death and are 
considered crucial regulators of cell homeostasis (Appelqvist et al., 2013). 
LSDs are a group of rare genetic disorders caused by specific mutations in 
genes encoding lysosomal enzymes that result in deficient lysosomal activity. 
The loss in enzymatic activity leads to the progressive accumulation of a wide 
variety of substrates such as glycolipids, glycoprotein, oligosaccharides and 
proteins in lysosomes and ultimately lead to cellular and organ dysfunctions 
(Ortolano et al., 2014). LSDs share some cellular changes with protein 
accumulation diseases such as Alzheimer’s, Parkinson’s and Huntington’s 
diseases and increasing evidence indicates that lysosomes are also involved in 
more widespread diseases, such as cancer, Alzheimer’s disease and 
amyotrophic lateral sclerosis (Appelqvist et al., 2013). Recently, approaches 
have been developed to improve targeting of lysosomal enzymes in LSDs 
using CPPs. The therapeutic strategy is based on, for example, using chimeric 
polypeptides consisting of a CPP (DPV3-RKKRRRESRKKRRRES or DPV15-
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LRRERQSRLRRERQSR) to facilitate cellular uptake of a lysosomal enzyme, 
beta-glucuronidase, to replace the missing/mutated enzyme (Arranz, 2007, 
Urbanelli et al., 2011).  
Examples of CPP delivering small molecules, proteins, peptides and 
nanoparticles were listed in sections 1.5.1-1.5.4. Some selective examples of 
CPPs delivering nucleic acids of various forms are given below and here, 
endosomal escape is a major requirement for effective delivery. 
CADY, a secondary amphipathic peptide (Table 1-1), has been shown to 
deliver functional siRNA that induced significant depletion of the target 
mRNA and protein (GAPDH) in a range of cell lines. CADY also delivered an 
siRNA-targeting p53 and induced 97% knockdown after 48 and 72 h that was 
maintained at 60% inhibition for 5 days (Crombez et al., 2009).  
PepFect6, a CPP comprising a proton-accepting moiety (chloroquine analog) 
covalently linked to a stearylated-TP10, delivered siRNA into a range of cells 
and caused siRNA-mediated gene silencing in vitro and in vivo models 
(Andaloussi et al., 2011). C6 (Ac-RLLRLLLRLWRRLLRLLR-NH2), an 
amphipathic CPP, is claimed to deliver siRNA into the cytosol of CHO-K1 
cells (Jafari et al., 2012) but despite achieving siRNA delivery the knockdown 
efficiency of the complex was low and this was attributed to endosomal 
entrapment (Xu et al., 2014). A related peptide, C6M1, was able to deliver 
non-covalently linked siRNA into CHO-K1 cells and cause a decrease in 
GAPDH mRNA levels. C6M1 (Ac-RLWRLLWRLWRRLWRLLR-NH2) 
contains three tryptophan residues in place of the C6 leucines (underlined). 
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C6M1 was successfully used in vivo (in a mouse model) to deliver Bcl-2 
siRNA and suppressed tumour cell proliferation and tumour volumes (Xu et 
al., 2014).  
ppTG1 (GLFKALLKLLKSLWKLLLKA), a basic amphipathic peptide, 
efficiently transfected HeLa cells with a luciferase expression plasmid 
pTG11236 and was found superior to other CPPs used in the same study: 
KALA (Table 1-1) and JTS1-K13 
(GLFEALLELLESLWELLLEACCWKAKKKKKKKKWKKKKQS) (Rittner 
et al., 2002). In a murine model, IV injection of the plasmid complexed with 
ppTG1 and ppTG20 (GLFRALLRLLRSLWRLLLRA), an amphipathic 
peptide, led to significant luciferase expression in the lung 24 h after injection.  
MPG (Table 1-1), a chimeric peptide derived from the fusion of the HIV 
glycoprotein 41 peptide and the NLS sequence of SV40 T-antigen, has a 
documented ability to form stable non-covalent complexes with single- and 
double-stranded DNA and promote their delivery into fibroblastic HS-68 and 
NIH-3T3 cells (Morris et al., 1997). A later study by Simeoni et al. has also 
showed that MPG can deliver both DNA and siRNA however, siRNA 
transfection was increased when a mutant of MPG (MP ΔNLS) was used, in 
which the second lysine residue in NLS motif was substituted with serine 
(Simeoni et al., 2003). 
5.1.2 Methods of complexation between CPPs and cargos 
Cargos can be associated with CPPs covalently (Lundberg et al., 2007, Keller 
et al., 2013), or by formation of non-covalent complexes, mainly through 
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hydrophobic and electrostatic interactions (Morris et al., 2008, Carter et al., 
2013, Keller et al., 2013). Covalent based strategies offer several advantages 
such as reproducibility and peptide quantity rationalisation, using lower 
amounts of peptide to achieve biological effects (Heitz et al., 2009). The 
limitation of CPP-cargo covalent linkage is the possible reduction or cleavage 
of chemical bonds before the complex reaches the target cells (Lundberg et al., 
2007). On the other hand, non-covalent strategies provide an easy procedure 
for generating a drug delivery formulation that may only require mixing the 
CPP and the cargo (Boisguérin et al., 2015). Non-covalent complexation also 
provides the benefit of protecting nucleic acid oligomers against digestion by 
intra- and extracellular nucleases (Margus et al., 2012). However, a limitation 
to the application of this strategy in vivo may be the difference in the 
pharmacokinetics and biodistribution profiles of both highly charged 
molecules. This may alter their efficiency to co-localise in sufficient doses at 
the target site and restrict their application to local administration (Lee et al., 
2013). 
The introduction presented for this chapter provide a brief description of the 
types of CPPs-delivery strategies that have been investigated to deliver 
nucleotides to the insides of cells. Noting that, descriptions of CPPs delivering 
proteins have been discussed in sections 1.5.4 and 1.6. There are clear 
opportunities for the design of new CPPs to deliver macromolecules to the 
insides of cells and this is the subject of this chapter using EJP-18 that was 
initially described in Chapter 4. 
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5.2 Summary, Aims and Objectives 
In chapter 4, EJP-18, as a rhodamine conjugate, was effectively internalised 
into HeLa cells. The aims of this chapter were to investigate the ability of this 
peptide to deliver larger and more therapeutically relevant cargos to ascertain 
whether it had any potential as a delivery vector and to determine whether it 
could be referred to as a CPP.  
The objectives of this chapter were to: 
1- Investigate the ability of EJP-18 to form non-covalent complexes with 
different cargos (protein, siRNA and plasmid DNA) using agarose gel 
shift assays and/or non-denaturing PAGE. 
2- Investigate the uptake of these non-covalent complexes into HeLa cells 
using live cell confocal microscopy. 
3- Investigating the endocytic traffic and subcellular localisation of EJP-
18/albumin complexes, in lysosome labelled cells, following their 
internalisation by endocytosis using live cell confocal microscopy. 
4- Investigate the biological effects of cargos delivered by EJP-18 with 
respect to silencing protein expression using siRNA or transfecting 
cells with plasmid DNA.  
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5.3 Results 
5.3.1 EJP-18 mediated cellular delivery of Bovine Serum Albumin (BSA-
Alexa647) 
5.3.1.1 EJP-18/BSA complexation 
Gel shift assays are routinely performed to assess the complexation of CPPs 
with nucleotides such as siRNA and plasmids (Rittner et al., 2002, Hyndman et 
al., 2004, Liu et al., 2005, Lundberg et al., 2007, Crombez et al., 2009, Jafari 
et al., 2012, Xu et al., 2014). Despite studies showing that intact proteins can 
be complexed with CPPs and delivered to cells, there is very little 
documentation of the characterisation of these complexes using similar or 
alternative methods. 
In this thesis, a CPP-protein gel shift procedure was developed to examine 
whether EJP-18 efficiently complexes BSA-Alexa647. Initially this was 
performed by simple mixing of the peptide and fluorescent protein as described 
in section 2.7.2.1 and then loading on to agarose gels as described in section 
2.7.3. The Typhoon variable mode scanner allows for direct visualisation of 
fluorescent molecules on gels and immediately after running, the gel was 
scanned using an excitation wavelength of 633 nm as described in section 
2.7.3. BSA-Alexa647 as an uncomplexed protein gave a single band (Figure 
5-1A) whose mobility was slightly retarded at molar peptide:protein ratios 
above 10:1. Despite the fact that the EJP-18 peptide used in this reaction was 
unlabelled, a faint band was observed in the EJP-18 alone lane. This had barely 
migrated into the gel and was also observed in all lanes of ≥ 20:1 molar ratios. 
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The BSA band became increasingly faint as the ratio increased and also 
smearing was observed suggesting the formation of high molecular weight 
complexes that were retarding migration of the protein.  
To further investigate the complexes, samples from identical experiments were 
loaded and separated on a native PAGE gel as described in section 2.6 and 
initially analysed using the Typhoon scanner but then subjected to Coomassie 
blue staining. The gel profile was very different from that obtained from the 
agarose gel (Figure 5-1B & C). EJP-18 was shown to retard the mobility of 
BSA-Alexa647 at a lower molar ratio (5:1) than that observed in the agarose 
gel. At molar ratio of 20:1, only a very faint band corresponding to BSA-
Alexa647 was detected that disappeared at higher molar ratios. Similar results 
were obtained from Coomassie staining that also allowed for the visualisation 
of molecular weight markers in lane 1. 
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Figure 5-1: Agarose gel shift assay (A) and Native-PAGE (B-C) analysis of the ability of 
EJP-18 to form complexes with BSA-Alexa647. EJP-18/BSA-Alexa647 complexes were 
prepared by mixing 1 μg BSA-Alexa647 with increasing concentrations of EJP-18 giving rise 
to molar ratios of peptide/siRNA ranging from 1-100:1. The complexes were analysed using 
(A) agarose gel electrophoresis and imaging on the Typhoon scanner or (B) Native-PAGE and 
imaging on the Typhoon scanner or (C) staining with Coomassie Brilliant Blue. Images shown 
are representative from (A) three independent experiments or (B) two independent 
experiments. 
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5.3.1.2 Cellular uptake (Internalisation) of EJP-18/BSA-Alexa647 
complexes in HeLa cells. 
The capacity of EJP-18 to deliver BSA-Alexa647 was examined in HeLa cells 
by confocal microscopy. Complexes were prepared and incubated with cells as 
described in section 2.4.1.3. For these experiments, a concentration of 10µg/ml 
BSA-Alexa647 was initially incubated with the cells and after 1 h, no cell 
associated fluorescence was observed suggesting none or very little had gained 
access to the cells (Figure 5-2 bottom row). Complexation of BSA-Alexa647 
with 2 μM   P-18 enhanced the internalisation BSA-Alexa647 (Figure 5-2 top 
row), and this was further increased by raising the concentration of the peptide 
to 10 µM (Figure 5-2 middle row). EJP-18/BSA-Alexa647 complexes were 
localised in vesicular structures that were predominantly concentrated in a 
distinct perinuclear region. This localisation was strongly suggestive of uptake 
by endocytic pathways. 
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Figure 5-2: Internalisation of EJP-18/BSA-Alexa647 complexes into HeLa cells in SFM. 
EJP-18 (2 or 10 μM) was complexed with BSA-Alexa647 and subsequently added to cells that 
were then incubated for 1 h at 37ºC, washed and imaged by confocal microscopy. Bottom row 
shows cells incubated with BSA-Alexa647 (10 μg/mL) alone. Representative images (N=2) 
show a single section through the cell at the mid-point of the nucleus, labelled in blue with 
Hoechst. Inset represents selected regions from the merged images. White arrows indicate 
distinct perinuclear fluorescence. Scale bars = 20 μm. 
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5.3.1.3 Cellular uptake (internalisation) of labelled BSA complexed with 
EJP-18, penetratin, R8 and R8-GC in HeLa cells in SFM or CM 
The efficiency of EJP-18 to deliver labelled BSA was compared with that of 
two well characterised CPPs, penetratin and R8, including an R8-GC peptide 
that is used for labelling with fluorophores. 
5.3.1.3.1 EJP-18 mediated internalisation of BSA-Alexa647 
The 10 μM peptide/BSA-Alexa647 complexes were prepared and incubated 
with HeLa cells as described in section 2.4.1.3. Figure 5-3A illustrates that 
EJP-18 effectively delivered BSA-Alexa647 to label punctate structures in 
these cells. Only very weak fluorescence signal was detected for 
penetratin/BSA-Alexa647 and interestingly, R8-GC exhibited a higher delivery 
efficiency compared with R8 alone; again clear labelling in vesicular structures 
was observed.   
EJP-18, R8 and R8-GC were then assessed for their ability to deliver the 
labelled albumin at a lower concentration (5 μM). Figure 5-3B demonstrated 
that only R8-GC and EJP-18 were able to deliver this protein to give consistent 
fluorescence readout above that of background noise. 
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Figure 5-3: Internalisation of peptide/BSA-Alexa647 complexes into HeLa cells in SFM. 
EJP-18, R8, penetratin and R8-GC peptides: (A) 10 μM or (B) 5 μM was incubated with BSA-
Alexa647 and subsequently added to cells that were then incubated for 1 h at 37ºC, washed and 
imaged by confocal microscopy. Bottom row in (A) shows cells incubated with BSA-Alexa647 
(10 μg/mL) alone. Representative images (N=3) showing either a single section through the 
cell at the mid-point of the nucleus or maximum projection of the whole cell. Nuclei were 
labelled blue with Hoechst. White arrows indicate distinct perinuclear labelling. Scale bars = 
20 μm. 
To test the effect of serum on the uptake of the complexes, experiments shown 
in Figure 5-3 employing EJP-18 and R8-GC were then repeated but here the 
complexes were diluted in serum containing medium (complete medium) 
rather than serum free medium and then incubated with cells. In complete 
medium, both CPPs were still able to deliver the labelled albumin into cells as 
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shown in Figure 5-4. This suggests that the precomplexing stage gives stable 
complexes that can withstand possible degradation by serum proteins. 
 
Figure 5-4: Internalisation of peptide/BSA-Alexa647 complexes into HeLa cells in CM. 
EJP-18 and R8- C (10 μM) were incubated with BSA-Alexa647 and subsequently added to 
cells that were then incubated for 1 h at 37ºC, washed and imaged by confocal microscopy. 
Bottom row shows cells incubated with BSA-Alexa647 (10 μg/mL) alone. Representative 
images (N=2) showing a single section through the cell at the mid-point of the nucleus, 
labelled in blue with Hoechst. Scale bars = 20 μm.   
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5.3.1.3.2 EJP-18 mediated internalisation of BSA-Alexa488 
As reported in the literature and discussed in section 4.4, fluorophores can 
influence the cellular distribution of CPP and CPP/cargo complexes. For this 
reason, the BSA delivery experiments were repeated using BSA-Alexa488 
rather than Alexa647 noting that these two fluorophores, despite bearing the 
prefix Alexa, have very different structures (Jones and Sayers, 2012). 
EJP-18/BSA-Alexa488 complex was prepared and incubated with HeLa in 
SFM as described above and in section 2.4.1.3. Figure 5-5 illustrates that 
EJP-18 effectively delivered BSA-Alexa488 to label distinct perinuclear 
regions of cells as was previously observed with EJP-18/BSA-Alexa647 
complexes. Once again no cell-associated fluorescence was observed when the 
same amount of uncomplexed BSA-Alexa488 was incubated with these cells.   
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Figure 5-5: Internalisation of EJP-18/BSA-Alexa488 complexes into HeLa cells in SFM. 
EJP-18 (10 μM) was complexed with BSA-Alexa488 and subsequently added to cells that were 
then incubated for 1 h at 37ºC, washed and imaged by confocal microscopy. Bottom row 
shows cells incubated with BSA-Alexa488 (10 μg/mL) alone. Representative images (N=2) 
showing a single section through the cell at the mid-point of the nucleus, labelled in blue with 
Hoechst. White arrows indicate distinct perinuclear labelling. Scale bars = 20 μm. 
5.3.1.4 Analysis of the subcellular distribution of Peptide/BSA-Alexa647 
complexes 
The localisation of the EJP-18/BSA-Alexa647 complexes in a distinct 
perinuclear region suggested they were internalised by endocytosis and 
delivered to lysosomes that in the HeLa cell line are often located in this region 
(Al-Taei et al., 2006). Endocytosis of dextran is well characterised in terms of 
initial fluid phase uptake into early endosomes, and traffic through late 
endosomes to lysosomes. To specifically label lysosomes, cells were incubated 
with dextran-Alexa488 for 2 h followed by an overnight chase into lysosomes 
that can be achieved via a further incubation in dextran-free complete medium 
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(Bright et al., 2005). The next day, the cells were washed and incubated for 1 h 
with EJP-18/BSA-Alexa647 or R8/BSA-Alexa647 complexes formed as 
described above and in section 2.4.1.6. Figure 5-6 demonstrates that 
BSA-Alexa647 delivered during this 1 h period by EJP-18 and by R8 
colocalised with dextran labelled lysosomes to the same extent (Pearson’s 
coefficient = 0.38 ± 0.09 and 0.38 ± 0.04 respectively). A higher degree of 
colocalisation between the labelled peptides and lysosomes was observed after 
the complexes were similarly incubated with the cells for 1 h and then chased 
for a further hour in complex free medium: EJP-18/BSA-Alexa647 and 
R8/BSA-Alexa647 giving Pearson’s coefficient of 0.57 ± 0.03 and 0.49 ± 0.07 
respectively. The difference between groups was statistically significant by 
one-way ANOVA F(3, 10) = 7.040, p = 0.0079. Tukey post-hoc tests revealed 
that increased colocalisation was only significant between 1 h pulse with EJP-
18/BSA complexes and 1 h chase with the same complex (p < 0.05).  
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Figure 5-6: Traffic of EJP-18/BSA-Alexa647 or R8/BSA-Alexa647 to lysosomes in HeLa 
cells. Cells were incubated at 37ºC with dextran-Alexa488 for 2 h followed by an overnight 
chase and were then incubated with EJP-18/BSA-Alexa647 or R8/BSA-Alexa647 complexes 
for (A) 1 h or (B) 1 h followed by 1 h chase. The cells were then washed and imaged by 
confocal microscopy. Representative images (N=4) showing a single section through the cells 
and the right panel in (A) and (B) shows a zoomed image of an identified cell in merge panel. 
Colocalisation is marked by white arrows. Scale bars = 20 μm.   
5.3.1.5 Cytotoxicity of Peptides/BSA-Alexa647 complexes 
EJP-18, R8 and penetratin were found to be nontoxic at 10 μM (Figures 4-2, 
4-4 and 3-3 respectively); the concentration used to deliver labelled albumin. 
To ensure that the peptide/BSA-Alexa647 complexes were also nontoxic, HeLa 
cells were incubated with the complexes (10 µM peptide/10 µg/mL BSA) 
under tissue culture conditions for 24 or 72 h. Cell viability was then 
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determined using CellTiter-Blue assay as described in section 2.3.2. Figure 5-7 
shows that none of these complexes were toxic to cells at the concentrations 
used here and this was confirmed using one-way ANOVA analysis (p < 0.05). 
 
Figure 5-7: Viability of HeLa cells incubated with peptide/BSA-Alexa647 complexes. 
Viability of cells was evaluated using CellTiter-Blue assay following (A) 24 h or (B) 72 h 
incubation with CPP/BSA-Alexa647 complexes in HeLa cells. Results represent means ± SD 
for (A) three independent experiments or (B) two independent experiments, performed in 
duplicate. 
5.3.2 EJP-18 mediated complexing and delivery of siRNA 
In section 5.3.1.3.1, EJP-18 was found able to complex and promote the 
cellular uptake of BSA-Alexa647. It was then decided to investigate the 
efficacy of EJP-18 to complex and deliver siRNA to inhibit the expression of 
proteins. 
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5.3.2.1 Agarose gel shift assay for investigating EJP-18/siRNA 
complexation 
An agarose gel shift assay was developed to detect the interaction between 
EJP-18 and siRNA targeting Cav-1 and PAK-1. EJP-18/siRNA complexes at 
increasing molar ratios were prepared as described in section 2.7.2.2. siRNA 
alone and oligofectamine/siRNA complex were used as controls. 
Oligofectamine is a commercial cationic polymer based transfection reagent 
that is routinely used in the laboratory for siRNA delivery and inhibiting the 
expression of proteins including Cav-1 and PAK-1 (Al Soraj et al., 2012). 
These specific siRNAs were selected here as examples of validated laboratory 
sequences. Complexes were prepared and analysed by agarose gel 
electrophoresis and ethidium bromide staining as described in section 2.7.3. 
Figure 5-8 (A & B) shows that EJP-18 clearly retarded the migration of both 
siRNAs at a molar ratio of 20:1. The siRNA retardation efficacy of EJP-18 
increased at molar ratios above 20:1 and at 160:1, the retardation of siRNA was 
complete as no ethidium bromide signal was detected in the gel itself. 
Interestingly, at molar ratios above 80:1, a faint shadow of ethidium bromide 
staining was observed above the loading well suggesting that the siRNA had 
migrated towards the cathode. For both siRNAs, oligofectamine gave two 
regions of ethidium bromide staining: one at the expected (unhindered) 
migration point and one in the loading well.  
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Figure 5-8: Agarose gel shift assay analysis of EJP-18 and oligofectamine/siRNA 
complexes (A) Cav-1 siRNA and (B) PAK-1 siRNA. EJP-18/siRNA complexes were 
prepared by mixing 0.5 μg siRNA with increasing concentrations of   P-18 giving rise to 
molar ratios of peptide/siRNA ranging from 1 to 200:1. The complexes were analysed using 
gel shift assay and imaged using a BioRad ChemiDoc system. Images (A & B) shown are 
representative from two independent experiments. Red arrows point to migration of siRNA 
towards the cathode. 
5.3.2.2 Cell uptake of Cy5-Cav-1 siRNA complexed with EJP-18 or 
oligofectamine in HeLa cells 
EJP-18 clearly demonstrated that it could complex siRNA and to analyse, using 
confocal microscopy, whether it could also deliver siRNA into cells, a custom 
Cy5 labelled version of the siRNA targeting Cav-1 was purchased. Cy5-Cav-1 
siRNA (Cy5-siRNA 50 or 100nM) was then mixed with increasing 
concentrations of EJP-18 or with oligofectamine as described in section 
2.4.1.4. For incubation with 50 nM Cy5-siRNA, molar ratios of up to 200: 1 
(EJP-18/siRNA) were used so that the final concentration for EJP-18 was 10 
μM (the concentration used to deliver labelled BSA). Lower molar ratios were 
also evaluated for siRNA delivery. When cells were transfected with 100 nM 
Cy5-siRNA, the highest molar ratio tested was 100:1 and the final 
concentration of EJP-18 was maintained at 10 μM. These complexes and 
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Cy5-siRNA alone were then incubated with HeLa cells for 3 h in Opti-MEM 
prior to cell washing and analysis by live cell imaging confocal microscopy.  
As expected, there was no evidence that Cy5-siRNA alone was able to interact 
with or enter cells. Figure 5-9 shows that EJP-18/Cy5-siRNA complexes (50 
and 100 nM) could be seen in punctate structures in the cell cytoplasm. The 
fluorescent siRNA was also seen after complexation with oligofectamine. From 
three independent experiments, a large degree of heterogeneity with respect to 
subcellular distribution of fluorescence was observed for siRNA (at both 
concentrations) complexed with EJP-18. This difference was observed within a 
single cell population and between repeat experiments (Figure 5-9). siRNA 
internalised by oligofectamine also showed distribution patterns that varied 
from small vesicles in the cytoplasm of some cells (Figure 5-9 A & B) to large 
aggregates that were spread throughout the cells (Figure 5-9 C & D). 
Experiments were also performed at lower molar ratios: 20:1 and 10:1 but the 
fluorescence signal was below the detection level of this microscopy method 
(Data not shown). 
The ring structures appearing on the overlay in Figure 5-9 are due to a fault on 
the confocal system. Despite numerous visits by the Leica engineers, this 
problem was only (partly) resolved at the later stages of the writing of this 
thesis.  
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Figure 5-9: Internalisation of EJP-18/Cy5-siRNA complexes into HeLa cells. EJP-18/Cy5-
siRNA or oligofectamine/Cy5-siRNA complexes (A & B) 50 nM siRNA and (C& D) 100 nM 
siRNA were incubated with cells for 3 h at 37ºC prior to analysis by confocal microscopy. 
Bottom row in A & C shows cells incubated with 50 and 100 nM Cy5-siRNA alone 
respectively. Images represent a single section through the cell at the mid-point of the nucleus, 
labelled in blue with Hoechst. Three separate experiments were performed and images from 
two of these are shown for 50 nM (A & B) and 100 nM (C & D). Scale bars = 20 μm.   
 
5.3.2.3 Transfection experiments with EJP-18 or oligofectamine/siRNA 
complexes 
Having achieved promising results from the complexation and cell uptake 
studies, it was then important to examine whether EJP-18/siRNA complexes 
were able to deliver siRNA to cells and into the cytosol to deplete protein 
targets i.e. Cav-1 and PAK-1 as can be performed with oligofectamine (Al 
Soraj et al., 2012).  
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5.3.2.3.1 Transfection experiments with EJP-18/Cav-1 siRNA complexes in 
HeLa cells 
Cav-1 depletion with Cav-1 siRNA (50 nM) was tested in three independent 
experiments performed in HeLa cells as previously described in section 2.9.1. 
The molar ratio tested for Cav-1 knockdown was 200:1 (peptide/siRNA) giving 
a final EJP-18 concentration of 10 μM i.e. the concentration found to deliver 
BSA and siRNA. As a positive control, siRNA transfection was performed 
with oligofectamine as previously described (Al Soraj et al., 2012). 
Transfection with a control GFP non-targeting siRNA was also performed with 
both oligofectamine and EJP-18 at the same molar ratio to assess specificity for 
Cav-1 depletion. Cav-1 expression in cells treated with 10 μM   P-18 alone 
was also investigated to exclude potential non-specific effects of this peptide 
on Cav-1 expression. Untransfected cells were included as a control for 
baseline Cav-1 levels. The cells were incubated with the siRNA for 48 h prior 
to preparing cell lysates as described in section 2.9.1 that were subjected to 
Western blotting for Cav-1 expression that was quantified using ImageJ 
software. One-way ANOVA was performed to determine the statistical 
significance of differences between groups. 
As expected, oligofectamine/Cav-1 siRNA complexes consistently reduced 
Cav-1 expression (Figure 5-10 B, D and F) and the average reduction in protein 
expression of three experiments was 80% (Figure 5-10G). In cells transfected 
with EJP-18/Cav-1 siRNA complexes, there was large intra assay variation in 
Cav-1 expression. Figure 5-10 (B & F) shows 45 and 25% reduction in Cav-1 
expression respectively but Figure 5-10D shows an increase of 30% under 
Chapter (5) 
 
195 
 
identical transfection conditions. The average of the three experiments showed 
 13% reduction in Cav-1 levels (Figure 5-10G) but this reduction was not 
statistically different from control cells. The difference between groups was 
statistically significant by one-way ANOVA F(7, 16) = 4.424, p = 0.0066. 
Tukey post-hoc tests revealed that the reduction in Cav-1 expression was only 
statistically significant between cells transfected with oligofectamine/Cav-1 
siRNA and untransfected cells (p < 0.05).  
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Figure 5-10: Relative levels of Cav-1 in HeLa cells treated with Cav-1 or GFP 
non-targeting siRNA complexed with oligofectamine or EJP-18. (A, C and E) Immunoblots 
from three independent experiments. (B, D, F) Relative Cav-1 expression quantified with 
ImageJ software and normalised to β-tubulin loading control. (G) Relative Cav-1 expression ± 
SD from three independent experiments (B, D, F). Cav-1 levels in EJP-18/Cav-1 siRNA 
transfected cells are highlighted in red. *** Statistical significance p ≤ 0.001.   
 
5.3.2.3.2 Transfection experiments with EJP-18/PAK-1 siRNA complexes in 
HeLa cells 
Identical experiments and data analysis (5.3.2.3.1) were then performed using 
100 nM final siRNA concentration for targeting PAK-1. The molar ratio tested 
for PAK-1 knockdown was 100:1 (peptide/siRNA) to keep the final 
concentration of EJP-18 at 10 μM. Figure 5-11G once again demonstrated very 
efficient protein depletion with oligofectamine giving close to 100% depletion 
of PAK-1 levels. Reduced levels of PAK-1 were also shown in cells 
transfected with EJP-18/PAK-1 siRNA complex (Figure 5-11 B, D and F) and 
the average reduction in PAK-1 expression of three experiments was  60%. 
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There was a problem with incorrect loading in the last two lanes of the gel in 
Figure 5-11E (third experiment). However, since PAK-1 band intensities were 
quantified relative to GAPDH loading control, this difference in loading was 
accounted for in the data analysis. The difference between groups was 
statistically significant by one-way ANOVA F(7, 16) = 11.77, p < 0.0001. 
Tukey post-hoc tests revealed that the reduction in PAK-1 expression was 
statistically significant between cells transfected with oligofectamine/PAK-1 
siRNA and untransfected cells (p < 0.001), cells transfected with 
EJP-18/PAK-1 siRNA and untransfected cells (p < 0.01). It was also found that 
oligofectamine/GFP non-targeting siRNA also reduced PAK-1 levels and the 
reduction was statistically significant (p < 0.05). EJP-18 alone, consistently 
reduced PAK-1 levels but this was not statistically significant. 
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Figure 5-11: Relative levels of PAK-1 in HeLa cells treated with PAK-1 or GFP 
non-targeting siRNA complexed with oligofectamine or EJP-18. (A, C and E) Immunoblots 
from three independent experiments. (B, D, E) Relative PAK-1 expression quantified with 
ImageJ software and normalised to GAPDH loading control. (G) Relative PAK-1 expression ± 
SD of three independent experiments (B, D, E). PAK-1 levels in EJP-18/PAK-1 siRNA 
transfected cells are highlighted in red. *** Statistical significance p ≤ 0.001. ** Statistical 
significance p ≤ 0.01. * Statistical significance p ≤ 0.05. 
5.3.3 Assessing the capacity of EJP-18 to complex and deliver plasmid 
DNA  
Finally, EJP-18 was tested for its ability to complex and deliver plasmid DNA 
to the cell nucleus. Here pEGFP-N1; a vector encoding enhanced green 
fluorescent protein (EGFP), was used as cargo (Liu et al., 2012), and the cells 
were visualised using wide field fluorescence microscopy. 
5.3.3.1 Agarose gel shift assay for investigating EJP-18/plasmid DNA 
complexation 
Agarose gel shift assay were initially performed to assess the DNA complexing 
capacity of EJP-18 for pEGFP-N1. The complexes were prepared by gently 
mixing 1 μg p  FP-N1 with increasing concentrations of EJP-18 to give 
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peptide/plasmid DNA charge ratios between 1:1 and 50:1 as described in 
section 2.7.2.3. Complexes were analysed by agarose gel electrophoresis and 
imaged as described in section 2.7.3. EJP-18 showed clear retardation of the 
plasmid at the lowest charge ratio of 1:1 (Figure 5-12). At higher ratios, a 
smear of DNA was visible from the loading wells and at 20:1 charge ratio, only 
a faint smear of DNA was visible and at higher ratios, the plasmid DNA could 
not be detected. 
 
Figure 5-12: Agarose gel shift assay analysis plasmid complexing ability of EJP-18 for 
pEGFP-N1. EJP-18/pEGFP-N1 complexes were prepared by mixing 1 μg p-EGFP-N1 with 
increasing concentrations of EJP-18 giving rise to charge ratios of peptide/plasmid DNA 
ranging from 1 to 50:1. Image shown is representative from two independent experiments. The 
gels were imaged on the BioRad ChemiDoc system. Red arrow denoting pEGFP-N1 bands. 
5.3.3.2 Transfection of HeLa with EJP-18/pEGFP-N1 vs FuGENE 6 
As EJP-18 effectively complexed plasmid DNA, experiments were performed 
to assess its capacity to deliver DNA to transfect cells. Here the same 
pEGFP-N1 plasmid was employed. HeLa cells were incubated with 
EJP-18/pEGFP-N1 complexes as described in section 2.9.2 to give a highest 
charge ratio of 50:1 (the final peptide concentration was 20.8 μM). Cells 
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transfected with commercial transfection agent, FuGENE 6, served as a 
positive control. This is a cationic polymer formulation and widely used in the 
laboratory. Post complex addition (48 h), the cells on coverslips were washed, 
fixed and mounted on coverslides as described in section 2.10 and analysed by 
wide field microscopy. As expected (Figure 5-13), FuGENE 6 provided high 
transfection efficiency ( 70%) but no EGFP expressing cells were observed 
following incubation with EJP-18/pEGFP-N1 complexes.  
 
Figure 5-13: Transfection experiments in HeLa cells incubated with pEGFP-N1/ 
FuGENE 6 or pEGFP-N1/EJP-18 complexes. Cells on coverslips were incubated with the 
complexes, fixed and analysed by fluorescence microscopy. Cell nuclei were labelled with 
Hoechst 33342. Shown are representative images from three independent experiments. Nuclei 
were labelled blue with Hoechst. Scale bars = 20 μm. 
 
5.4 Discussion 
The aim of this chapter was to investigate the capacity of a novel membrane 
active peptide, termed EJP-18, to deliver different cargos to cells. For each of 
these cargos, the initial experiments focused on assessing complex formation. 
The assays developed are, with the exception of analysing peptide/protein 
complexes, routine in many laboratories. As they represent new 
characterisation procedures for the Jones laboratory, some time was required to 
develop and optimise the methods.  
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Initially an agarose gel shift assay was utilised to assess EJP-18s ability to 
complex BSA. These gels are very straightforward to prepare and run. There 
are, however, only a few examples in the literature of characterisation of CPP/ 
protein complexes as much of the research focuses on experiments employing 
CPPs that are covalently (peptide bond) linked to the protein cargo i.e. as CPP-
protein conjugates. BSA has an isoelectric point of 4.7 so has a net negative 
charge in water (Peng et al., 2005) and EJP-18 has an isoelectric point of 14 
(pepcalc.com) making it positively charged in the same solution allowing for 
the possibility of electrostatic interaction between the two components. Two 
different electrophoresis systems were employed to assess whether any 
complexes had been formed. The agarose gel methods highlighted some 
retardation in BSA mobility and also clear evidence that some of the 
complexes were being retained on the loading wells. The data at between 20:1 
and 100:1 molar ratio were similar suggesting that maximum complexation 
was occurring at 20:1 ratios. Native gel electrophoresis gave very different 
profiles clearly showing a reduction in the expected band at 67 KDa at 20:1 
ratios and then complete disappearance of the band at higher ratios. Methods 
employing direct analysis of the gel on the Typhoon analyser followed by 
Coomassie staining were developed to gain this information and this represents 
a robust method to detect complexes of this nature. During the course of these 
studies, an undergraduate student was supervised in the laboratory by me to 
conduct similar experiments with the CPP R8. Similar to findings with EJP-18 
and BSA interactions, the native gel method provided a better characterisation, 
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compared with agarose gels, of peptide-BSA complex formation (data not 
shown).   
Non-denaturing PAGE of the type used in this thesis has been previously used 
to analyse peptide/protein complexation but only one example of this could be 
found in the literature. Here, Gramicidin A based membrane active peptide 
vector (V AIAvVvWIWIWIWβA S PKKKRKVC) was shown to complex 
and deliver β-gal into HeLa cells (Stoilova et al., 2008). Despite numerous 
examples of CPP mediated delivery of proteins, including BSA, as non 
covalent complexes there is very little information on complex formation of the 
type shown in this thesis. 
BSA has been shown to be internalised into cells via receptor mediated 
endocytosis and fluid phase endocytosis (Synnes et al., 1999, Ikehata et al., 
2008) but in this chapter, no uptake could be detected by confocal microscopy 
at 10µg/mL (0.15 µM) in HeLa cells. However as an EJP-18 complex, at the 
same concentration, BSA was effectively internalised into punctate structures 
strongly suggesting the involvement of endocytosis. Increasing the 
concentration of EJP-18 but keeping the BSA concentration the same 
significantly enhanced cell uptake (Figure 5-2). In these experiments, the 
labelled BSA was confined to punctate structures and there was no evidence 
that any significant fraction was localised to the cytosol. The ability of 10 μM 
EJP-18 to deliver labelled albumin was compared with well characterised 
CPPs, penetratin, R8 and also R8-GC. Toxicity studies were conducted 
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(EJP-18, penetratin, R8) at this point showing that none of these complexes 
were toxic to HeLa cells after 24 and 72 h incubation.  
From these analysis, the extent of cell uptake was EJP-18 >R8 > penetratin 
(Figure 5-3). The data for penetratin are in agreement with Mussbach et al. 
who reported that no detectable amount of ATTO488-BSA in HeLa cells when 
it was non-covalently complexed with penetratin (Mussbach et al., 2011). In a 
seperate study, penetratin was able to deliver rhodamine tagged BSA (as non-
covalent complexes) but this was in different epithelial cell lines; A431 (skin), 
A549 (lung) and Caco-2 (gut) and at a higher 20 μM peptide concentrations 
(Carter et al., 2013). In the latter study, fixed cells were analysed for the 
detection of labelled albumin uptake with penetratin and two other CPPs; Tat 
and transportan. It should be noted however that fixation of CPPs is known to 
give different results relative to live cells due to artefactual localisation induced 
by the fixation process (Richard et al., 2003). This apparent difference in 
penetratin’s ability to deliver albumin may be due an artefact of fixation, to the 
differences in cell lines used, the effect of the different fluorophores attached to 
BSA or combinations of these (Fischer et al., 2004, Jones and Sayers, 2012). 
In this thesis, R8 showed moderate BSA delivery capacity and interestingly, 
the addition of GC to the C-terminus significantly increased uptake. This could 
have been due to the presence of the reactive cysteine amino acid at the 
C-terminus which could have caused disulphide bond formation on the 
peptides or with the peptide and BSA but much more likely is the possibility 
that the reactive thiol groups on the cysteine were interacting with plasma 
Chapter (5) 
 
205 
 
membrane components. In support of this, cysteine-containing CPPs were 
shown to react with thiol membrane proteins, resulting in significantly higher 
uptake compared to that observed with cysteine free equivalent sequences 
(Aubry et al., 2009). It has also been reported that introducing a single cysteine 
residue to penetratin and PenArg (RQIRIWFQNRRMRWRR) enhanced the 
transfection capacity for plasmid DNA (pDNA) in human embryonic kidney 
cells (HEK293T). The peptides alone were poor at delivering pDNA but 
transfection capacity increased when transfection was performed in the 
presence of chloroquine that is known to aid endosomal escape. The influence 
of the cysteine was thought to be via enhanced stabilisation of the complex 
(Amand et al., 2012). In the same study, addition of cysteine residue to the 
penetratin analogue EB1 enhanced transfection in the absence of chloroquine 
suggesting that dimerization can also improve endosomal escape properties. 
The distinct perinuclear and vesicular distribution of EJP-18 and R8/BSA-
Alexa647 complexes suggested these were being delivered to endo-lysosomal 
compartments. Colocalisation analysis demonstrated that 38% of both 
complexes colocalised with lysosomal dextran after 1 h pulse period. Here, a 
portion of the complexes would be localised in early and late endosomes and 
also in lysosomes. The degree of colocalisation increased to 57% and 49% for 
EJP-18/BSA-Alexa 647 and R8/BSA-Alexa 647 complexes respectively 
confirming that more of the complexes had trafficked to lysosomes. It has been 
shown that uncomplexed BSA labelled with a fluorophore can be used as a 
marker for endolysosomal system (Hanaki et al., 2003, Shi et al., 2010). It is 
clear here that the peptide significantly enhanced BSA uptake and that it did 
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not modify the trafficking of the protein. This suggests that CPPs could still 
have a therapeutic role in delivering proteins such as therapeutic enzymes or 
albumin conjugated to drugs to the lysosomes of cells. Although endosomal 
entrapment is believed to be a rate-limiting step in efficient intracellular 
delivery of cargos by CPPs (El-Sayed et al., 2009), lysosomes represent 
important therapeutic targets (Ortolano et al., 2014, Moody et al., 2015). The 
methodology developed for analysing BSA uptake was subsequently used for 
generating new data on cell uptake of novel CPPs associated with labelled 
albumin and also quantum dots. This was recently published with 
acknowledgement of my contribution in the author list (Sayers et al., 2014).  
There is considerable interest in delivering siRNA as a therapeutic targeting a 
range of different diseases. The fact that so many CPPs are positively charged 
makes them attractive candidates as tools for both complexing negatively 
charged nucleotides (siRNA, pDNA) and delivering them to the cytosol of cells 
(Hassane et al., 2010, Boisguérin et al., 2015). Non-covalent complexing 
between CPPs and siRNA has been well described in literature as have reports 
showing CPP mediated delivery of siRNA to cells to reduce protein expression 
(Lundberg et al., 2007, Crombez et al., 2009, Youn et al., 2014). Translation of 
in vitro data to in vivo models and the clinic has however not progressed as 
hoped and the search continues for more effective CPPs. As EJP-18 
represented a novel sequence, it merited further study as a delivery vector for 
nucleotides. 
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Experiments were therefore undertaken to investigate whether EJP-18 could 
also act as a delivery vector for nucleotides. Initially, agarose gel shift assays 
demonstrated that the peptide efficiently complexes two different siRNA 
sequences. This was not surprising based on the number of positive charges (K, 
R) in the peptide and that it has an isoelectric point of 14 and a net charge of 
8.1 at pH 7 (pepcalc.com). 
Effective retardation of siRNA was observed at 20:1 molar ratio peptide: 
siRNA. The observation of reversed mobility of complexes at molar ratios 
above 80:1 (Figure 5-8) suggests that as observed with other CPPs, there is a 
threshold above which increasing the concentration of EJP-18 completely 
neutralises the charge on the siRNA and causes retardation of mobility (Xu et 
al., 2014). In this thesis, reverse mobility was observed as the siRNA moved 
towards the cathode rather than the anode. The retardation of siRNA mobility 
when complexed with EJP-18 could therefore be attributed to the formation of 
high molecular weight complexes (Crombez et al., 2009) and also exclusion of 
ethidium bromide from siRNA (Lundberg et al., 2007, Ramakrishna et al., 
2014).  
EJP-18 was able to deliver Cy5-labelled siRNA (50 and 100 nM) into distinct 
perinuclear region of HeLa cells within 3 h incubation. Of note from these 
experiments was a very heterogeneous labelling pattern within separate 
experiments and within a single field of view. This heterogeneity was observed 
with EJP-18 mediated delivery of siRNA and also for oligofectamine 
complexes that were very effective at delivering functional siRNA into the 
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cytosol. The data with both delivery vectors did not give clear evidence of 
siRNA localisation in the cytosol, but using the microscopy approaches used 
here makes analysing the cytosolic siRNA fraction very difficult. It is much 
easier to identify it in punctate structures that can only be assigned to being in 
the cytoplasm. Different subcellular distribution of siRNA in similar punctate 
structures was observed in CHO-K1 cells incubated with 
oligofectamine/siRNA complexes and also siRNA complexed with the CPP, 
C6 (Jafari et al., 2012). The subcellular labelling pattern of siRNA delivered by 
C6 was also heterogeneous and in comparison with oligofectamine, C6 was a 
poor transfection agent for siRNA. Another study using a modified analogue of 
C6, named C6M1, gave higher transfection but also resulted in heterogeneous 
siRNA labelling in CHO-K1 cells (Xu et al., 2014). It should be noted that in 
both studies, the cells were fixed before imaging while in this thesis, only live 
cell imaging was performed. Tat was also shown to deliver Cy3-labelled 
siRNA into HeLa cells and here the siRNA was localised to distinct perinuclear 
regions in the cytoplasm (Chiu et al., 2004). At 400 nM siRNA, Tat effectively 
reduced the expression of CDK9 protein comparable with incubating the cells 
with lipofectamine/siRNA (150 nM) complexes. Perinuclear siRNA 
distribution was also observed in the lipofectamine transfection suggesting that 
delivery to this region aids in endosomal escape and siRNA activity. 
Heterogeneity of labelling was not mentioned in this study as the microscopy 
images were of single fixed cells only rather than a group of live cells as shown 
in this thesis.   
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Although EJP-18 was able to deliver Cy5-labelled Cav-1 siRNA, 
EJP-18/siRNA complexes at the molar ratio of 200:1 (EJP-18 concentration 10 
μM) were unable to reproducibly reduce Cav-1 expression in HeLa cells 
compared with oligofectamine (Figure 5-10). This could be due to endosomal 
entrapment of the complexes and/or the possibility that EJP-18 binding to 
siRNA is very strong giving little opportunity for disassociation and release 
towards dicer and the RISC loading complex. Further investigations using 
chloroquine could be performed to examine whether endosomal entrapment is 
the limiting step in knockdown efficiency. As there was some evidence of 
EJP-18 mediated siRNA delivery, experiments were performed with another 
siRNA targeting PAK-1. An experiment using 50 nM PAK-1 siRNA once 
again gave disappointing results (data not shown) but at 100 nM siRNA 
concentration, EJP-18 reproducibly delivered PAK-1 siRNA giving an average 
reduction in PAK-1 levels of 60% (Figure 5-11). However, it should be noted 
that transfection with GFP non-targeting siRNA with oligofectamine also 
caused a significant reduction in PAK-1 expression which raises some concern 
regarding the use of this siRNA and/or oligofectamine as a control. It should be 
noted that both expression of Cav-1 and PAK-1 was sensitive to some of the 
controls in here. EJP-18 alone could conceivably have an effect on EGFR 
biology that could then have indirectly influenced the expression of Cav-1 and 
PAK-1. This was one of the reasons why this peptide was initially studied. 
Studies are underway assessing any influence the peptide has on EGFR 
signalling and a cell line constitutively expressing eGFP is now available in the 
laboratory to further assess the capacity of EJP-18 to deliver siRNA (eGFP).  
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EJP-18 was able to complex pEGFP-N1 plasmid (Figure 5-12) however; it 
failed to transfect HeLa cells, despite it like Tat having a NLS. Time did not 
allow for similar experiments investigating the uptake of fluorescent plasmid 
DNA or alternative plasmids. Endosomal entrapment and strong peptide-
pDNA association are again factors that cannot be overlooked. Experiments 
involving the addition of chloroquine could again highlight whether endosomal 
entrapment is the major hurdle as addition of chloroquine increased the 
transfection efficiency of Tat-oligomers/plasmid complexes (Rudolph et al., 
2003).  
5.5 Conclusions 
The aim of this chapter was to develop techniques to assess the capacity of the 
previously uncharacterised EJP-18 to deliver three types of cargos into cells. 
The data from these developed methods including gel shift assays and non-
denaturing gels confirmed that the peptide could effectively complex both 
nucleotides and a protein. In the case of protein and siRNA, EJP-18 
demonstrated that it could respectively deliver cargo into cells with higher 
efficiency compared with two established CPPs and a commercial siRNA 
transfection reagent. The peptide showed no transfection capacity for plasmid 
DNA but was able to deliver fluorescent siRNA to cells and it remains to be 
determined whether it can also deliver functional siRNA to silence expression 
of proteins. All this suggests that EJP-18 or variants of could be further studied 
as bioportides and/or delivery vectors and some of these are described in the 
next chapter. 
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6 Chapter 6: Cellular Uptake and Protein Delivery of EJP-21 
and E-64562 
6.1 Introduction 
During studies investigating the capacity of EJP-18 to bind to cells and deliver 
cargo to cells, a study was published where a peptide sequence termed E-64562 
(RRRHIVRKRTLRRLLQER) was conjugated to the Tat sequence to give 
TE-64562 (RKKRRQRRRG-RRRHIVRKRTLRRLLQER (Boran et al., 2012). 
The cargo here is, like EJP-18, derived from the EGFR juxtamembrane region 
but is missing the N-terminal LFM sequence and gaining a QER at the 
C-terminus (Table 2-1). In breast cancer MDA-MB-231 cells, E-64562 was 
non toxic up to 100 µM but TE-64562 was 100% toxic at the same 
concentration and displayed an EC50 of 12.6 μM. T -64562 also had in vivo 
activity in nude mice bearing MDA-MB-231 tumors.  
The other main findings from the Boran et al. manuscript are summarized here: 
1. In cancer cell lines, the effect of TE-64562 on cell viability varied 
according to cancer cell type, relative ErbB levels and the presence of 
serum. TE-64562 was more toxic to cells with medium and high 
expression of these receptors. NR6 (NIH/3T3 fibroblasts) which is an 
EGFR-null cell line was relatively resistant to the effect of TE-64562 
(EC50= 104.2 μM). The effect of T -64562 appeared to be specific to 
cancer cells as normal lung fibroblasts (IMR-90) were very resistant to 
TE-64562 treatment although these fibroblasts express EGFR. The 
activity of TE-64562 was reduced ( C50= 38.4 μM) in normal breast 
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(human mammary epithelial cell, HMEC) compared to EGFR/Her2 
overexpressing breast cancer cells. 
2. A fluorescein derivative of TE-64562 was shown at only 1.25 µM 
extracellular concentration to label the entire cytoplasm of cells after 
50 min incubation and clearly demonstrating that it was entering the 
cytosol. 5-carboxyfluorescein (FAM)-E-64562 alone also labelled cells 
but the staining suggested it was aggregating and there was no 
evidence of cytosolic labeling. Further microscopy and cell uptake 
analysis were not performed, but there was also evidence of significant 
aggregation of FAM-TE-64562. 
3. In an in vivo model of nude mice bearing MDA-MB-231 tumors, IP 
injection of TE-64562 reduced tumor growth and increased the survival 
rate of the treated-mice. 
4. Evidence was provided that TE-64562 (12.5 μM) inhibited   FR 
signaling and dimerization and caused a dose-dependent reduction in 
EGFR levels in MDA-MB-231 cells.  
Of the 28 residues in the TE-64562 chimera, 17 are either lysines or arginines 
and thus this represents a highly basic peptide and of interest from a delivery 
perspective was the contribution made by the cargo to cell uptake. 
Data presented on EJP-18 in Chapter 4 showed that it was able to enter cells to 
an extent comparable to R8. Interestingly, it showed toxicity in a manner that 
appeared to be dependent on EGFR expression; this was also noted for 
TE-64562 i.e. high EGFR expressing cell lines were more resistant. EJP-18 
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was also able to complex and deliver different cargos other than a fluorophore. 
One of the initial criteria for investigating EJP-18 was the fact that it had a 
hydrophobic N- and C-terminus that was hypothesised to influence cell 
interaction and uptake. Noting here that previous studies on a Bcl-2 targeting 
peptide had demonstrated that single hydrophobic residues several residues 
away from the CPP sequence can influence uptake and affect cell toxicity 
profiles (Watkins et al., 2011). 
6.2 Summary, Aims and Objectives 
In view of the data presented in chapters 4 and 5 and new published 
information, a new sequence termed EJP-21 (642-
LFMRRRHIVRKRTLRRLLQER-662) was purchased to investigate the role 
of N- and C-terminal modifications and in view of the Boran et al. study, the 
E-64562 peptide i.e. lacking the Tat extension was also investigated. As 
unmodified peptides, E-64562 and EJP-21 have masses of 2442.92, and 
2834.45 respectively but the same isoelectric point of 12.58 and net charge of 
8.1 at pH 7.0 (pepcalc.com). The specific aims of this chapter were to study the 
cellular uptake and toxicity of sequences- EJP-21 and E-64562, and to 
investigate their ability to deliver fluorescent albumin to HeLa cells. 
The objectives of this chapter were then to: 
1- Analyse the effect of EJP-21, E-64562 and their rhodamine conjugates 
on viability of cancer cell lines using CellTiter-Blue assay.  
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2- Analyse the cellular uptake of fluorescent conjugates of EJP-21 and 
E-64562 under different experimental conditions using live cell 
confocal microscopy. 
3- Study the colocalisation of rhodamine conjugates of EJP-18, EJP-21 
and E-64562 with dextran that was pre-loaded into the endolysosomal 
system. 
4- Analyse the cellular delivery capacity of EJP-21 and E-64562 for BSA-
Alexa647. 
6.3 Results 
6.3.1 Cell Viability assays for EJP-21, E-64562 and their rhodamine 
conjugates 
6.3.1.1 Effect of EJP-21 and E-64562 on the cell viability in a panel of 
cancer cell lines 
In order to assess the cytotoxicity of EJP-21 and E-64562, cell viability was 
examined in a panel of cancer cells as used in EJP-18 experiments from 
Chapter 4. Cells seeded in 96-well plates were incubated with 0-100 μM 
EJP-21 or E-64562 for 24 h under tissue culture conditions. Viability was then 
determined using the CellTiter-Blue assay. Figure 6-1 shows that EJP-21 and 
E-64562 had a different cell viability profile from EJP-18 (Figure 4-2). 
E-64562 had no effect on viability in any of the tested cell lines at all studied 
concentrations. EJP-21 was also non toxic to all cell lines at the studied 
concentrations except for KG1a where 100 μM of the peptide induced 25% 
loss in cell viability.  
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Figure 6-1: Viability of different cell lines incubated with EJP-21 and E-64562. Viability 
of cells was evaluated using CellTiter-Blue assay following 24 h incubation with 0-100 μM 
EJP-21 or E-64562 and is expressed as the percentage of viable cells relative to untreated 
controls. Results represent means ± SD for three independent experiments performed in 
duplicate. 
 
6.3.1.2 Effect of Rh-EJP-21 and Rh-E-64562 on the cell viability in HeLa 
cell line 
Cell viability experiments were also performed for the rhodamine labelled 
peptides (Rh-EJP-21 and Rh-E-64562) on HeLa cells that were then going to 
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be used for cell uptake studies. Rhodamine correction was performed as 
described in section 4.3.1.2. Figure 6-2 shows that up to 20 μM, Rh-EJP-21 
had no significant effect on viability but at 100 µM there was complete cell 
death. Cells treated with Rh-E-64562 were > 85 % viable up to 100 μM peptide 
concentration.  
 
Figure 6-2: Viability of HeLa cells incubated with Rh-EJP-21 and Rh-E-64562.  
Rhodamine corrected viability of cells was evaluated using CellTiter-Blue assay following 24 
h incubation with 0-100 μM Rh-EJP-21 or Rh-E-64562. Cell viability is expressed as the 
percentage of viable cells relative to untreated controls. Results represent means ± SD for three 
independent experiments performed in duplicate. 
 
6.3.2 Cellular uptake (subcellular distribution) of Rh-EJP-21 and 
Rh-E-64562 in HeLa cells  
To evaluate the cellular uptake and distribution of EJP-21 and E-64562, HeLa 
cells were seeded into 35 mm MatTek dishes and after 24 h incubation, were 
treated for 1 h with 5-20 μM Rh-EJP-21 or 5-20 μM Rh-E-64562. The cells 
were washed then imaged as live cells by confocal microscopy. Figure 6-3 
shows clear uptake of 5 μM Rh-EJP-21 into punctate vesicles whose intensity 
increased at 10 μM. At 20 μM, the localisation changed significantly: some 
cells have only punctate cytosolic vesicles while others exhibit additional 
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diffuse cytosolic labelling and nucleolar labelling was also observed (Figure 
6-3).  
 
Figure 6-3: Uptake of Rh-EJP-21 peptide into HeLa cells at 5-20 μM in SFM. Cells were 
incubated with 5-20 μM Rh-EJP-21 in SFM for 1 h at 37ºC, washed and imaged by confocal 
microscopy. Representative images (N=3) showing either a single section through the cell at 
the mid-point of the nucleus or maximum projection of the whole cell. Nuclei were labelled 
blue with Hoechst. White arrows indicate nucleolar labelling. Scale bars = 20 μm. 
 
Rh-E-64562 (10 μM) also labelled punctate vesicles but only very weak 
fluorescence was observed at 5 μM (Figure 6-4). Again at 20 μM and similar to 
Rh-EJP-21, some cytosolic distribution of Rh-E64562 was observed but there 
was no evidence of nucleolar labelling. 
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Figure 6-4: Uptake of Rh-E-64562 peptide into HeLa cells at 5-20 μM in SFM. Cells were 
incubated with 5-20 μM Rh-E-64562 in SFM for 1 h at 37ºC, washed and imaged by confocal 
microscopy. Representative images (N=3) showing either a single section through the cell at 
the mid-point of the nucleus or maximum projection of the whole cell. Nuclei were labelled 
blue with Hoechst. Scale bars = 20 μm. 
To detect whether the cytoplasmic labelling observed at 20 µM for both 
peptides was due to general plasma membrane leakage, the cells following 
incubation with peptides were further incubated for 5 minutes with imaging 
medium containing the fluorescent probe DRAQ7. Figure 6-5 shows the 
distribution of the peptides (pseudocolour green) and also some orange 
DRAQ7-stained nuclei in cells treated with 20 μM Rh-EJP-21. All cells that 
had clear cytosolic peptide labelling were not also DRAQ positive. All cells 
treated with 20 μM Rh-E-64562 were free from DRAQ7 (Figure 6-5). The data 
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here further highlight the higher capacity of Rh-EJP21 to enter cells compared 
with Rh-E-64562 but viability data (Figure 6-1 and 6-2) suggest that 
rhodamine may have significant influence on membrane binding and integrity 
and also potentially on cell uptake. 
 
Figure 6-5: Uptake of 20 μM Rh-EJP-21 and Rh-E-64562 peptides into HeLa cells in 
SFM. Cells were incubated with 20 μM Rh-EJP-21 or Rh-E-64562 in SFM for 1 h at 37ºC, 
washed and imaged by confocal microscopy. Representative images (N=2) showing either a 
single section through the cell at the mid-point of the nucleus or maximum projection of the 
whole cell. Dead or permeabilized nuclei were labelled red with DRAQ7 and the rhodamine 
peptide labelled green. Scale bars = 20 μm.   
 
6.3.3 Cellular uptake of 10 μM Rh-EJP-21 and Rh-E-64562 in HeLa cells 
at 4 and 37ºC 
To test the effect of temperature on Rh-EJP-21 and Rh-E-64562 uptake, HeLa 
cells were incubated for 1 h with 10 μM of both peptides at 4 or 37ºC. The 
cells were then examined by live cell confocal microscopy. As expected, 
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vesicular peptide was observed for both peptides at 37ºC but there was no 
evidence of cell uptake at 4˚C (Figure 6-6). 
 
Figure 6-6: Uptake of Rh-EJP-21 and Rh-E-64562 into HeLa cells at 10 μM in SFM at 
(A) 37ºC or (B) 4ºC. Cells were incubated with 10 μM Rh-EJP-21 or Rh-E-64562 in SFM for 
1 h at (A) 37ºC or (B) 4ºC, washed and imaged by confocal microscopy. Representative images 
(N=3) showing either a single section through the cell at the mid-point of the nucleus or 
maximum projection of the whole cell. Nuclei were labelled blue with Hoechst. Scale bars = 
20 μm. 
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6.3.4 Analysis of the subcellular distribution of Rhodamine conjugates of 
EJP-18, EJP-21 and E-64562  
The observation that the rhodamine conjugates of EJP-18 (Figure 4-7), EJP-21 
and E-64562 at 10 μM labelled vesicular structures when incubated at 37ºC 
suggested the involvement of endocytosis in cell uptake. To investigate this, 
fluorescent dextran was utilised as an endocytic probe to specifically label 
lysosomes. For this, cells were incubated with dextran-Alexa488 for 2 h 
followed by an overnight chase in dextran-free medium as described in section 
2.4.1.5. The next day the cells were washed and incubated for 1 h with the 
Rh-peptides or for 1 h followed by a 1 h chase in peptide free medium. Figure 
6-7A shows low colocalisation between lysosomes and Rh-EJP-18 (Pearson’s 
coefficient = 0.28 ± 0.04). A higher degree of traffic to these organelles was 
noted for Rh-EJP-21 and Rh-E-64562 (Pearson’s coefficient = 0.37 ± 0.02 and 
0.39 ± 0.03 respectively). Increasing the time of incubation with the peptides (1 
h pulse- 1 h chase) increased the degree of colocalisation between the two 
fluorophores with Rh-EJP-18, Rh-EJP-21 and Rh-E-64562 giving Pearson’s 
coefficients of 0.42 ± 0.05, 0.56 ± 0.05 and 0.45 ± 0.02 respectively. The 
difference in lysosomal dextran colocalisation was statistically significant 
between the different peptides by one-way ANOVA F(5, 12) = 18.72, p < 
0.0001 and Tukey post-hoc tests was performed to reveal the statistical 
significance between groups (Figure 6-7C). 
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Figure 6-7: Traffic of Rh- EJP-18, Rh-EJP-21 and Rh-E-64562 to lysosomes in HeLa 
cells. Cells were incubated with dextran-Alexa488 for 2 h followed by an overnight chase and 
were then incubated with 10 μM Rh-peptides for (A) 1 h or (B) 1 h followed by a 1 h chase. 
The cells were then washed and imaged by confocal microscopy. Representative images (N=3) 
showing a single section through the cells and the right panel in (A) and (B) shows a zoomed 
image of an identified cell in merge panel. (C) plot for Pearson’s coefficient values and 
statistical significance between groups. Statistical Significance *** p ≤ 0.001, ** p ≤ 0.01 and 
* p ≤ 0.05. White arrows denote colocalisation. Scale bars = 20 μm.  
6.3.5 Cellular uptake (Internalisation) of labelled BSA complexed with 
EJP-21 and E-64562 in HeLa cells in SFM 
To examine the capacity of EJP-21 and E-64562, for protein delivery they, like 
EJP-18 in Chapter 5, were mixed with BSA-Alexa647 and then incubated with 
HeLa cells. Here, 5 and 10 μM peptide/BSA-Alexa647 complexes were 
prepared and incubated with HeLa cells as described in section 2.4.1.3. At 10 
μM, there was no evidence that  -64562 delivered the cargo (Figure 6-8A). 
Upon mixing with EJP-21, BSA-Alexa647 was clearly identified in vesicular 
structures in the distinct perinuclear region of the cell at 10 μM (Figure 6-8A) 
and to a lesser extent at 5 μM (Figure 6-8B).   
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Figure 6-8: Internalisation of peptides/BSA-Alexa647 complexes into HeLa cells in SFM. 
(A) 10 μM   P-21 or E-64562 or (B) 5 μM   P-21 were incubated with BSA-Alexa647 and 
subsequently added to HeLa cells that were then incubated for 1 h at 37ºC, washed and imaged 
by confocal microscopy. Bottom row in (A) shows cells incubated with BSA-Alexa647 (10 
μg/mL) alone. Representative images (N=3) showing either a single section through the cell at 
the mid-point of the nucleus or maximum projection of the whole cell. Nuclei were labelled 
blue with Hoechst. White arrows indicate distinct perinuclear labelling. Scale bars = 20 μm.   
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6.3.6 Cytotoxicity of peptides/BSA-Alexa647 mixtures 
EJP-21 and E-64562 were found to be nontoxic at 10 μM (Figure 6-1); the 
concentration used to deliver labelled albumin. To ensure that peptide/BSA-
Alexa647 complexes were also nontoxic, HeLa cells were incubated with the 
complexes (10 µM peptide/10 µg/mL BSA) under tissue culture conditions for 
24 or 72 h. Cell viability was then determined using CellTiter-Blue assay as 
described in section 2.3.2. Figure 6-9 shows that none of these complexes were 
toxic to cells at the concentrations used here and this was confirmed using one-
way ANOVA analysis. 
 
Figure 6-9: Viability of HeLa cells incubated with peptide/BSA-Alexa647 complexes. 
Viability of cells was evaluated using CellTiter-Blue assay following (A) 24 h or (B) 72 h 
incubation with peptides/BSA-Alexa647 complexes in HeLa cells. Results represent means ± 
SD for (A) three independent experiments or (B) two independent experiments performed in 
duplicate. 
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6.4 Discussion 
The primary aim of this final section of the project was to test the cellular 
uptake, subcellular distribution and cytotoxicity of two peptide sequences 
related to EJP-18. E-64562 was a peptide that was reported, as a Tat-chimera, 
to have, in an EGFR dependent manner, anti-cancer activity (Boran et al., 
2012). Also of significant interest is that a peptide termed EGFR-13 
corresponding to amino acids 645-657 (RRREIVRKRTLRR) of the  EGFR JM 
domain was found to increase the tyrosine kinase activity and 
autophosphorylation of EGFR (Poppleton et al., 1999). EGFR-13 resembles 
the sequence of E-64562 with five missing residues at the C-terminus and the 
fourth residue (underlined) is glutamic acid rather than histidine that is present 
in the original sequence. This H-E change was not discussed and may in fact 
represent a typographical error. Peptide T654 (RKRT(PO3H2)LRRLK, with a 
phosphorylated T, has some overlap with EJP-18 and E-64652 and in a 
separate study, was able to enter cells in the absence of a CPP and affect EGFR 
biology (Dittmann et al., 2010). This linked with previous studies in our 
laboratory showing the effects of hydrophobicity on the terminus of bioactive 
peptides, with respects to cell interaction and uptake, in part led to the 
investigations in this thesis using two other peptides based on EJP-18. 
Viability assays revealed that E-64562 was not toxic in any of the cell lines 
tested up to 100 μM. This is in line with data published by Boran et al. (2012) 
using several other cell lines with only the MDA-MB-231 line overlapping 
between this study and presented thesis. EJP-21 had no effect on cell viability 
up to 100 μM in any of the cell lines tested except for K 1a were minimal 
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toxicity (15%) was noted at 100 µM. A study of a sequence from the JM 
region of EGFR (643-FMRRRHIVRKRTLRRLLQERE-663) that is very close 
to the EJP-21 sequence conjugated to the CPP PTD-4 (YARAAARQARA), 
termed EJ1, was toxic to two breast cancer cells: MDA-MB-468 and T47D at 
20 μM, however, MDA-MB-231 cells were less sensitive to EJ1 peptide at the 
same concentration (Hart et al., 2013). The difference was attributed to K-ras 
mutations that protected the cells from EJ1. 
E-64562, EJP-18 and EJP-21 are all peptides from the JM region of EGFR and 
the later two have an additional LFM at the N-terminus and this triplet resides 
within the membrane. Toxicity profiles of E-64562 and EJP-21 differed 
considerably from EJP-18 (Figure 4-2). Noted here is that EJP-18 has two 
hydrophobic termini (LF and LL), E-64562 has two very hydrophilic termini 
(RR and ER) and EJP-21 has the N-terminus of EJP-18 and the C-terminus of 
E-64562. This difference in the terminal hydrophobicity of the peptides may 
have altered peptide-membrane interaction and possible downstream effects 
including plasma membrane perturbation or influx of the peptides into the cells 
to exert some other effect. It would now be interesting to study the interaction 
of these peptides with artificial membrane models (Di Pisa et al., 2014). 
In this study, Rh-E-64562 was clearly shown to enter HeLa cells, in a 
concentration dependant manner, i.e. in the absence of a CPP. At 5 µM, 
fluorescence was observed at very low levels in the cytoplasm within 1 h 
(Figure 6-4). The Boran et al. study (2012) showed that FAM-E-64562 at 5 μM 
was unable to enter MDA-MB-231 cells even after an overnight incubation 
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however, the uptake of higher concentrations (as in our study) was not 
included. Conjugation of Tat to E-64562 was shown to be essential for 
internalisation of the FAM conjugated peptide and for this Tat conjugate, 
strong cytosolic labelling was observed at 5 μM (Boran et al., 2012). The 
reason for the difference between results presented in this thesis and Boran et 
al. could have been due to differences in the cell lines used in the studies or 
potentially due to the use of different peptide concentrations. It may also be 
that the differences in uptake (at 5 μM) were due to the use of different 
fluorophores, FAM vs rhodamine. As described, the incorporation of a 
fluorescent label can change the cellular uptake and intracellular localisation of 
CPPs (Puckett and Barton, 2009, Madani et al., 2011, Palm-Apergi et al., 2012, 
Bechara and Sagan, 2013). Further to the discussion in chapter 4, the CPP- 
Dmt-D-R-F-K (Dmt, 2′,6′-dimethyltyrosine) attached to relatively small, amino 
acid-based fluorophores ß-dansyl-L-α,ß-diaminopropionic acid (dns) or 
ßanthraniloyl-L-α,ß-diaminopropionic acid (atn) had different subcellular 
localisation patterns in Caco-2 cells. The dns form showed diffuse cytoplasmic 
distribution and caused mitochondrial swelling and cell death while the atn 
form exhibited a mitochondrial localisation and served as a mitoprotective 
agent (Szeto et al., 2005). Additionally, conjugation of fluorescein 
isothiocyanate (FITC) to the N-terminus of 
19
F-octaarginine using a ɣ-
aminobutyric acid (GABA) spacer, has been shown by in-cell fluorine-19 
nuclear magnetic resonance (NMR) spectroscopy to increase uptake. This was 
attributed to the hydrophobic nature of the fluorophore which was thought to 
increase the peptide’s affinity for cell membranes (Okamura et al., 2005). 
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The mixed pattern of distribution (punctate vesicles and cytosolic labelling) 
observed when HeLa cells were incubated with 20 μM Rh-E-64562 (Figure 
6-4) was similar to that seen in the Boran et al. study for MDA-MB-231 cells 
following incubation with FAM-TE-64562 at 1.25 μM (Boran et al., 2012). 
This may suggest that E-64562 can enter cells at relatively high concentrations, 
but as expected, Tat promotes cell uptake at lower concentration that may be 
aided by the cargo. 
Figures 6-3, 6-7A and data from chapter 4 (Figure 4-7) reveal that the uptake 
of Rh-EJP-21 at 5-10 µM exhibited similar distribution to Rh-EJP-18 in 
vesicular structures of HeLa cells. Rh-EJP-21 fluorescence intensity was, 
however, higher and at 20 µM, cytosolic labelling was more prominent and 
some cells incubated with Rh-EJP-21 had fluorescent nucleoli. Cytosolic 
labelling at this concentration was associated with plasma membrane 
permeabilization illustrated by red staining of nuclei by DRAQ7. However, 
there was also clear evidence of cytosolic peptide localisation in DRAQ7 
negative cells suggesting that the peptide entry was not solely due to plasma 
membrane disruption. Viability assays showed that 20 μM Rh-EJP-21 was 
non-toxic to HeLa cells but this could be due to the difference in the duration 
of incubation with the peptide and the possibility that the DRAQ7 positive cells 
recover from the initial damage. Alternatively, this could be due to serum 
effects. Cell viability assays were performed in the presence of serum while in 
the uptake experiment; the cells were incubated with Rh-EJP-21 in absence of 
serum. The absence of serum may have increased the cell sensitivity to the 
peptide’s effect. In the study of Boran et al. (2012), the presence of serum 
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reduced the sensitivity of MDA-MB-231 to TE-64562-induced toxicity. A 
separate study showed that increasing serum concentrations in the medium 
decreased the toxicity induced by phosphorodiamidate morpholino oligomers-
R9F2C (PMO-R9F2C) conjugates (Moulton et al., 2004). Further comparative 
analysis investigating the cytotoxic and delivery capacity of these peptides in 
the absence and presence of serum are required. 
 Rh-E-64562 and Rh-EJP-21 entered cells in a temperature-dependent manner 
(Figure 6-6). Both peptides, as with Rh-EJP-18, were internalised at 37ºC and 
their uptake was abolished at 4ºC which confirms the involvement of an active 
process and endocytosis being prominent at concentrations ≤ 10 µM. At 20 
µM, there was strong evidence that direct translocation was occurring manifest 
as strong cytosolic labelling. Colocalisation studies at 10 µM showed that after 
1 h incubation with the Rh-peptides followed by 1 h chase, a significant 
fraction had been delivered to lysosomes. This further confirms the 
involvement of endocytosis in the uptake of these peptides.   
EJP-21 (10 μM), efficiently delivered labelled BSA into HeLa cells (Figure 
6-8) and the protein was found localised in a distinct perinuclear region, 
showing similar uptake and distribution to that by EJP-18 (Figure 5-3). 
Somewhat surprisingly, E-64562 was unable at the same concentration to 
deliver BSA although it effectively delivered rhodamine. Due to time 
constraints, the ability of E-64562 to complex BSA was not assessed by native 
PAGE in this thesis but subsequent studies using a Zetasizer Nano ZS 
instrument that was only recently purchased by the department showed similar 
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BSA complexation ability for this EJP-18 and EJP-21 (Dr Edward Sayers). It 
may be that the N-terminal LFM in EJP-18 and EJP-21 is critical for enhancing 
cell entry of the peptide as a fluorescent entity but also when it is attached to 
much larger cargo such as BSA. Placing hydrophobic residues at either the N- 
or C-terminus of CPPs has been found in a number of studies to enhance 
membrane interaction and uptake of CPPs (Jones and Sayers, 2012). For 
example the addition of a distal phenyl alanine to different CPPs (penetratin, 
R8 and TP10) has been found to enhance the delivery capacity of range of 
macromolecules (Sayers et al., 2014). pVEC (Table 1-1), a CPP derived from 
the murine vascular endothelial-cadherin protein, has an extremely 
hydrophobic N-terminus (LLIIL) (Elmquist et al., 2001). The deletion of the 
three amino acids from the N-terminus or replacement of the entire N-terminal 
hydrophobic domain by alanine completely abolished the uptake in human 
bowes melanoma cells (Elmquist et al., 2006). In another study, the addition of 
two phenylalanine residues to the C-terminus of nonaarginine (R9) improved 
the delivery of phosphorodiamidate morpholino oligomers (PMO) and R9F2C-
PMO conjugates corrected splicing more effectively than PMO conjugated 
with Tat, penetratin or PTD4 (Moulton et al., 2004). A single hydrophobic 
residue mutation (Alanine-Phenylalanine) at the N-terminus of the Nur77 
derived D-Nu-BCP-9-r8 (fsrslhsll) was shown to significantly enhance 
membrane interaction and cellular uptake of the peptide and to mediate rapid 
cell death via a Bcl-2 independent mechanism. Mutating the first and last 
residue of D-NuBCP-9-r8 cargo to an alanine led to loss of activity of the 
peptide (Watkins et al., 2011). In conclusion, it is apparent that the 
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hydrophobic (LFM) N-terminus in EJP-21 is essential for the delivery 
properties of the peptide.  
There are also important issues here regarding the different cargos used to 
show delivery capacity for the EGFR derived peptides; rhodamine vs BSA and 
their influence on CPP uptake. In the case of E-64562, the hydrophobicity of 
rhodamine at the N-terminus may have aided cell association and entry, but 
BSA that would interact very differently with the peptide, may serve as a 
hindrance to cell entry either via endocytosis or especially via direct plasma 
membrane translocation. 
6.5  Conclusions 
The initial aims of this chapter were to study the cellular uptake, subcellular 
distribution and cytotoxicity of two peptides related to EJP-18 that also 
originated in the JM region of EGFR. Although having closely related 
sequences, they gave distinct cell cytotoxicity profiles compared with EJP-18. 
Both EJP-21 and E-64562 as rhodamine conjugates were internalised by HeLa 
but only the former delivered BSA. Key identified factors that influenced cell 
uptake were the hydrophobicity at the N- or C-terminus and the nature of the 
cargo. 
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7 Chapter 7: General Discussion 
Cell penetrating peptides (CPPs) have received significant research interest in 
the last two decades as potential delivery vectors for a range of therapeutic 
cargo. Studies have generally focused on areas such as: (1) using CPPs as 
delivery vectors for a variety of macromolecules including peptides, proteins, 
plasmid DNA and siRNA in vitro and in vivo, (2)   elucidating the mechanisms 
of cell entry of CPPs and the numerous factors that influence uptake and also 
subcellular distribution- attached cargo or fluorophore, cell line, temperature 
and serum (3) defining the structural basis of internalisation capacity in order 
to develop new CPPs with improved activity. Hundreds of CPP sequences have 
now been described that are covalently or non-covalently associated with cargo 
not forgetting bioportides that serve as single entity delivery vectors and 
modifiers of cell physiology (Howl et al., 2012). However, despite this huge 
effort spent to study and cover the above research areas, the translation of CPP 
based delivery systems from preclinical research to human subjects and clinical 
trials has been disappointing. 
One of the aims of this project working in conjunction with Newcastle 
University was to extend the research about an existing CPP; penetratin, and its 
capacity to deliver the NBD targeting the NF-B pathway. Pen-NBD peptide 
(commercially available) is well described in the literature to influence NF-B 
activity; albeit at high concentrations. To achieve this aim, there was a need to 
develop reliable in house in vitro models for analysing activation or attenuation 
of NF-B signalling. In these respect, the project was successful and two 
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assays were developed and are now available in the laboratory for subsequent 
studies: (1) Western blotting and immunodetection of IB-α degradation in 
lysates of cells treated with the NF-B activator TNF-α and (2) luciferase assay 
in a HeLa cell line that expresses luciferase in response to NF-B activation. 
Extending from previous reports, the ability of Pen-NBD peptide to interfere 
with NF-B signalling via inhibition of TNF-α-induced NF-B activation 
using the developed assays was assessed before designing and studying new 
peptide sequences. Surprisingly, Pen-NBD peptide was unable to reduce 
TNF-α-induced IκB-α degradation however, the results for the NF-B reporter 
HeLa cell line showed a significant reduction in TNF-α-induced luciferase 
activity when cells were pre-treated with the peptide. Interestingly, the 
reduction in TNF-α-induced luciferase activity was not limited to the effect of 
Pen-NBD chimera and reduced luciferase activity was also observed in the 
stable HeLa cells pre-treated with penetratin or DMSO (the diluent). This 
reduction in luciferase activity was not observed when the same experiment 
was performed using R8 instead of penetratin. In line with published findings, 
penetratin was considered to have intrinsic biological activity rather than just 
being an inert delivery vector (Bolton et al., 2000, Fotin-Mleczek et al., 2005, 
Letoha et al., 2006). The results presented in Chapter 3 highlighted some 
potentially significant issues involving a number of factors that could influence 
the CPP studies including: the influence of the CPP alone, the specifics of the 
assays with respects to when and how long the reagents are incubated with 
cells and the choice of cell lines. Another critical factor that was explored in 
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this chapter was the influence of diluents on the conducted studies. A major 
factor hampering studies employing NF-B targeting peptides was their 
insolubility in aqueous solutions. This significantly hindered progress towards 
designing new peptide based systems for targeting this pathway. Because of 
this and the availability of EJP-18 as a novel membrane active peptide, the 
work on targeting NF-B was halted but we continued to interact with 
collaborators and our work with them was presented as a poster in two 
international conferences (see publications on page xviii). 
Some very preliminary work had been performed on EJP-18 before this PhD 
studentship commenced. EJP-18 represented a novel peptide, appeared to be 
membrane active and had an interesting sequence of alternating 
hydrophilic/cationic and hydrophobic residues. From initial data and published 
work that appeared during the course of this thesis (Boran et al., 2012), other 
peptides based on the EJP-18 sequence were also studied- EJP-21 and 
E-64562. The difference in the N- and C-terminus between the three peptides 
resulted in very interesting observations regarding their cytotoxicity, cell 
uptake and capacity to deliver cargo. The hydrophobic N-terminus was clearly 
important for cell interaction and delivery capacity. EJP-21, sharing the 
hydrophobic N-terminus with EJP-18, was able to deliver labelled albumin as 
efficient as EJP-18, however, E-64562 that lacks the hydrophobic N-terminus 
was unable to deliver albumin at the same concentration. This is in line with 
publications and previous observations in Jones laboratory and others that 
highlighted the significant effect of placing hydrophobic residues to either 
termini of CPPs or associated cargo on CPP-membrane binding and uptake 
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(Elmquist et al., 2006, Watkins et al., 2011, Jones and Sayers, 2012, Sayers et 
al., 2014).  
The effects of the three peptides on cell viability were unexpected and although 
the three peptides were from the same origin, a significant difference in 
viability profiles was observed with EJP-18 being the most toxic and in a 
seemingly EGFR-dependent manner. Studies are now underway to investigate 
the effects of these peptides on EGFR signalling. EJP-18 and EJP-21 were able 
to deliver BSA into the cells by endocytosis and in the case of EJP-18 to 
deliver it to lysosomes. Again confirming endocytosis as the mechanism, all 
three peptides, as fluorescent conjugates, were localised to this organelle after 
1 h incubation at ≤ 10 μM. In the thesis, a non denaturing PAGE based assay 
was developed to assess the capacity of EJP-18 to complex BSA and this will 
be a useful tool for subsequent studies looking at protein complexation by 
CPPs for cell delivery. Studies in the laboratory are now comparing protein 
complexing ability of the three EGFR derived peptides using this new assay 
and also the newly acquired Zetasizer that will provide additional information 
with respects to charge and size of the complexes. The work presented on BSA 
delivery here was instrumental for studies investigating uptake by other novel 
CPP-based system differing only in single residue hydrophobic changes at the 
N-terminus of a cell impermeable cargo –(SG)4 (Sayers et al., 2014). 
Although endolysosomal entrapment and degradation has always been 
considered as a rate-limiting step in efficient cytosolic delivery of cargos by 
CPPs (El-Sayed et al., 2009), delivery to lysosomes is required for targeting 
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lysosomal storage diseases (LSDs) with enzymes (Urbanelli et al., 2011). The 
ability of EJP-18 to deliver therapeutic cargos targeting LSDs could be further 
explored but its effects on cell viability and potentially EGFR signalling cannot 
be ignored. It would be interesting to obtain an all D-form of this peptide to 
investigate whether it is still cytotoxic in an EGFR dependant manner. This 
could also highlight the possibility that EJP-18 is able to enter cells and 
specifically interfere with the JM domain of the receptor. The D-form would 
also be less sensitive outside and inside cells to degradation by proteases. 
Single amino acid substitutions in EJP-18 (or EJP-21) could also be introduced 
with a view to further enhancing cell uptake and/or avoid interaction with 
EGFR. 
As expected, based on charge, EJP-18 proved to be an efficient complexing 
reagent for both siRNA and plasmid DNA. Unfortunately, the results regarding 
its capacity to deliver siRNA to the right location in cells was inconclusive. 
Additional experiments using lysosomotropic agents such as chloroquine could 
be performed to examine whether endosomal entrapment is the limiting step in 
transfection efficiency. The same is true for plasmid DNA and here there was 
no evidence that it could deliver to the cytosol and nucleus. It is interesting that 
like Tat, EJP-18 has an NLS but based on microscopy there was no real 
evidence that this was functioning to enrich the peptide in the nucleus. Nuclear 
labelling was observed at high peptide concentrations that revealed cytosolic 
staining; this fraction is likely to have come from direct translocation across the 
plasma membrane and through nuclear pores that also occurs with R8 that is 
able to do this at higher efficiency and, importantly also in the absence of 
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energy that abolished cell labelling of all studied EGFR JM peptides. Figure 
7-1 summarizes the findings and hypothesis regarding EJP-18. 
Although many questions remain to be answered, this project has provided new 
information on in vitro activity of some well explored CPPs and CPP-chimeras. 
Additionally new CPP(s) derived from a human protein of significant medical 
interest has been discovered that may in fact interfere with its biology. Can we 
now label EJP-18 as a new CPP? Its membrane activity and ability to complex 
biological cargo and also deliver them and fluorophores to cells suggest the 
answer is YES. Whether it has any future, as it stands or as a modified 
sequence, as a single entity bioportide-delivery vector remains to be 
determined.  
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Figure 7-1: Summary of EJP-18-mediated delivery of macromolecules and possible 
membrane interactions. (1) EJP-18-EGFR interaction in the JM region following 
translocation of the peptide across the plasma membrane or following endosomal escape, (2) 
EJP-18-EGFR interaction via mechanisms described in 1, in the JM region inhibiting receptor 
dimerization at the plasma membrane causing internalisation of the receptor to the 
endolysosomal pathway, (3) direct translocation of EJP-18, as a fluoroscent conjugate, across 
the plasma membrane, (4) receptor-mediated or fluid phase uptake of EJP-18, as a fluorescent 
conjugate, (5) intracellular delivery of EJP-18/BSA complexes by endocytosis, (6) intracellular 
delivery of EJP-18/siRNA complexes by endocytosis, (7) EJP-18/plasmid complexes were 
formed but studies showed no evidence of delivery to transfect cells (?) denotes the unknown 
capacity of the peptide and associated cargo to escape from endosomes.  
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8 Appendix A 
List of reagents used in the project, manufacturer and catalogue number: 
Biorad (Hemel Hempstead, UK):  
- Precision plus protein dual colour standards (#161-0374)  
- Clarity, Western ECL substrate (#170-5060)  
- Agarose (#161-3100)  
- SDS (#161-0301)  
- Mini-PROTEAN® TGXTM Gels 10% (#456-1033) 
- Mini-PROTEAN® TGXTM Gels 12% (#456-1043) 
 
Biostatus (Leicestershire, UK):  
- DRAQ7TM (DR71000) 
 
DAKO (Ely, UK):  
- Fluorescence mounting medium “Dako oil” / (#S3023)  
 
Fisher Scientific (Loughborough, UK):  
- Coverslips No. 1 circle 16mm diameter (#12313138)  
- 40% acrylamide/Bis (#10376643)  
- PVDF membrane (#10344661)  
- SuperSignal West Femto Chemiluminescent Substrate (#34094)  
 
Life Technologies (Paisley, UK):  
- DMEM (#21885)  
- RPMI 1640 (#21875)  
- FBS (#16000-044)  
- 0.05% Trypsin EDTA (#25300062)  
- Hoechst 33342 (#H3570)   
- Oligofectamine transfection reagent (#12252-011)  
- Dextran, Alexa fluor® 488 (#D22910) 
- BSA-Alexa fluor® 488 (#A13100) 
- BSA-Alexa fluor® 647 (#A34785) 
 
New England Biolabs (Hitchin, UK):  
- 100 bp DNA Ladder (#N3231S)  
- dsRNA ladder (#N0363S) 
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Promega (Loughborough, UK): 
- Fugene 6 transfection reagent (#E2691)  
- CellTiter Blue viability assay (#G8080)  
- Luciferase Assay system (#E1500) 
 
Roche Diagnostics (Burgess Hill, UK):  
- Complete Protease Inhibitor Cocktail Tablets (#11836153001)  
- Hygromycin (#10843555001)  
 
Sigma Aldrich (Poole, UK):  
- Triton X-100 (#X100)  
- BSA (#A7906)  
- Saponin (#47036)  
- Bicinchoninic Acid solution (#B9643)  
- Copper (II) Sulphate solution (#C2284)  
- TEMED (#T9281)  
- Ponceau S solution (#P7170)  
- Tween 20 (#P1379)  
- Ethidium bromide (#E1510) 
- Trypan Blue solution (0.4%) (#T8154) 
- LookOut® Mycoplasma PCR Detection Kit (#MP0035) 
 
VWR (Lutterworth, UK):  
- Coomassie brilliant blue (#44329)  
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9 Appendix B 
 
Table B-1: Confocal microscope settings 
 
 
Table B-2: Wide field microscope settings 
 
Hardware/Software Settings 
Objective magnification 10X 
Numerical aperture (NA) of 
objective 
0.25 
Objective type Air 
Thickness of cover slip No. 1.5 (0.16-0.19 mm) 
Illumination Mercury lamp 
Filter cubes Leica code A BP 340-380 nm (UV 
excitation) 
Leica code I3 BP 450-490 nm (Blue 
excitation) 
Immersion oil Leica type F (refractive index = 1.518) 
Rastor size 1280 x 1024 
Binning 1  
Pixel size 640 x 640 nm 
Resolution 12 bit 
 
 
Hardware/Software Settings 
Objective magnification 63X 
Numerical aperture (NA) of 
objective 
1.4 
Objective type  il immersion λBlue HCX PL AP  
Thickness of cover slip No. 1.5 (0.16-0.19 mm) 
Lasers 
405 (Diode), 488 (Argon), 543 and 633 
(HeNe) nm 
Immersion oil Leica type F (refractive index = 1.518) 
Pinhole size 95.5 μm (1 Airy unit) 
Imaging speed 400 or 700 Hz 
Imaging direction Bidirectional (offset -30.5) 
Line average 3 
Rastor size 1024 x 1024 
Zoom 1 (Figure BSA) and 1.5 (Rh-peptides) 
Pixel size 240 nm x 240 nm 
Resolution 8 bit 
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10 Appendix C 
Table C-1: 50 nM Cy-5-siRNA and increasing concentration of peptide to 
achieve increasing molar ratios 
Molar ratio of 
EJP-18/Cy5-
siRNA 
complexes 
Cy5-siRNA 
(10 μM 
stock) 
EJP-18 
(50 μM 
stock) 
Opti-MEM 
(to 50 μL) 
EJP-18 final 
working 
concentration 
200:1 1 μL 40 μL 9 μL 10 μM 
160:1 1 μL 32 μL 17 μL 8 μM 
80:1 1 μL 16 μL 33 μL 4 μM 
40:1 1 μL 8 μL 41 μL 2 μM 
20:1 1 μL 4 μL 45 μL 1 μM 
10:1 1 μL 2 μL 47 μL 0.5 μM 
50 nM Cy5-
siRNA alone 
1 μL - 49 μL - 
 
Table C-2: 100 nM Cy5-siRNA and increasing concentration of peptide to 
achieve increasing molar ratios 
Molar ratio of 
EJP-18/Cy5-
siRNA 
complexes 
Cy5-siRNA     
(10 μM 
stock) 
EJP-18   
(50 μM 
stock) 
Opti-MEM 
(to 50 μL) 
EJP-18 final 
working 
concentration 
100:1 2 μL 40 μL 8 μL 10 μM 
80:1 2 μL 32 μL 16 μL 8 μM 
40:1 2 μL 16 μL 32 μL 4 μM 
20:1 2 μL 8 μL 40 μL 2 μM 
10:1 2 μL 4 μL 44 μL 1 μM 
100 nM Cy5-
siRNA alone 
2 μL - 48 μL - 
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11 Appendix D 
 
Figure D-1: Enlarged sections of single section images from Figure 4-6. 
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Figure D-2: Enlarged sections of single section images from Figure 4-7. 
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Uptake of 20 μM Rh-R8 peptides into HeLa cells in SFM for assessment of 
membrane integrity 
HeLa cells were initially incubated with 20 μM Rh-R8 for 1 h. The medium 
was removed and the cells were incubated in imaging medium containing the 
fluorescent probe DRAQ7 and imaged by confocal microscopy. The data 
shown below (Figure D-3) show that none of the cells were labelled with 
DRAQ7. 
 
Figure D-3: Uptake of 20 μM Rh-R8 peptides into HeLa cells in SFM. Cells were 
incubated with 20 μM Rh-R8 (pseudo labelled green) in SFM for 1h at 37ºC, washed and 
imaged in imaging medium containing DRAQ7 by confocal microscopy. Representative 
images (N=2) showing either a single section through the cell at the mid-point of the nucleus or 
maximum projection of the whole cell. Scale bars = 20 μm. 
